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Introduction
Cerebral Small Vessel Disease 
Cerebral small vessel disease (cSVD) has first been described in pathology studies in 
patients with a history of dementia and cardiovascular disease in the 19th century.1-4 Much 
progress in our understanding came with the introduction of CT scans in the 70’s followed 
by the Magnetic Resonance Imaging (MRI) scans in the 80’s.5 The frequently observed white 
matter hyperintensities (WMH) and lacunes,6,7 together with prominent perivascular spaces 
(EPVS),  were among the first to be recognized as part of the small vessel disease spectrum, 
followed by cerebral microbleeds (MB),8 (sub)cortical atrophy9 and recent small subcortical 
infarcts. More recently cortical superficial siderosis (cSS),10 microinfarcts,11 and intra-cerebral 
haemorrhage were added to the cSVD spectrum. Standards for nomenclature and imaging 
of these cSVD markers were recently published as the STRIVE-criteria12 by an international 
working group from the Centres of Excellence in Neurodegeneration. (PANEL 1) 
cSVD encompasses all pathological processes that affect the small vessels of the brain 
supplying the white matter, the brainstem, the deep grey nuclei and the cortex. These 
small vessels cannot be visualized on cerebral imaging yet, therefore these parenchymal 
lesions have been adopted as imaging markers of cSVD. Vascular risk factors, probably via 
the development of arterio(lo)sclerosis are thought to be most important in the aetiology 
of cSVD, and this type of cSVD will therefore be the focus of this thesis. The other types 
(hereditary cerebral amyloïd angiopathy, genetic, inflammatory or venous collagenosis) will 
not be discussed.13 
Prevalence and progression of cSVD
WMH are very common in persons aged above 60 years6 and progression of WMH is estimated 
between 0.2 and 2.5 mL/year.14-16 Lacunes are present in a fifth of individuals over 60 years 
of age,7 with a yearly incidence of 0.7 to 6 percent.17,18 Microbleeds are less frequent with a 
prevalence of about 5% in this elderly population8 with a yearly incidence between 3 and 9 
percent.19,20 Progression of these characteristics however are suggested to be non-linear, and 
related to baseline cSVD load, age and vascular risk factors, 21 however actual proof for these 
assumptions is lacking. 
WMH can be categorized into mild, moderate and severe. (PANEL 2) These different categories 
of WMH volume possibly are of non-uniform origin, ranging from non-ischemic  to almost 
complete infarction. 22,23 For this reason different WMH volumes might have different clinical 
correlates, and therefore might differ in incidence of clinical syndromes such as dementia. 
Macrostructural versus microstructural cSVD
With the advent of the development of MRI techniques, including diffusion tensor imaging 
(DTI), the radiologic spectrum of cSVD has extended beyond lesions visible on conventional 
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MRI, including impaired WM microstructural integrity.24 DTI measures the movement of 
water (both the magnitude and the direction) within the cerebral white matter. Two main 
measures provide  information on this WM microstructure: the Fractional Anisotropy (FA) and 
the Mean Diffusivity (MD). A lower FA and corresponding higher MD are generally believed 
to reflect lower microstructural integrity.25 The opportunity to assess not only the WMH but 
also the normal appearing white matter (NAWM) surrounding the on FLAIR MRI visible WMH 
is interesting, because the initial stages of cSVD may already develop beyond the detection 
limits of conventional MRI.26 Knowledge on the additional value of these DTI parameters in 
the early identification of those at risk of dementia or depressive symptoms, especially taking 
into account the macrostructural MRI characteristics, thus far is not unravelled yet.
PANEL 1: SVD markers according to the STRIVE criteria 
2006 2015 SVD marker; STRIVE Numbers 
White matter 
hyperintensity of 
presumed vascular origin 
 WMH
 Located in WM
 No cavitation
 Variable size
 FLAIR MRI
Prevalence: 
90% > 60 yrs 
Progression: 
 0.2 to 2.5 
mL/yr 
Lacune of presumed 
vascular origin 
 Lacune
 Usually
hyperintense rim
 Round or ovoid
 Subcortical
 Fluid-filled cavity
 3-15 mm
 FLAIR MRI and T1
Prevalence: 
20% > 60 yrs 
Progression: 
0.7 to 6 %/yr 
Cerebral microbleed 
 MB
 Round or ovoid,
blooming
 2-5 mm, ≤ 10 mm
 T2*
Prevalence: 
5% > 60 yrs 
Progression: 
3 to 9 %/yr 
 (sub)cortical atrophy (lower brain volume not related to a specific macroscopic focal injury
such as trauma or infarction) can also be observed in the FLAIR sequence
 Perivascular spaces (PVR) can also be observed in the FLAIR sequence
 In our study in the WMH volume, we included hypertintensities in the deep grey matter (also
called subcortical hyperintensities)
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Clinical consequences of cSVD
The clinical spectrum and the prognosis of cSVD is highly heterogeneous and ranges from 
very mild symptoms to full blown stages of dementia or parkinsonism. Thus far it is very 
difficult to predict which patients with cSVD are at highest risk to develop these severe 
clinical symptoms, and who will not. As brain changes, measured by MRI, are thought to 
exist long before the clinical symptoms become apparent, the investigation of these imaging 
characteristics in relation to the presence of clinical symptoms or its progression seems a 
plausible next step. 
There is a thin line between ‘neurodegenerative’ and ‘vascular’ dementias, especially in 
the late onset dementias.27-32 Therefore both neurodegenerative (hippocampal and cortical 
atrophy)33 and cSVD MRI characteristics should be investigated together in  their role on 
incident dementia at older age. The added clinical value of DTI characteristics on top of the 
macrostructural MRI characteristics in explaining the clinical variance has not been studied 
very often, and longitudinal studies investigating microstructural integrity and incident 
dementia as an outcome measure are lacking. By investigating these imaging characteristics, 
macrostructural (both cSVD characteristics as brain volumes) and microstructural combined, 
PANEL 2: Mild, Moderate and Severe WMH 
  
Mild (Fazekas 0-1) Moderate (Fazekas 2) Severe (Fazekas 3) 
   
  
 
Focal or punctuate lesions Beginning confluent lesions Confluent lesions 
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clinical variance in older adults with cSVD. 
Hippocampal volume (PANEL 3) is known to be related to incident dementia and progression 
of cSVD has previously been related with hippocampal atrophy.31,32 This hippocampal 
atrophy, however, is visible on conventional MRI at a relatively late stage of dementia, most 
of the time when the cognitive disturbances have already become apparent. For this reason 
early detection of hippocampal damage on a microstructural level might provide earlier 
insight in the aetiology and course of dementia, and provide a better correlation with clinical 
symptoms. Prospective studies however, investigating hippocampal microstructural integrity 
with incident dementia as an outcome measure are lacking. 
Cognitive disturbances in patients with cSVD, (usually consisting of a characteristic 
‘subcortical’ pattern including psychomotor slowing due to impaired executive function, 
problems in attention and planning)34 are thought to be caused by a disruption of the white 
matter tracts (both on a macro- and microstructural level), resulting in a loss of connectivity; 
a ‘disconnection-syndrome’, and the attendant clinical function.35 As associations with 
traditional markers of cSVD and cognitive decline are weak, possibly DTI parameters might 
provide a better clinical correlate with cognitive decline at follow-up.
Traditional cSVD markers in relation to depressive symptoms are well investigated.36 
Especially for depressive symptoms that occur for the first time in life after the age of 
60 years, an important role for structural abnormalities (such as cSVD) of the brain are 
hypothesized.36-38 The dominant view is that cSVD disrupts the white matter tracts of the 
neural circuit that mediates emotion perception and mood regulation,39 which might lead 
to the same ‘disconnection-syndrome’, resulting in depressive symptoms. Because not every 
individual with cSVD experiences depressive symptoms, other factors than the ‘traditional 
cSVD markers’ might play a role. Such factors could be a lower amygdala volume (known to 
be involved in mood regulation), (PANEL 3) or white matter microstructural integrity. Thus 
far, the limited studies investigating amygdala volume and WM microstructural integrity in 
relation to depressive symptoms, have small sample sizes or did not take the confounding 
role of cSVD into account.
Furthermore, the exact relation between depressive symptoms and cognitive problems has 
not been elucidated yet. It is unclear whether depressive symptoms increase the dementia 
risk by itself or whether this is mediated by the same underlying cSVD.36,38,40,41 Therefore the 
role of depressive symptoms in the development of cognitive decline must be taken into 
account and vice versa. 
More knowledge on the role of cSVD (both macro and microstructural) and its progression 
in relation to clinical symptoms is important for several reasons. First the pathophysiology 
of cSVD might be better understood, and it could lead to a better understanding of the 
clinical correlates in patients with cSVD. The detection of those who develop dementia (or 
other clinical consequences) early in the disease, might offer possible intervention targets 
PANEL 2: Mild, Moderate and Severe WMH 
  
Mild (Fazekas 0-1) Moderate (Fazekas 2) Severe (Fazekas 3) 
   
  
 
Focal or punctuate lesions Beginning confluent lesions Confluent lesions 
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before the symptoms progress to a clinical end stage, and those who are not at risk can be 
comforted. Possibly these MRI markers could help us to identify those at risk to deteriorate 
early in the disease. Finally these imaging characteristics might offer more sensitive outcome 
measures in therapeutic trials.42  
Aim en outline of the thesis
The aim of this thesis was therefore to investigate the relation between both macro and 
microstructural aspects cSVD, brain volumes and the behavioural consequences (cognitive 
decline, dementia and depressive symptoms). Furthermore the temporal aspects of cSVD 
was investigated because of the availability of 3 MRI assessments, giving us the opportunity 
to get more insight into the aetiology and development of cSVD, and a better understanding 
of the clinical correlates in the future. 
This was done within the Radboud University Nijmegen Diffusion Tensor and Magnetic 
resonance Cohort (RUN DMC) study, a prospective cohort study among 503 non-demented, 
older adults with cerebral cSVD on MRI, and investigates risk factors and clinical consequences 
of brain changes during aging. Participants were between 50 and 85 years old at baseline 
(2006). The first follow-up was completed in 2012 and the second follow-up was completed 
in 2015. This thesis is based on cross-sectional data and foremost the first follow-up moment.
PANEL 3: Segmented hippocampus and amygdala 
 
Right amygdala is presented in blue, left amygdala is presented in red 
Right hippocampus is presented in yellow, left hippocampus is presented in green 
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value of DTI over conventional MRI measures of cSVD with respect to cognitive performance 
(van Norden*, van Uden* et al. JAD, 2012)43 
Part II prospectively describes the relation between baseline brain structures, both assessed 
with MRI (FLAIR, T1 and DTI) and the development of incident dementia or cognitive 
decline after 5 years. In chapter 3 we report on both micro and macrostructural imaging 
characteristics on the risk of dementia (van Uden et al. JAD, 2015)44. In chapter 4 we 
additionally investigated the relation between diffusion parameters of the hippocampus 
and the risk of dementia risk, independent of hippocampal volume, brain volume and cSVD 
markers (van Uden*, Tuladhar* et al, HBM, 2016)45 In chapter 5 we report on baseline global 
WM DTI parameters and cognitive decline (different cognitive domains) after 5 years, taking 
into account demographics and previous described imaging parameters (both volumetric 
and cSVD).  (van Uden et al. BBA Clin, 2015)46
In Part III we report on depressive symptoms, and the relation between depressive symptoms 
and cognition in older adults with cSVD. The association between amygdala volume  and 
depressive symptoms is described in chapter 6 on a cross-sectional level. (van Uden et 
al. JAR, 2011)47 In chapter 7 we investigated the white matter integrity of older adults with 
and without depressive symptoms, using Tract-Based-Spatial-Statistics (TBSS), on a cross-
sectional level (van Uden*, Tuladhar* et al. AJGP, 2014)48 In chapter 8 we prospectively report 
on the role of depressive symptoms on incident all-cause dementia after 5 years follow-up, 
taking both the age of onset and baseline cognitive performance into account (van Uden et 
al. Neurology, 2016)49
In part IV (chapter 9)  we review the clinical consequences; (cognitive, motor, mood) and 
the risk factors of microstructural damage of the white matter, as assessed with diffusion 
tensor imaging. (Pasi, van Uden et al. Stroke, 2016)50 
Finally in part V we describe the 9-year change of cSVD markers, using two follow-up 
assessments (2011 and 2015). In this chapter 10 we elaborate on the dynamics of cSVD, 
taking both newly developed as well as apparent decline of the traditional cSVD markers into 
account. We calculated incidence rates of cSVD markers (WMH, lacunes, microbleeds) using 2 
follow-up moments, allowing us to report on the non-linear progression of cSVD. (van Uden*, 
van Leijsen* et al. submitted)  

Part I: 
‘Conventional MRI’ compared to Diffusion Tensor Imaging (DTI)

2.
Cognitive function in cerebral small vessel disease: 
the additional value of Diffusion Tensor Imaging to 
Conventional Magnetic Resonance Imaging
Anouk G.W. van Norden*, Ingeborg W.M. van Uden*, Karlijn F. de Laat, 
Ewoud J. van Dijk and Frank-Erik de Leeuw
Journal of Alzheimer’s disease 2012;32(3):667-76
* Both authors contributed equally 
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Abstract
The structural integrity of the cerebral white matter, including that of the white matter 
lesions (WML) and of the surrounding normal appearing white matter (NAWM), can be 
assessed with diffusion tensor imaging (DTI), which is suggested to be of added value 
in the explanation of cognitive dysfunction in cerebral small vessel disease (cSVD). We 
investigated the value of DTI of NAWM and WML in addition to conventional magnetic 
resonance imaging (MRI) parameters in the variance of cognitive performance in subjects 
with cSVD. 499 individuals with cSVD, 50–85 years, without dementia, underwent MRI 
scanning, including a DTI sequence. Grey matter (GM), white matter (WM), and WML 
volume, number of microbleeds, lacunar and territorial infracts, and mean diffusivity 
(MD) and fractional anisotropy (FA) in NAWM, WML, and total WM were related to 
cognitive performance in multivariate regression analyses, after adjustment for age, 
gender, and education. All MRI parameters together accounted for 1–6% of the variance 
in cognitive function on top of 22–36% already explained by age, gender, and level of 
education. Both mean MD and FA of the NAWM, WML, and total WM did not substantially 
contribute to the explained variance of cognitive function, to that already explained 
by conventional MRI parameters. When considered separately, the MD of the (NA)WM 
had the strongest association with cognitive performance. In conclusion, DTI of NAWM 
and WML has limited additional value to conventional MRI parameters in the etiological 
explanation of the variance in cognitive function among individuals with cSVD. 
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Introduction
Conventional magnetic resonance imaging (MRI) plays an essential role in the diagnosis of 
cerebral small vessel disease (cSVD), including white matter lesions (WML), lacunar infarcts, 
and microbleeds.
Both hospital- and population-based studies have shown that severe cerebral SVD is an 
important cause of cognitive impairment and may ultimately contribute to the development 
of dementia, including Alzheimer’s disease.51-53 Despite the high prevalence of cSVD in 
the population over 60 years of age only few individuals with cSVD ultimately develop 
dementia.6,8,54
Apparently, factors other than cSVD as seen on conventional MRI play a role in this transition 
to cognitive disturbances that, in some, will eventually lead to cognitive decline and 
dementia. With respect to cSVD, conventional MRI differentiates normal appearing white 
matter (NAWM) from WML and lacunar infarcts. Within WML, the extent of white matter (WM) 
tract disruption substantially varies.55 The integrity of NAWM surrounding the cSVD related 
lesions may be another potential factor contributing differential cognitive decline. cSVD on 
conventional MRI usually affects only a few percent of the total WM, leaving the remainder of 
the WM appearing normal.26
Diffusion tensor imaging (DTI) has proven beneficial in assessing the microstructural integrity 
of both the WML and the NAWM.25,56  DTI provides quantitative information about the structural 
integrity of the WM.57,58 This technique is based on the principle of molecular diffusion of 
water and provides, amongst others, two parameters: fractional anisotropy (FA) and mean 
diffusivity (MD). FA reflects the directionality of diffusion, whereas MD reflects the degree 
of diffusivity. FA decreases and MD increases are typical indications of impaired structural 
integrity.59 However, the relative importance of each of these MRI and DTI parameters in 
explaining the variance of cognitive performance in patients with cSVD, and with that the 
value of DTI in clinical practice, is not clear. It is unknown which (combination of) conventional 
MRI parameter(s) explains most of the variance in cognitive function and to what extent the 
microstructural integrity of the WML and NAWM contributes to cognitive disturbances, on top 
of the abnormalities already seen on conventional MRI.
We therefore investigated which (combination of) conventional MRI parameter(s) accounted 
for the largest portion of variance explained in cognitive function. Furthermore, we determined 
the additional variance in cognitive function explained by the microstructural integrity of the 
WML and the NAWM to that explained by cSVD, and  other brain lesions, including territorial 
infracts and grey matter (GM) and WM volume, visible on conventional MRI.
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Methods
Study population
The Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort 
(RUN DMC) study prospectively investigates the risk factors and clinical consequences of 
brain changes among 503, 50-85 years old non-demented elderly individuals with cerebral 
SVD. The selection procedure of the participants and the study rationale and protocol were 
described in detail previously.60 
In short, on the basis of established research criteria cSVD was defined as the presence of 
lacunar infarcts and/or WML on neuroimaging.61 Accordingly, in 2006, consecutive patients 
referred to the Department of Neurology between October 2002 and November 2006, were 
selected for participation and investigated from 2006 to 2007. MRI scanning was performed in 
this same time window. Inclusion criteria were: (a) age between 50 and 85 years; (b) cerebral 
SVD on neuroimaging (WML and/or lacunar infarcts). The main exclusion criteria were 
dementia,62 (psychiatric) disease interfering with cognitive testing or follow-up, WML or cSVD 
mimics and MRI contraindications or known claustrophobia. 
From 1,004 invited individuals by letter, 727 were eligible after contact by phone of whom 
525 agreed to participate. In 22 individuals, exclusion criteria were found during their visit to 
our research centre, yielding a response of 71.3% (503/705). All participants signed informed 
consent. The local Medical Review Ethics Committee approved the study. For the present 
study four subjects were excluded because of MRI artefacts, yielding a sample of 499 subjects.
MRI scanning protocol
The complete scanning protocol on a single 1.5 Tesla scanner was described in detail 
previously.60 The scanning protocol included whole brain 3D T1 magnetization-prepared 
rapid gradient-echo (MPRAGE) sequence, FLAIR pulse sequences, transversal T2* weighted 
gradient echo sequence and a DTI sequence.
Conventional MRI analysis
WML were manually segmented, and the number of lacunar infarcts, territorial infarcts 
(diameter >15 mm in known arterial territories) and microbleeds were rated according to a 
standardized protocol.60
GM, WM and cerebrospinal fluid (CSF) probability maps were obtained by automated 
segmentation using Statistical Parametric Mapping 5 unified segmentation routines on the T1-
weighted MPRAGE images (SPM5; Wellcome Department of Cognitive Neurology, University 
College London, UK).63 Total GM, WM, and CSF volumes were calculated by summing all voxel 
volumes that had a p > 0.5 for belonging to the tissue class. Total brain volume was taken as 
the sum of total GM and WM. Intracranial volume (ICV) was a summation of all tissue classes, 
i.e., total GM, total WM, and CSF volume. To normalize for head size, total brain volume was 
expressed as percentage of total ICV. Mutual information co-registration (SPM5) was used to 
align WML maps to the T1 image and to yield a NAWM map (the complement of WML in WM).60
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Measurement of DTI parameters
The diffusion weighted images of each subject were realigned on the unweighted image 
using mutual information based co-registration routines from SPM5. Then, the diffusion 
tensor and its eigenvalues were computed using an SPM5 add-on (http://sourceforge.net/
projects/spmtools). Unphysical spurious negative eigenvalues of the diffusion tensor were 
set to zero, after which the tensor derivatives the MD and FA were calculated.64 The mean 
unweighted image was used to compute the co-registration parameters to the anatomical 
reference T1 image (SPM5 mutual information co-registration), which were then applied to 
all diffusion weighted images and derivates. All images were visually checked for motion 
artefacts and co registration errors. The mean MD and FA were then calculated in the WML, 
NAWM, and total WM. 
Measurement of cognitive function  
Cognitive function was assessed by a standardized neuropsychological test battery that has 
proven to be sensitive and suitable for this purpose in other large epidemiological studies53 
and has been described in detail elsewhere.60 In short, we calculated compound scores for 
seven cognitive domains; 1) Global cognitive function was evaluated by the a )Mini Mental 
State Examination (MMSE) and b) the Cognitive Index. The Cognitive Index is a compound 
score that was calculated as the mean of the z-scores of the 1-letter subtask of the Paper-
Pencil Memory Scanning Task, the mean of the reading subtask of the Stroop test, the mean 
of the Symbol-Digit Substitution Task and the mean of the added score on the three learning 
trials of the Rey Auditory Verbal Learning Test (RAVLT) and the delayed recall of this last test.53 
2) Verbal memory was assessed as the compound score of the mean of two z-scores from 
the RALVT; one for the added scores of the three learning trials of this test, and one for the 
delayed recall of this test. 3) Visuospatial memory was assessed as a compound score of 
the mean of the z-scores of the immediate recall trial and the delayed recall trial of the Rey 
Complex Figure Test. 4) Psychomotor speed was calculated as the mean of the z-scores of the 
1-letter subtask of the Paper-Pencil Memory Scanning Task, the reading subtask of the Stroop 
test, and the Symbol-Digit Substitution Task.53 5) Fluency was calculated from the mean of 
the z-scores of both verbal fluency tasks. 6) Concept shifting was calculated as the z-score of 
the third subtask of the Stroop. 7) Attention was assessed as a compound score of the z-score 
of the total time of the verbal series attention test.53
Other measurements
Level of education was assessed (classified using 7 categories; 1 being less than primary 
school and 7 reflecting an academic degree).65 Cardiovascular risk factors were assessed by 
structured questionnaires and an experienced research nurse measured blood pressure (3 
times in the supine position after 5 minutes of rest). Cardiovascular risk factors were defined;
hypertension as mean blood pressure ≥ 140/90 mmHg and/or use of antihypertensive 
medications,66 diabetes as treatment with anti-diabetic medications, hypercholesterolemia 
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as treatment with lipid lowering medications, and smoking as current, former, or never 
smoker.
Statistical analysis 
The baseline characteristics are presented as mean ± standard deviation (SD) and for the 
positively skewed WML volume distribution, the median and inter quartile range were 
calculated. WML volume distribution was normalized by log-transformation. 
First, we used Pearson’s correlations to assess the associations between age and MRI 
parameters. Second, to establish which MRI parameters (conventional MRI or DTI parameter) 
explained most of the variance in different cognitive domains, we performed a multiple linear 
regression analysis (with age, gender, and education included in every model), for each MRI 
parameter separately. Territorial infarcts and brain atrophy were taken into account, because 
these abnormalities often co-exist with cSVD-related MRI abnormalities26 and are related to 
cognition as well. Third, we assessed which combination of conventional MRI parameters 
(only those conventional MRI parameters that showed significant correlations when analyzed 
separately, as described above in the second step) and DTI parameters (MD and FA of both 
WML and NAWM) accounted for the largest variance in cognitive performance. For each 
cognitive domain, a multiple regression analysis was performed with the introduction of age, 
gender, and education prior to the MRI parameters. The MRI parameters were subsequently 
added in an automated (forward) stepwise fashion to optimize the model fit.
Finally, we assessed the increase of variance explained in cognitive performance by DTI on top 
of conventional MRI parameters in order to assess the added value of DTI over conventional 
MRI. We did so by using a multiple linear regression model in which age, gender, and level 
of education were introduced first, followed by all conventional MRI parameters (those that 
showed significant correlations when analyzed separately in step two), and subsequently the 
DTI parameters (MD of NAWM or WML or total WM).
Results
Demographics and neuroimaging characteristics of the 499 subjects are shown in Table 1. 
Mean age was 65.6 years (SD 8.8) and 56.5% were male. Mean WM volume was 464.4 ml (SD 
66.5), the largest part of the WM consisted of NAWM, with a median percentage of 98.5 (IQR 
96.0–99.2).
Table 2 represents the Pearson’s correlations between the different MRI and DTI parameters. 
Almost all MRI parameters were significantly correlated to each other, apart from some 
correlations with territorial infarcts and microbleeds. The correlations with the mean FA and 
MD in the NAWM were almost similar for both the NAWM and total WM. Mean FA and MD of 
the WML, NAWM, and total WM strongly correlated with WML volume (correlation coefficients 
for FA between –0.42 and –0.54, p < 0.001; for MD between 0.62 and 0.66, p < 0.001) and age. 
Second, we determined the additional amount of variance in cognitive performance explained 
by each MRI parameter separately on top of age, gender, and education (Table 3). Most of the 
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MRI parameters were significantly associated with all cognitive domains, except for FA and 
MD in the WML, WM volume, and territorial infarcts. Mean MD in the NAWM and in the total 
WM explained most variance of the MMSE, cognitive index, verbal memory performance, and 
attention. In addition to age, gender, and education, it explained another 1.5–2.4% of the 
performance in the different cognitive domains, resulting in explained variance between 23% 
and 38% for the different cognitive domains. WM volume explained most of the variance in 
psychomotor speed, followed by the mean MD in the NAWM and total WM. In all cognitive 
domains, DTI parameters accounted for only slightly
Table 1: characteristics of the study population
Characteristics n=499
Demographic and clinical characteristics
Age, yrs. 65.6 (8.8)
Male, no. 282 (56.5)
Subjects with hypertension, no. 367 (73.5)
Subjects with diabetes, no. 73 (14.6)
Subjects with hypercholesterolemia, no. 234 (46.9)
Current smokers, no. 75 (15.0)
Former smokers, no. 275 (55.1)
MMSE 28.1 (1.6)
Subjects who finished primary school, no. 450 (90.2)
Neuroimaging characteristics
Grey matter volume, ml 628.8 (67.0)
White matter volume, ml 464.4 (66.5)
Intracranial volume, ml 1676.3 (156.3)
WML volume, ml† 7.1 (3.4; 18.1)
NAWM volume, ml 450.3 (70.3)
Subjects with microbleeds, no. 52 (10.4)
Subjects with lacunar infarcts, no. 171 (34.3)
Subjects with territorial infarcts, no. 58 (11.6)
Mean MD in NAWM * 10^-3 mm2/s 0.89 (0.04)
Mean MD in WML * 10^-3 mm2/s 0.10 (0.67)
Mean MD in total WM * 10^-3 mm2/s 0.89 (0.05)
Mean FA in NAWM mm2/s 0.33 (0.02)
Mean FA in WML mm2/s 0.34 (0.03)
Mean FA in total WM mm2/s 0.33 (0.02)
Data represent numbers (%), mean (Standard deviation) or median † (inter quartile range). WML  = white matter 
lesions; NAWM = normal appearing white matter; WM: white matter; MD = mean diffusivity; FA = fractional 
anisotropy. 
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more variance in cognitive performance than the conventional cSVD parameters (WML 
volume, number of lacunar infarcts and number of microbleeds).
Third, we determined which combination of MRI parameters explained most variance 
in cognitive performance, on top of age, gender, and level of education, which already 
accounted for 21.7%–35.7% (Table 4). The mean MD of the NAWM explained most of the 
variance of the MMSE (1.4%), cognitive index (1.9%), verbal memory performance (1.4%), 
attention (2.4%), and visuospatial memory (0.7%; data not shown). WM volume was the most 
important determinant of psychomotor speed (2.6%) and concept shifting (2.2%; data not 
shown). GM volume explained most of the variance in fluency (1%; data not shown). The total 
explained variance of all MRI parameters (both conventional and DTI) together, on top of age, 
gender, and education ranged from 1–6%.
Finally, Table 5 shows the results of the added value of the mean MD of the NAWM, WML, 
and total WM over conventional MRI parameters in terms of explained variance of cognitive 
function. Conventional MRI parameters accounted for 1.0% to 4.2% on top of age, gender, 
and level of education in the variance of all cognitive domains. A significant increase in 
variance, on top of conventional MRI measures, was explained by MD in the NAWM and total 
WM for the cognitive index, verbal memory performance, psychomotor speed and attention, 
but no more than 1.0%.
This was not found for MMSE, visuospatial memory performance, fluency, and concept 
shifting (data not shown for latter three). The MD in the WML did not explain an increase in 
variance in any of the cognitive domains. 
We performed the same analyses for FA in the NAWM, WML and total WM and all cognitive 
domains and found a similar amount of variance in cognitive domains explained by the 
mean FA.
Discussion
In this large cohort of individuals with cerebral SVD, all MRI parameters together explained 
1–6% variance in performance on different cognitive domains, in addition to the 22–36% 
variance already explained by age, gender, and level of education. Both the mean MD and FA 
of the NAWM, WML, and total WM did not substantially contribute to the variance explained 
of cognitive function, to that already explained by conventional MRI parameters. Conversely, 
when each MRI parameter (conventional and DTI) was investigated separately, the MD of the 
(NA)WM had the strongest association with most cognitive domains.
Strengths of our study included the large sample size, the single centre design, with a high 
response, the extensive assessment of cognitive function, and all participants examined 
by only two investigators. In addition, we performed all MRI scans (conventional and DTI 
sequences) on a single scanner, and with quantitative assessment of WML, GM, and WM 
volume. Other strengths are the manual segmentation of the WML without prior knowledge 
of the clinical data and the assessment of microbleeds as another manifestation of cSVD. 
A limitation is the cross-sectional analysis of this part of the study, which prevents us from 
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Table 4  Combination of MRI and DTI parameters that best explains variance for the various 
cognitive domains
Cognitive 
domain and 
step in model
MRI parameters
(independent 
variables remaining 
in model)
Added 
variance 
explained
Total 
explained 
variance (%)
Stand.
beta
p-value
MMSE
1 21.7
2 NAWM, mean MD 1.4 23.1 -0.15  0.003
Cognitive index
1 35.7
2 NAWM, mean MD 1.9 37.6 -0.12 0.006
3 Microbleeds, no. 2.8 38.5 -0.11 0.023 
4 White matter volume 3.6 39.3 0.11 0.025
5 Territorial infarcts, no. 4.1 39.8 -0.08  0.046
Verbal memory
1 24.3
2 NAWM, mean MD 1.4 25.7 -0.15 0.003
Psychomotor speed
1 35.0
2 White matter volume 2.6 37.6 0.19 <0.001
3 White matter lesions† 4.9 39.9 -0.13 0.004
4 Territorial infarcts, no. 5.6 40.6 -0.09 0.012
5 Microbleeds, no. 6.4 41.4 -0.10 0.012
Attention
1 27.9
2 NAWM, mean MD 2.4 30.3 -0.13 0.001
3 Microbleeds, no. 3.0 30.9 0.11 0.028
Age, gender, and education were introduced in the model prior to MRI parameters (model 1). MRI parameters 
(those significant in Table 3 and MD in the WML and NAWM and mean FA in WML and NAWM) were then added 
in a stepwise fashion. Total explained variance and standardized beta-value describe the values till that step 
as variables are progressively added to the model. NAWM: normal appearing white matter, WML: white matter 
lesions MD: mean diffusivity, FA: fractional anisotropy, †log transformed. 
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drawing conclusions about the predictive value of MRI parameters in cognitive decline and 
Alzheimer’s dementia (AD). However, the RUN DMC study has a longitudinal design and 
follow-up is currently being executed.60 Second, cognitive function is also influenced by 
several factors that intentionally were not taken into account in this study such as medial 
temporal lobe atrophy, as we wanted to investigate the effect of cSVD on cognitive function. 
Finally, we investigated a rather healthy study population with a relatively intact cognitive 
function (mean MMSE 28.1; SD 1.6) and most of them had mild to moderate white matter 
damage on conventional MRI. Consequently the integrity of the NAWM in most participants 
will probably be relatively intact, limiting the statistical power to detect an additional effect 
of DTI parameters in the NAWM to that of conventional MRI parameters.
There might be several reasons why only a small part of the variance in cognitive function 
was accounted for by conventional MRI parameters for cSVD (4%) and by the microstructural 
integrity of the (NA)WM (an additional 1%). Non-differential misclassification in both 
determinant and outcome could have played a role in the little contribution found. In 
addition, other imaging parameters, such as medial temporal lobe atrophy, and the presence 
of depressive symptoms might be other important factors in the variance of cognitive function 
in individuals with cSVD, as both have been related to cSVD and cognitive performance 
as well.32,67 In addition, selective survival may have played a role in the relative minor 
contribution of MRI parameters to cognitive performance due to a decreased susceptibility of 
the effect of cSVD on the cerebral WM among survivors. Moreover there is probably a selective 
nonparticipation of survivors with a higher degree of cSVD and more cognitive disturbances. 
Another explanation for the relative small contribution of cSVD in the variance of cognitive 
performance may be due to so called ‘competing risks’. Competing risks occur in an aging 
population where multiple risk factors for one single disease are present, thereby limiting 
each individual (relative) contribution to the disease. 
Our findings furthermore showed that GM and WM volume play an important role in the 
explained variance of psychomotor speed, fluency, and concept shifting. These findings 
are consistent with previous studies in cSVD patients that have shown a relation between 
cognitive function and markers of cerebral atrophy,68 such as atrophy of the corpus callosum,69 
GM volume, and hippocampal volume.70
Other cross-sectional studies investigated the value of DTI compared to conventional MRI 
in relation to cognitive function and found inconsistent results. While some small studies 
among individuals with WML showed that DTI parameters correlated stronger with cognition 
than conventional MRI parameters, 71,72 a diffusion weighted imaging study on 147 CADASIL 
patients found brain atrophy to have a stronger independent influence on cognitive function 
than the mean apparent diffusion coefficient of the whole WM.73 However, it is difficult to 
compare our results with the results from these studies because of different study populations, 
the much larger sample size of our study, different methods in lesion quantification and 
different outcome measures. In addition we took more conventional MRI markers into 
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Table 5: Added value of DTI to conventional MRI parameters in the explained variance of the various 
cognitive domains
Step in 
model
MRI parameter Total explained 
variance (%)
Standardized 
beta-value
p-value
MMSE
1 Age, sex and education  21.7
2 Conventional MRI parameters 23.1
3a
3b
NAWM, mean MD
WML, mean MD
23.5
23.3
-0.11
-0.07
0.097
0.214
3c Total WM, mean MD 23.6 -0.12 0.076
Cognitive index
1 Age, sex and education 35.7
2 Conventional MRI parameters 38.7
3a
3b
NAWM, mean MD
WML, mean MD
39.4
39.0
-0.13
-0.08
0.020
0.150
3c Total WM, mean MD 39.5  -0.15 0.015
Verbal Memory
1 Age, sex and education 24.3
2 Conventional MRI parameters 25.3
3a
3b
NAWM, mean MD
WML, mean MD
26.3
25.5
-0.13
-0.04
0.017
0.262
3c Total WM, mean MD 26.3 -0.13 0.018
Psychomotor speed
1 Age, sex and education 35.0
2 Conventional MRI parameters 39.2
3a
3b
NAWM, mean MD
WML, mean MD
39.7
39.4
 -0.11
  -0.10
0.046
0.065
3c Total WM, mean MD 39.7 -0.12 0.039
Attention
1 Age, sex and education 27.9
2 Conventional MRI parameters 30.6
3a
3b
NAWM, mean MD
WML, mean MD
31.2
31.0
-0.10
-0.07
0.047
0.103
3c Total WM, mean MD 31.2 -0.10 0.042
Age, gender, and education were introduced in the model prior to conventional MRI parameters (model 1). 
Conventional MRI parameters (those related to cognitive function in Table 3) were then added and subsequently 
the mean MD of the NAWM (3a) the WML (3b) or the total WM (3c). Total explained variance and standardized 
beta-value describe the values till that step as variables are progressively added to the model. NAWM: normal 
appearing white matter; WML, white matter lesions; WM, white matter; MD, mean diffusivity.
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account, including brain atrophy, territorial infarcts, lacunar infarcts, and microbleeds, which 
may have led to the lower additional value of DTI parameters compared to
other studies. 
DTI parameters of the total WM and NAWM are highly correlated and explained the same 
variance in cognitive performance. This is probably due to the fact that the NAWM constitutes 
the largest part of the WM (median percentage of 98.5%). Damage to the structural integrity 
of the NAWM accounted for very little variance in cognitive performance in addition to the 
cSVD related lesions visible on conventional MRI. This might be due to the high correlation 
between WML volume and the mean FA and MD of the NAWM which we found (Table 2), which 
suggests that WML volume is a marker for the microstructural integrity of the NAWM. This is in 
line with findings in other studies.74
Our results show that DTI does not seem to have additive clinical value in understanding 
cognitive impairment in patients with cSVD. However, despite the small contribution of 
DTI parameters in the variance of cognitive performance at the cross-sectional level, DTI 
parameters may be of additional value in longitudinal studies and clinical trials in which 
there is interest in a surrogate marker for progression of cognitive disturbances, eventually 
resulting in dementia in some and in the evaluation of potential therapeutic effects of 
disease modifying drugs. This is of great interest as the rate of cognitive decline is slow, 
neuropsychology is time consuming, expensive and of limited value in repeated testing due 
to learning effects; these limitations require very large samples and/or long duration studies.42 
A few longitudinal studies showed that DTI is sensitive to change over a short period of time 
and correlated with change in cognitive test scores, while this is not the case for conventional 
MRI markers.72,75,76 However, more longitudinal studies are needed to replicate these results 
with serial DTI analysis to establish the predictive value of DTI parameters in cognitive decline 
additional to conventional MRI parameters. 
In conclusion, DTI of the WM (NAWM, WML or total WM) does not seem to be of added value to
the conventional MRI parameters, in the etiological explanation of the variance of cognitive 
impairment in subjects with cSVD. Future longitudinal studies are needed to demonstrate 
the sensitivity of both conventional MRI and DTI markers to changes in lesion load over 
time and their association with cognitive performance and AD and to determine whether 
DTI measures of the (NA)WM or (a combination of) conventional MRI markers, such as WML 
volume, and atrophy could be a surrogate in therapeutic trials in cSVD. 

Part II: 
Baseline MRI characteristics and incident 
dementia or cognitive decline 
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Abstract:
Background: The relationship between cerebral small vessel disease (cSVD) and 
dementia has been studied without considering white matter (WM) volume, the 
microstructural integrity of the WM surrounding the cSVD, and grey matter (GM).
Objective: We prospectively investigated the relationship between these structures and 
the risk of dementia, and formed a prediction model to investigate which characteristics 
(macro- or microstructural) explained most of the variance.
Methods: The RUN DMC study is a prospective cohort study among 503 non-demented 
participants with an age between 50 and 85 years at baseline, with baseline assessment 
in 2006 and follow-up assessment in 2012. Two were lost to follow-up (yielding a 99.6% 
response-rate). Cox regression analysis was used, to calculate hazard ratios for dementia, 
of baseline MRI characteristics.
Tract-Based Spatial Statistics (TBSS) analysis was used to assess the added value of 
microstructural integrity of the WM.
Results: Mean age at baseline was 65.6 years (SD 8.8) and 56.8%was male. 43 participants 
developed dementia (8.6%), resulting in a 5.5-year cumulative risk of 11.1% (95%CI 7.7–
14.6). Low WM and hippocampal volume are significant predictors for dementia. WM, 
white matter hyperintensities (WMH), and hippocampal volume (HV) explained most of 
the variance. TBSS analyses showed no additional value of diffusion parameters. 
Conclusion: WM and hippocampal volume were the main predictors for the 
development of incident dementia at 5-year follow-up in elderly with cSVD. There was 
no additional diagnostic value of the diffusion tensor imaging parameters on top of the 
macrostructural characteristics.
WHITE MATTER AND HIPPOCAMPAL VOLUME AND THE RISK OF DEMENTIA 
41
Ch
ap
te
r 3
Introduction
White matter hyper intensities (WMH) and lacunes occur in over 90% of all individuals aged 
60 years and over. Expressions of cerebral small vessel disease (cSVD),12 including white 
matter hyperintensities (WMH),41 lacunes51 and microbleeds77 have always been studied in 
isolation, rather than in conjunction with respect to incident dementia, often without taking 
the surrounding (volume of) normal appearing white matter (NAWM) into account. The 
approach is usually similar for grey matter (GM) structures that have found to be related with 
dementia, such as neocortical or hippocampal volume (HV).78 Obviously, the white matter 
(WM) connects and thereby influences the structure and function of these GM areas.79 Given 
this, it seems plausible to also take these GM structures into consideration when  assessing 
the relation between cSVD and cognitive performance or dementia and vice versa.
Apart from the with conventional MRI visible cSVD,  the microstructural integrity of the WMH 
itself and that of the surrounding normal appearing white matter (NAWM), which can be 
assessed with DTI25,80  has suggested to play a role in dementia in cross sectional studies.81 
However prospective studies are lacking.
We therefore investigated the relation between the total spectrum of cSVD, the GM (neocortex, 
basal ganglia, thalamus), the hippocampus, and the microstructural integrity of the WM 
altogether on the risk of dementia. With these macro- and microstructural parameters we 
constructed a prediction model to indicate which MRI- parameter accounts for the highest 
variance. We did so within the RUN DMC study, a prospective cohort study among  503 
individuals with cSVD after a mean follow-up of over 5 years.
Materials and Methods:
Study population
The Radboud University Nijmegen Diffusion Tensor and Magnetic resonance Cohort (RUN 
DMC) study prospectively investigates risk factors and clinical consequences of brain 
changes during aging as assessed with MRI among 503 50-85 year old non-demented 
elderly with cerebral SVD. On the basis of established research criteria, cSVD was defined 
as the presence of lacunes and/or WMH on neuro-imaging. 61 Patients were referred either 
because of acute symptoms, such as transient ischemic attack (TIA) or lacunar syndromes, 
or subacute complaints such as cognitive, motor disturbances and/or depressive symptoms 
61. The baseline data collection was performed in 2006. Participants who underwent routine 
diagnostic brain imaging, (for amongst others: vascular causes (TIA, stroke), headache, mild 
traumatic brain injury and cognitive complaints) were eligible for participation. Inclusion 
criteria were: age between 50- and 85 and cerebral SVD on neuro-imaging (WMH and/
or lacunes). Main exclusion criteria were dementia, (psychiatric) disease interfering with 
cognitive testing or follow-up; WMH or cSVD mimics (e.g., Multiple Sclerosis) and MRI contra-
indications .60
Follow -up was completed in 2012. Of 503 baseline participants, two were lost to follow-up 
(but not deceased according to the Dutch Municipal Personal Records database), 49 had 
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died, and 54 refused in person follow-up, but clinical endpoints were available. (Figure 1) 
One was additionally excluded because of baseline MRI artefacts, yielding a final sample of 
500 participants. This study was approved by the Medical Review Ethics Committee region 
Arnhem-Nijmegen and all participants gave written informed consent prior to inclusion.
Baseline study-population 
n = 503 
No dementia, parkinsonism 
completed MRI protocol 
Lost to follow-up
n = 2
Follow-up study population 
n = 501
Deceased n = 49
but clinical endpoints were assessed 
Follow-up cognitive, motor and MRI investigation 
n = 398
Unable to visit our research centre 
clinical endpoints were assessed 
n = 54  
19 illness that prevented visit 
5 moved out of the area 
30 lack of time 
Participants available for renewed assessment 
n = 452
Potential participants invited by letter 
n = 1004
Eligible after telephone conversation 
n = 727
Participants 
n = 525 
172 exclusion criteria 
105 contra-indication MRI / claustrophobia 
Non responders 
n = 202
exclusion: 
14 claustrophobia / metal 
1 died before MRI 
1 multiple sclerosis 
1 parkinsonism 
4 dementia 
1 language problem 
Figure 1: Flowchart study design baseline and follow-up. 
Baseline and Follow-up study population are indicated by double-lined boxes. MRI: Magnetic Resonance Imaging
Dementia case finding 
At baseline all participants were free of dementia. Dementia case finding was performed for 
those who participated in the face-to-face follow-up and for those who died or refused follow-
up participation (they gave permission to perform follow-up based on available clinical 
data). The Mini–Mental State Examination (MMSE)82 was used as a first screen among face-
to-face participants. A score below 26 or a decline of three points or more from baseline was 
considered screen positive (n=34), of whom 20 were subsequently examined for dementia 
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at the Radboud Alzheimer Center (7 were diagnosed with dementia, and 13 were not). For 
the remaining 14, who refused additional analysis, a consensus diagnosis of dementia was 
made by a panel, consisting of a neurologist, clinical neuropsychologist and a geriatrician 
with expertise in  dementia. They reviewed all available neuropsychological 60 and imaging 
information, which included (I) the difference in neuropsychological performance between 
baseline and follow-up, (II) outcome of the Mini International Neuropsychiatric Interview 
MINI,83 (III) the follow-up MRI scan, or, if not available (in 7 cases), the baseline MRI-scan; 
and (IV) for the interpretation of these tests, age and level of education were taken into 
account ,65 next to interference with daily living, confirmed by family or caregivers. Of these 14 
participants, seven were diagnosed with dementia. 
Medical records were reviewed from the participants who were not available for follow-
up assessment (49 deceased, 54 follow-up data available, no center visit); in addition their 
general practitioners and medical specialists were contacted for information on their 
cognitive status. Dementia was mentioned in 37 participants. After  review by members from 
the panel, 29 were diagnosed with dementia, and eight were not. In total, this resulted in 43 
incident cases of dementia during a mean follow-up period of 5.2 (SD 0.7) years. 
The diagnosis of dementia was based on the Diagnostic and Statistical Manual of Mental 
Disorders (IV)62 criteria; probable Alzheimer’s disease was based on the NIA-AA criteria,84 and 
vascular dementia was based on NINDS-AIREN criteria.85 Individuals not fulfilling these criteria 
were classified as possible Alzheimer’s Dementia with etiologically mixed presentation 84 and 
fronto-temporal dementia (FTD). The onset of dementia was defined as the date on which 
the clinical symptoms allowed for the diagnosis.51 When the date of diagnosis was not exactly 
known, we used the mid-point between the baseline visit and the first date the diagnosis was 
confirmed, 86 or the date someone was placed in a nursing home because of dementia. 
MRI resonance imaging protocol and analysis
MRI scans of all participants were acquired on a single 1.5-Tesla MRI (Magnetom Sonata, 
Siemens Medical Solutions, Erlangen, Germany). The protocol included the following whole 
brain scans: a  T1-weighted 3D magnetization-prepared rapid gradient-echo (MPRAGE) 
imaging (voxel size 1.0 x 1.0 x 1.0mm);  Fluid-attenuated inversion recovery (FLAIR); voxel 
size 1.0 x 1.2 x 5.0mm, with an interslice gap of 1 mm);  a transversal T2* weighted gradient 
echo s (voxel size 1.3 x 1.0 x 6.0mm, with an interslice gap of 1 mm) and a Diffusion Tensor 
Imaging  (DTI) sequence (voxel size 2.5 x 2.5 x 2.5mm; 4 unweighted scans, 30 diffusion 
weighted scans with b-value = 900 s·mm-²) WMH were manually segmented on FLAIR images 
and the total WMH volume was calculated by summing the segmented areas multiplied by 
slice thickness. The rating of baseline lacunes and microbleeds were rated according to the 
recently published Standards for Reporting Vascular changes on neuro-imaging (STRIVE), by 
trained raters blinded to all clinical data12 with good intra- and inter-rater variability (weighted 
kappa’s of 0.87 and 0.95 for lacunes and 0.85 and 0.86 for microbleeds, calculated in 10 
percent of the scans). To obtain GM (volume of the neocortex, basal ganglia and thalamus), 
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WM and cerebrospinal spinal fluid (CSF) volume, the T1 MPRAGE images were segmented 
using Statistical Parametric Mapping 5 unified segmentation routines.60,63 Total GM, WM and 
CSF volumes were subsequently calculated by summing all voxel volumes that had a p > 0.5 
for belonging to that tissue class. The intracranial volume (ICV) was a summation of total GM, 
total WM and CSF volume. Hippocampal volumes were manually segmented on the MPRAGE 
image using the interactive software program “ITK-SNAP” as described previously .87 88 (http://
www.itksnap.org). All volumes were normalized to total ICV.89 
DTI analysis
Diffusion data were analyzed in the total WM, according to an earlier detailed procedure. 90 In 
short, diffusion data were pre-processed using an in-house developed algorithm for patching 
artifacts from cardiac and head motion.91 Corrections of Eddy current and motion artifacts 
from affine misalignment were performed simultaneously, which was based on minimization 
of the residual diffusion tensor error.92 FA and MD images were calculated using DTIFit within 
the FSL toolbox, which were fed into the TBSS pipeline.93 A FA skeleton was created by 
conducting a thinning procedure on the mean FA image. This skeleton was thresholded at 
0.3 and the skeleton projection vectors were then applied to the MD.  
  
Other measurements
Education was classified using 7 categories (1 being less than primary school, 7 reflecting 
academic degree).65 We then dichotomized in primary or less (level 1 and 2), or more than 
primary education (level 3 to 7). Depressive symptoms were assessed with the Centre of 
Epidemiologic Studies Depression Scale (CES-D); they were considered present with CES-D ≥ 
16 and/or current use of anti-depressive medication, taken for depression.48,60  
Statistical analysis
Person-years at risk were calculated from date of the baseline assessment, until onset of 
dementia, death, or date of the follow-up whichever came first. Patients who died or did not 
reach the endpoint were censored. WMH volume was log transformed because of the skewed 
distribution of the data. As frontotemporal dementia is basically genetic, we excluded this 
participant from the analysis.
The cumulative risk of incident dementia was estimated with Kaplan-Meier analysis, 
stratified by severity (in quartiles) of cSVD characteristics (WM and WMH volume, lacunes and 
microbleeds), GM characteristics and MD within WMH and NAWM.  Subsequently, Kaplan-
Meier curves were compared between the subgroups using a log-rank test. 
Cox regression analysis was used, to calculate hazard ratios for dementia. Three models were 
constructed to predict dementia. First, age, sex education and baseline MMSE were forced 
into the model and a backward stepwise selection procedure was used to enter imaging 
characteristics into the model until all variables in the model had p values smaller than 0.15. 
Among the imaging characteristics, only cSVD characteristics were considered in model 1, 
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GM volumes were added in model 2 and DTI characteristics were added in model 3. C-statistic 
was used to assess the discriminatory performance of the three models. Two-sided p-values 
of less than 0.05 were considered to indicate statistical significance. For the TBSS analyses, 
we assessed voxel-wise correlations between the skeletal DTI parameters (FA and MD) and 
dementia, adjusting for age, sex, education, brain volume, MMSE and cSVD characteristics. 
Statistical analysis were performed using IBM SPSS Statistics version 20 and R version 2.15 
(http://www.R-project.org) software packages.
Results
Baseline characteristics are shown in Table 1. 43 Participants developed dementia during a 
mean follow-up of 5.2 years (SD 0.7) resulting in a  5.5-year cumulative risk of dementia of 
11.1% (95% CI 7.7-14.6). 
The risk of dementia was highest in participants with the highest WMH volume compared 
with the lowest volume (14.4% vs. 0.8%, Log-Rank p< 0.001), whereas this risk did not differ 
by absence or presence of lacunes or microbleeds at baseline. Lower baseline WM, GM and 
HV were associated with a higher 5-year risk of dementia (risks for lower versus upper quartile 
of the volume 13.9% vs.0.8%, log-rank p< 0.001 for WM, 24.5% vs.4.0% Log-rank p<0.001 for 
GM, and  21.2% vs. 5.8%, log-rank p=0.003 for HV). Participants with the lowest quartile of 
microstructural integrity (both within WMH and NAWM), had a higher risk for dementia than 
participants in the highest quartile of structural integrity (Figure 2).
Low WM, CSF and HV at baseline were significant predictors of incident dementia, with 
adjustment for age, sex, education, baseline MMSE and territorial infarcts (Table 2). 
After additional adjustment for hippocampal and GM volume, WM volume remained 
a significant predictor of incident dementia  (HR 0.65 95%CI 0.44-0.96, p=0.034). After 
subsequent adjustment for all SVD characteristics separately, a lower HV also remained a 
risk factor of dementia (HR 0.68, 95%CI 0.47-0.99,p=0.045), but CSF volume did not. After 
additional adjustment for baseline depressive symptoms the strength of the associations did 
not markedly change.
Finally, in the prediction models of incident dementia, model 1 showed that WM volume, WMH 
volume and microbleeds retained in the model. After adding the volumes of GM structures 
(GM and HV) in model 2, HV was also retained in the model. Adding  DTI characteristics in 
model 3 did not alter the predictive characteristics (Table 3). There were no indications that 
the proportional hazards assumption was violated. The performance of the three models 
was comparable for the three models (model 1: C-statistic 0.84; 95%CI 0.74-0.93, model 
2:C-statistic 0.85; 95%CI 0.76-0.95) and for model 3:C-statistic 0.86; 95%CI 0.76-0.95). TBSS 
analysis revealed no significant differences between participants with and without incident 
dementia, for both FA and MD parameters (data not shown).
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 Figure 2: cumulative risk of dementia, stratified by MRI characteristics  
Cumulative risk of dementia, stratified by MRI characteristics. Curves represent cumulative risk of dementia per 
5-years follow-up, stratified by MRI characteristics; cerebral small vessel disease (white matter volume, white 
matter hyperintensity volume, lacunes, and microbleeds), grey matter characteristics (grey matter volume and 
hippocampal volume) and microstructural integrity (mean diffusivity in white matter hyperintensities and mean 
diffusivity in normal appearing white matter). 
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Discussion 
Lower WM and HV at baseline significantly increased the 5-year risk of dementia in individuals 
with cerebral SVD, but WMH, lacunes and microbleeds did not. The degree of microstructural 
integrity of the WM did not affect this risk. To the best of our knowledge, this is the first 
longitudinal study that assessed the relation between the whole spectrum of cSVD, GM 
structures and the microstructural integrity altogether and the risk of dementia in elderly 
with cSVD. 
Other studies on dementia or cognitive performance were cross-sectional, did not include 
both GM and WM volume, did not include the whole cSVD spectrum, did not use TBSS 
analysis, or did not take dementia as a clinical endpoint 94-97. 
Strengths of our study include its longitudinal assessment of a population that covers 
the whole spectrum of cerebral SVD and the large sample size, and the ascertainment of 
endpoints in 99.6% of our participants. Collection of our data in a single centre, allowed us 
to assemble baseline and follow-up data according to identical procedures, reducing the 
risk of procedural bias. Furthermore, we manually segmented the WMH and HV without 
prior knowledge of the clinical data. The relation between brain imaging characteristics and 
dementia was investigated with extensive adjustments for other brain imaging characteristics, 
reducing confounding. Finally, brain volumes were normalized to the total intracranial 
volume.
Several methodological issues need to be addressed. First, the nosological dementia 
diagnosis in our study was a clinical diagnosis, supported by MR imaging at the moment of 
diagnosis, and if not available, baseline MR imaging. In some cases, a distinction between 
Alzheimer’s Dementia and Vascular Dementia (VaD) based on clinical data is hard to make, 
because neurodegeneration and vascular diseases often co-occur.98,99 For this reason we 
investigated ‘overall dementia’ as outcome measure.100 Second, it is possible that we missed 
some patients with incident dementia, because the cut-off point of 26 in the MMSE, although 
widely used, might not be sensitive enough, especially for early cases, Vascular Dementia, or 
dementia in higher educated participants. We think that if misclassification has occurred, it 
may have led to an underestimation of the effect. Third, we were not informed on the genetic 
APOE status, CSF biomarkers or positron emission tomography (PET) scan at baseline of our 
participants, which prevented us from further increasing the predictive value of the model. 
Finally, we feel that our study has a high generalizability to patients between 50 and 85 years 
presenting with cSVD on neuroimaging in a general neurology clinic due to comparable 
baseline complaints and baseline characteristics across studies. All our participants were 
functionally independent at baseline, with a mean MMSE of 28.1 (SD 1.6), reflecting estimates 
in the general population.101 The median of WMH in our study is higher than found in 
population based studies. For this reason it is not surprising that our overall incidence rate of 
16.4 per 1000 person years is higher than the overall incidence rate of 10.7 per 1000 person 
years found in a large population based study.86
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We investigated both cSVD and GM structures on the risk of dementia, because the WM 
represents the structural connectivity between different brain structures, including the 
neocortex and hippocampus, which are altogether crucial for cognitive function. It might 
be that the loss of neocortical volume is, at least in part, secondary to cSVD, although the 
exact mechanisms remain to be elucidated. It could be that severe WMH represent areas 
of axonal loss that result in, reduced structural connectivity of the cortical areas once 
connected by these axons (with attendant loss of volume) for example by anterograde or 
Wallerian degeneration). 102,103 However, it might also be possible that neocortical atrophy 
leads to axonal damage as visualized by WMH on conventional FLAIR imaging. Irrespective 
of the actual mechanism, this may result in disconnection of the areas crucial in cognitive 
function, with attendant cognitive decline or even dementia. 
In contrast to another longitudinal study,51 the risk of dementia was not significantly 
increased per increasing volumes of WMH, although the strength of the association was 
strikingly similar to that observed in the Rotterdam Study (HR 1.78, p=0.167, compared with 
an HR of 1.6, p < 0.05). However, similar to our study after  additional adjustments for cSVD 
characteristics this association was no longer significant. Furthermore we have adjusted 
for additional confounders, including HV, which the other study did not.100 In accordance 
with our findings, it may be that the relation between WMH and dementia in that study was 
confounded by hippocampal volume given the strong relation between WMH volume and 
hippocampal volume.31 
Conflicting reports exist on impaired WM integrity in dementia compared to healthy controls.81 
Two recent longitudinal studies,76,104 showed that microstructural changes in the WM predict 
a faster decline in several cognitive domains, but dementia has never been included as an 
outcome measure. We found no additional effect of microstructural integrity of the WM on the 
risk of dementia. Possibly the microstructural changes have a more subtle clinical correlate, 
such as lower scores on separate cognitive domains, but are not severe enough to result in a 
dementia syndrome; especially not in the presence of presumably more severe expressions 
of cSVD already visible on conventional imaging such as WMH and lacunes. Furthermore, at 
baseline, most participants had a relatively intact WM integrity, with only a mild to moderate 
WMH load. This might have limited the statistical power to detect additional value of the DTI 
parameters.
In our prognostic models, age is the foremost important predictor of dementia. The addition 
of WM, WMH and HV did only marginally increase the variance explained. We did not find any 
additional diagnostic value of the DTI parameters. We did not cross-validate the prediction 
model in our dataset, because of the relatively low number of outcome events, therefore 
validation in an independent dataset should be performed as a gold standard.
Our results imply a pre-clinical period, with lower WM and HV in those who might develop 
dementia in the future, where intervention might be possible before onset of clinical 
symptoms. 
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We demonstrated that  in elderly with cerebral SVD, low WM volume, next to HV is significantly 
related to the development of incident dementia after 5 years. Baseline diffusion parameters 
(both the global parameters in the prediction model as well as assessed voxel-wise by TBSS 
analyses) were not related to incident dementia, and had no diagnostic value on top of the 
macrostructural characteristics. Possibly the microstructural changes have a more subtle 
clinical correlate, and are therefore not severe enough to result in a dementia syndrome in 5 
years time. Possibly  these novel markers of subtle damage need to be assessed years or even 
decades before the first clinical symptoms emerge. Future research is needed to investigate 
additional value of change in DTI parameters over time in relation to incident dementia. 
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4.
Diffusion Tensor Imaging of the hippocampus 
predicts the risk of dementia
Ingeborg W.M. van Uden*, Anil .M. Tuladhar*, Helena. M. van der Holst, 
Esther M.C. van Leijsen, Anouk .G.W. van Norden, Karlijn F. de Laat, 
Loes C.A. Rutten-Jacobs, David G. Norris, Jurgen A.H.R Claassen, 
Ewoud. J. van Dijk, Roy P.C. Kessels and Frank-Erik de Leeuw
Human brain mapping. 2016; Jan;37(1):327-37
* Both authors contributed equally 
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Abstract
Introduction: Cerebral small vessel disease (cSVD) is one of the most important risk 
factors for dementia, and has been related to hippocampal atrophy, which is among 
the first observed changes on conventional MRI in patients with dementia. However, 
these volumetric changes might be preceded by loss of microstructural integrity of 
the hippocampus for which conventional MRI is not sensitive enough. Therefore we 
investigated the relation between the hippocampal diffusion parameters  and the risk 
of incident dementia, using diffusion tensor imaging (DTI), independent of hippocampal 
volume (HV).
Methods: The RUN DMC study is a prospective study among 503 elderly with cerebral 
small vessel disease, without dementia, with 5 years follow-up in 2012 (99.6% response-
rate).  Cox regression analysis was performed to calculate hazard ratios for dementia, of 
fractional anisotropy (FA) and mean diffusivity (MD) within the hippocampus, adjusted 
for demographics, HV and white matter (WM). This was repeated in participants 
without evident hippocampal volume loss, because in these participants the visible 
damage might not yet have already started, whereas damage might have started on a 
microstructural level.
Results: 43 participants developed dementia (8.6%), resulting in a 5.5-year cumulative 
risk of 11.1% (95% CI 7.7-14.6). Higher mean diffusivity was associated with an increased 
5-year risk of dementia. In the subgroup of participants with the upper half hippocampal 
volume, higher hippocampal mean diffusivity, more than doubled the 5-year risk of 
dementia. 
Conclusion: This is the first prospective study showing a relation between  a higher 
baseline hippocampal mean diffusivity and the risk of incident dementia in elderly with 
small vessel disease at 5-year follow-up, independent of hippocampal volume and white 
matter volume. 
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Introduction
The spectrum of cerebral small vessel disease (cSVD) includes white matter hyperintensities 
(WMH) and lacunes of presumed vascular origin (lacunes), microbleeds and subcortical 
atrophy.12 cSVD increases the risk of cognitive decline, including memory loss, ultimately 
leading to dementia in some.51,105 The presence and progression of cSVD has previously been 
related to the progression of hippocampal atrophy ,31,32 which is thought to be a major cause 
of the profound deficit in memory consolidation in Alzheimer’s dementia (AD).33
However this hippocampal atrophy, visible on conventional MRI, occurs at a relatively late 
stage of dementia when the cognitive disturbances have already become apparent. Earlier 
detection of  hippocampal pathology may provide insights in the aetiology and course 
of dementia and offer opportunities for early treatment strategies, before irreversible 
degenerative damage of the hippocampus has occurred. Conceptually, there may be 
changes in the microstructural integrity of the hippocampus before macroscopic loss of 
volume occurs. 
As conventional MRI is not sensitive to loss of microstructural integrity of the hippocampus, 
diffusion tensor imaging (DTI) might be of use to provide an early marker for dementia, using 
the diffusion properties of unbound water molecules.25,80 Two DTI parameters are of special 
interest: mean diffusivity (MD) a measure water diffusion averaged in all spatial directions, 
and fractional anisotropy (FA), which provides information about the directionality of water 
diffusion. A low FA and high MD are believed to be an indication for lower microstructural 
integrity.56 Cross-sectionally we showed that hippocampal diffusion parameters (especially 
high MD) were related to verbal memory performance, in participants with a volumetric 
intact appearing hippocampus.106 One prospective study in 13 MCI patients showed higher 
left hippocampal MD at baseline in those who converted to AD after a follow up of 1.5 years, 
compared to those who did not convert .107 To the best of our knowledge there is a lack of large 
longitudinal studies which predict dementia using diffusion data from the hippocampus, 
independent of hippocampal and grey matter (GM) volume.
We therefore aimed to investigate the role of the diffusion parameters FA and MD within 
the hippocampus in the development of incident dementia, independent of hippocampal 
volume, GM volume and cSVD.  Additionally, we investigated the role of hippocampal diffusion 
parameters as an early marker for dementia in older adults without evident hippocampal 
volume loss, because in those the irreversible degenerative damage might not have started 
yet. The study was part of the RUN DMC study, a prospective cohort study of 503 individuals, 
with cSVD yet without dementia at the baseline assessment in 2006, with a subsequent 
follow-up assessment in 2012.
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Methods:
Study population
The Radboud University Nijmegen Diffusion Tensor and Magnetic resonance Cohort (RUN 
DMC) study prospectively investigates risk factors and clinical consequences of brain changes 
as assessed by MRI among 503 50-85 year old non-demented elderly with cerebral SVD. On 
the basis of established research criteria, cSVD was defined as the presence of lacunes and/
or WMH on neuro-imaging.61 Symptoms of cSVD include acute symptoms, such as Transient 
Ischemic Attacks or lacunar syndromes, or sub acute manifestations such as cognitive, motor 
disturbances and/or depressive symptoms.61 The baseline data collection was performed 
in 2006. Inclusion criteria were: age between 50 and 85 years and cerebral SVD on neuro-
imaging. Main exclusion criteria were dementia, (psychiatric) disease interfering with 
cognitive testing or follow-up; WMH or cSVD mimics (e.g., MS) and MRI contra-indications or 
known claustrophobia.60 
Follow-up was completed in 2012. Of 503 baseline participants, two were lost to follow-up 
(but not deceased according to the Dutch Municipal Personal Records database) and 49 had 
died. In person follow-up was performed in 398 participants (Figure 1), while 54 refused in 
person follow-up, but clinical endpoints were available for this group. 
Dementia case finding
Dementia screening of participants was performed during a face-to-face follow-up 
examination (n=398) as follows. The Mini–Mental State Examination (MMSE)82 was used as a 
first screening tool. A score below 26 or a decline of three points or more from baseline was 
considered screen positive (n=34). Of all screen-positives, 20 were subsequently examined 
for the presence of dementia at the Radboud Alzheimer Centre (7 were diagnosed with 
dementia, and 13 were not). The remaining 14 refused additional analysis. For them, a 
consensus diagnosis of dementia was made by a panel, consisting of a neurologist, clinical 
neuropsychologist and a geriatrician, all with expertise in dementia. They reviewed all 
available neuropsychological 60 and imaging information, which included (I) the difference 
in neuropsychological performance between baseline and follow-up, (II) outcome of the Mini 
International Neuropsychiatric Interview MINI,83 (III) the follow-up MRI scan, or if not available, 
the baseline MRI-scan (in 7 cases) for classification. (IV) For the interpretation of these tests, 
age and level of education were taken into account,65 next to interference with daily living, 
confirmed by family or caregivers. Of these 14 participants, 7 were diagnosed with dementia. 
Medical records were reviewed from the participants who were not available for follow-up 
assessment (49 deceased, from 54 follow-up data were available, but did not visit the centre). 
In addition their general practitioners and medical specialists were contacted for information 
on their cognitive status. Dementia was suspected in 37 participants. After review by panel 
members, 29 of these were classified as having dementia (Figure 2). In total, this resulted in 
43 incident cases of dementia during a mean follow-up period of 5.2 years (SD 0.7). 
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The diagnosis of dementia was based on the Diagnostic and Statistical manual of mental 
disorders (IV)62 criteria; probable Alzheimer’s disease was based on the NIA-AA criteria (n=28), 
84 and vascular dementia (VaD) was based on NINDS-AIREN criteria (n=11).85 Individuals 
not fulfilling these criteria were classified as having possible AD with etiologically mixed 
presentation (n=3)84 or frontotemporal dementia (n=1). The onset of dementia was defined 
as the date on which the clinical symptoms allowed for the diagnosis.51 When the date of 
diagnosis was not exactly known, we used the mid-point between the baseline visit and the 
first date the diagnosis was confirmed,86 or the date the participant was admitted to a nursing 
home because of dementia.
Figure 1: Flowchart study design baseline and follow-up 
Baseline and Follow-up study population are indicated by double-lined boxes. MRI: Magnetic Resonance Imaging
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MRI resonance scanning protocol
MRI scans of all participants were acquired on a single 1.5-Tesla MRI (Magnetom Sonata, 
Siemens Medical Solutions, Erlangen, Germany). The protocol included, the following whole 
brain scans: a T1-weighted 3D magnetization-prepared rapid gradient-echo (MPRAGE) 
imaging (TR/TE/TI 2250/3.68/850 ms; flip angle15°; voxel size 1.0 x 1.0 x 1.0mm); Fluid-
attenuated inversion recovery (FLAIR) pulse sequences TR/TE/TI 9000/84/2200 ms; voxel size 
1.0 x 1.2 x 5.0mm, with an interslice gap of 1 mm);  a transversal T2*weighted gradient echo 
sequence (TR/ TE 800/26ms; voxel size 1.3 x 1.0 x 6.0mm, with an interslice gap of 1 mm) and 
a Diffusion Tensor Imaging (DTI) sequence (TR/TE 10100/93 ms; voxel size 2.5 x 2.5 x 2.5mm; 4 
unweighted scans, 30 diffusion weighted scans with b-value = 900 s·mm-²).60
503 Non-demented elderly 
 2 Lost to follow-up  
501 Follow-up study population 
37 events mentioned by general 
practitioner, family or participant 
398 renewed cognitive assessment No renewed assessment 
• 49 deceased 
• 54 unable to visit 
Clinical endpoints assessed 34 screening positive 
20 analysis 
memory clinic 
14 refused analysis: 
consensus meeting 
8 non- 
demented 
7 
dementia 
13 non- 
demented 
7 
dementia 
7 non-
demented 29 dementia 
2 
AD 
4 
VaD 
1 
FTD 
4 
MCI 
9 
VCI 
6 
AD 
1  
AD/VaD 
2 mood 
 
5 other 
18 
AD 
7 
VaD 
4  
AD/VaD 
2 MCI 
2 VCI 
1 mood 
1 hypochondria 
2 incomplete 
data 
Total 43 incident dementia 
at Follow-up: 8.5% 
Figure 2: Flowchart diagnostic work-up dementia 
AD: Alzheimer’s dementia, VD: vascular dementia, FTD: fronto-temporal dementia, AD/VD: possible Alzheimer’s 
Dementia with mixed aetiology, MCI: mild cognitive impairment, VCI: vascular cognitive impairment
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Conventional imaging  analysis
WMH were manually segmented on FLAIR images and the total WMH volume was calculated 
by summing the segmented areas multiplied by slice thickness. The rating of lacunes, 
microbleeds and territorial infarcts were revised according to the recently published Standards 
for Reporting Vascular changes on neuro-imaging (STRIVE), by trained raters blinded to all 
clinical data.12 There were good intra- and inter-rater variability’s with weighted kappa of 
0.87 and 0.95 respectively for the presence of lacunes and 0.85 and 0.86 for the presence of 
microbleeds, calculated in 10 percent of the scans. Inter-rater variability (assessed by intra-
class correlation coefficient) for total WMH volume was 0.99. 
The left and right hippocampus were manually segmented on the MPRAGE image, using 
the interactive software program “ITK-SNAP” version 2.1 88 (http://www.itksnap.org). 
Segmentation was performed using a previously published protocol 108 in which segmentation 
was performed from posterior to anterior. Inter-rater studies showed an intraclass correlation 
coefficient of 0.73 and 0.79 for the left and right hippocampus respectively; intra-rater showed 
an intraclass correlation coefficient for the left and right hippocampus of 0.97 and 0.96. All 
imaging analyses were performed by raters blinded to clinical information.
To obtain the GM (which was composed of the volume of the cortex, basal ganglia and 
thalamus), WM and cerebrospinal fluid (CSF) volume, the T1 MPRAGE images were segmented 
using Statistical Parametric Mapping 12 unified segmentation routines (SPM12; Wellcome 
Department of Cognitive Neurology, University College London, UK (http://www.fil.ion.ucl.
ac.uk/spm/software/spm12/). All images were visually  checked for co-registration errors and 
for motion and/or segmentation artefacts. The GM, WM and CSF volumes were calculated by 
summing all voxels that had a p > 0.5 for belonging to that tissue class multiplied by the voxel 
volume in ml. The intracranial volume (ICV) was calculated by summing the volumes of GM, 
WM and CSF. All volumes were normalized to total ICV.89
DTI-analysis
The raw diffusion weighted images of each patient were first denoised using the Local 
Principal Component Analyses filter.109 Diffusion data were then pre-processed using an in-
house developed algorithm named ‘patching artefacts from cardiac and head motion’.110 
In short, this iteratively reweighted-least-squares algorithm produces robust diffusion 
tensor estimates and provides weightings that are used to detect and correct head and 
cardiac motion artefacts in the diffusion-weighted data. Next, affine misalignments from 
eddy currents and subject motion were corrected simultaneously which is based on the 
minimization of the normalized mutual information measure. 
We then unwarped echo planar imaging (EPI) distortions by normalizing the EPI-images to the 
T1-image only in the phase-encoding-direction. DTI calculations were generated using DTIFIT 
from FSL’s FDT toolbox. The skull-stripped T1-images were then non-linearly registered to the 
FA map using FSL’s Non-linear Image Registration Tool (FNIRT) with standard parameters. 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FNIRT) The transformation matrix derived from the non-
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linear registration was then used to register the manually segmented hippocampus masks 
to the subject’s DTI native space. The boundary voxels of these hippocampal masks were 
eroded to avoid potential partial volume effects. Mean FA and MD were then calculated within 
both hippocampi. All images were visually checked for motion artefacts and co-registration 
errors, especially for not including peri-hippocampal CSF.
Other measurements
Education was classified using 7 categories (1 being less than primary school, 7 reflecting 
academic degree) and then dichotomized in a group having only or less than primary school 
and a group having more than primary education.65 Depressive symptoms  were assessed 
with the Centre of Epidemiologic Studies Depression Scale (CES-D); they were considered 
present in participants with CES-D ≥ 16 and/or participants who currently used anti-
depressive medication, taken for depression.48,60  
 
Statistical analysis
Person-years at risk were calculated for each patient from date of the baseline assessment, 
until onset of dementia, death, or date of the follow-up assessment. Patients who died or did 
not reach the endpoint were censored. WMH volume was log transformed because of the 
skewed distribution of the data. In view of the fact that aetiology of frontotemporal dementia 
is basically genetic, as opposed to the vascular aetiology of vascular dementia and dementia 
due to Alzheimer’s disease, we excluded this participant from the analysis. Cumulative risk of 
incident dementia was estimated with Kaplan-Meier analysis stratified by quartiles of total, 
left and right MD and FA within the hippocampus.  Subsequently, Kaplan-Meier curves  were 
compared between the subgroups using log-rank test. 
We used Cox regression analyses to calculate hazard ratios (HRs) with 95% confidence 
intervals (CI’s) for baseline GM, HV, and the DTI parameters within the hippocampus, adjusted 
for age, sex, education, baseline MMSE and territorial infarcts (no.). Second the HRs for the 
DTI parameters were calculated after additional adjustment for hippocampal and WM 
volume, because those were the only conventional MRI parameters independently related to 
the development of dementia, whereas WMH volume, GM volume, microbleeds and lacunes 
were not.  Finally, in order to identify diffusion parameters of the hippocampus as an early 
marker for incident dementia, we investigated the mean hippocampal FA and MD in patients 
with a “normal” hippocampal volume (median split; cut-off of the normalized hippocampal 
volume 6.81 mL). In these participants the visible (volumetric)  damage might not yet have 
started, but damage might possibly have started on a microstructural level. HRs for dementia 
were calculated for the DTI parameters within the hippocampus in that particular subgroup. 
After correction for age, sex, education, baseline MMSE and territorial infarcts (no.), these 
HRs were additionally adjusted for white matter volume. Two-sided P values of < 0.05 were 
considered to indicate statistical significance. Statistical analysis were performed using IBM 
SPSS Statistics version 20.
DTI OF THE HIPPOCAMPUS AND THE RISK OF DEMENTIA 
63
Ch
ap
te
r 4
Results
The final sample consisted of 501 participants from which  clinical endpoints could be 
obtained (two were lost to follow up). One participant was additionally excluded because 
of baseline T1 and T2 artefacts. Baseline demographic and neuro-imaging characteristics of 
500 participants are shown in Table 1. Dementia developed in 43 participants during a mean 
follow-up of 5.2 years (SD 0.7). Mean age at follow-up was 70.8 years (SD 8.7) and 56.8% was 
male. Mean MMSE at baseline was 28.1 (SD 1.6). At baseline, median WMH volume was 7.2 ml 
(IQR 3.6;18.4), mean WM volume was 464.5 ml (SD  44.4 ml), 26.8% had lacunes and 16.1% 
had microbleeds. Mean normalized hippocampal volume was 6.8 ml (SD 0.9). Mean FA in the 
hippocampus was 0.11 (SD 0.02), and mean MD in the hippocampus was 0.99 10-3 mm2/s (SD 
0.06). The 5.5-year cumulative risk of dementia was 11.1% (95%CI 7.7-14.6). 
This risk of dementia was higher in participants with the lowest quartile hippocampal  FA at 
baseline compared with participants with the highest quartile FA (lowest 19.1% vs. highest 
10.0%, Log-Rank p< 0.022). The risk of dementia also was higher in participants with the 
highest quartile hippocampal MD at baseline compared with those with the lowest quartile 
MD (highest 24.7% vs. lowest 0.8% , Log-Rank p<0.001 (Figure 3). Baseline hippocampal 
diffusion parameters were a significant predictor of the risk of dementia, corrected for age, sex, 
education, baseline MMSE and territorial infarcts (no.) (Table 2). After additional adjustment 
for baseline WM and hippocampal volume, FA values of the hippocampus no longer were 
significant predictors. The mean MD of the hippocampus (left and right combined) (HR 1.44; 
95%CI 1.10-1.88 per SD increase) remained a significant predictor of incident dementia at 
follow-up, as did the mean MD in the left hippocampus (HR 1.44; 95%CI 1.10-1.90 per SD 
increase). The analysis was rerun with an interaction term for hippocampal volume and 
mean hippocampal MD, which was however not significant.  Furthermore, investigating 
whole brain FA and MD values as a predictor of dementia we found no significant relation 
with dementia (data not shown).
The mean hippocampal MD (of both hippocampi combined and the left hippocampus 
separately), was a significant predictor of the risk of dementia, corrected for age, sex, 
education, baseline MMSE and territorial infarcts in the subgroup of participants without 
evident hippocampal volume loss (Table 3). This association remained significant after 
additional correction for WM volume. This was not found for the mean hippocampal MD in 
participants with the lowest half of hippocampal volume (data not shown).
Discussion
The present study in elderly participants with cSVD initial free of dementia, demonstrated 
that higher hippocampal MD increased the risk of developing  dementia after a 5-year 
follow-up. This was independent of demographics, WM and hippocampal volume and most 
pronounced in the left hippocampus, and the subgroup of elderly participants without 
evidence of hippocampal atrophy on conventional MRI. These findings are in line with the 
knowledge that the loss of function and structure of the hippocampus is a hallmark in the 
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aetiology of AD. 111,112 Furthermore lower hippocampal microstructure, especially measured 
by MD in association to cognitive function, is consistent with previous cross-sectional studies 
in both non-demented elderly and elderly with MCI 113-116.
Strengths of our study include its longitudinal design in a population that covers the whole 
spectrum of cerebral SVD and the large sample size. Also the assessment of endpoints in 
99.6% of our participants is a major strength. Collection of our data in a single centre allowed 
us to assemble baseline and follow-up data according to identical procedures, reducing the 
risk of procedural bias. Furthermore, we manually segmented the WMH and hippocampal 
volumes without prior knowledge of the clinical data. We performed a non-linear algorithm 
for the registration between the DTI and T1-image in order to deal with possible differential 
susceptibility effects. Furthermore the boundary voxels of the manually segmented 
hippocampal masks were eroded, to deal with potential partial volume effects.  Finally, the 
relation between hippocampal diffusion parameters and dementia was investigated with 
adjustment for demographics, baseline global cognitive status and other brain imaging 
characteristics including WM and hippocampal volume, reducing confounds. Adjusting the 
associations between hippocampal diffusion parameters and dementia-risk for hippocampal 
volume, this remained a significant predictor for dementia, suggesting that this association 
was not accounted for by concomitant small hippocampal volumes. Due to the relatively 
small number of incident dementia cases in our analyses (n=41 in Table 2 and n=11 Table 3), 
the analyses could not be adjusted for all possible confounders (WMH, presence of lacunes 
, microbleeds and GM volume,  on top of age, sex, education, baseline MMSE and territorial 
infarcts (no.), WM and Hippocampal volume), to avoid over-fitting.  However, investigating 
this association between the hippocampal diffusion parameters and the risk of dementia for 
all above mentioned confounders, the results did not change. 
 Several methodological issues need to be addressed. First, the nosological dementia 
diagnosis in our study was a clinical diagnosis supported by MR imaging at the moment 
of diagnosis, and if not available, baseline MR imaging. In some cases, especially in the 
elderly, a distinction between AD and Vascular Dementia (VaD) is hard to make, because 
neurodegeneration and vascular diseases often co-occur.30,98,99,117 For this reason we 
investigated ‘overall dementia’ as outcome measure. Second, it is possible that some patients 
with incident dementia were missed, because the cut-off point of 26 in the MMSE, although 
widely used, might not be sensitive enough, especially for cases of dementia in early stage 
of the disease, Vascular Dementia, or dementia in participants with higher education levels. 
We think that if misclassification has occurred, it may have led to an underestimation of the 
effect. Third, we were not informed on the APOE status of our participants, which prevented 
us from further increasing the predictive value of our analysis. Fourth, we measured WMH 
using the FLAIR images with a non-isotropic voxel size. For this reason some over or under-
classification could not be excluded. 
We think that our study has a high generalizability to patients between 50 and 85 years 
presenting with cSVD on neuro-imaging in a general neurology clinic. At baseline we included 
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independent living, participants, with a mean MMSE of 28.1, corresponding with estimates 
in the general population.53,101 All had some degree of cSVD on neuro-imaging, which has a 
prevalence of over 90% in the elderly population over 60 years of age.6 However the median 
of WMH in our study is higher than found in population based studies. For this reason it is 
not surprising that our overall incidence rate of 16.4 per 1000 person years is higher than the 
overall incidence rate of 10.7 per 1000 person years found in a large population based study.86 
Comparing our cases of incident dementia with another study in participants with cerebral 
SVD118 we had less cases of incident dementia (43/501 after 5 years of follow up vs. 90/588 
after 3 years of follow up). This could be due to the fact that our population had a mean age 
which was approximately 10 years younger and has less severe WMH at baseline; both factors 
are known to be related with the incidence of dementia.86,119  
We found that the relation between the FA of the hippocampus and dementia was less 
prominent than for MD. This may be because FA mostly reflects the dominant directionality 
of the water diffusion. Multiple fibres present on the same location may all have different 
directions (crossing-fibres), influencing FA. It might be that because of this, low FA may not 
necessarily reflect a lower underlying structural integrity in the hippocampus.25 In contrast, 
MD is less affected by fibre-crossing because it reflects the magnitude of water diffusion, 
which is not influenced by direction.25 A recent meta-analysis comparing DTI parameters and 
volume measures in MCI and AD, indicated that MD values had more discriminative power 
than FA values,120 which is in line with our findings. 
It could be that the discriminative power of the DTI parameters, is higher in the group of 
elderly classified in the upper half of hippocampal volume, because the low microstructural 
integrity of the hippocampus may reflect changes that have not yet resulted in visible 
hippocampal volume loss. Possibly, once the hippocampal atrophy has started, this atrophy 
is of more predictive value for the development of dementia, than the diffusion changes, 
lowering the discriminative power of the DTI parameters. Furthermore,  DTI parameters are 
less sensitive in a smaller hippocampus than in a volumetric intact one, which also might 
contribute to a stronger effect for the DTI parameters in our participants with the upper half of 
hippocampal volume. We did not find a significant relation between whole brain DTI metrics 
and dementia, which might indicate that hippocampal DTI parameters are more specific 
predictors for the development of dementia . In contrast, a recent longitudinal study104 
showed that microstructural changes in the WM predict a faster decline in several cognitive 
domains, but dementia has never been included as an outcome measure.
The underlying mechanisms of higher hippocampal MD (and lower FA), indicating a lower 
microstructural integrity still remains to be elucidated. Several mechanisms, whether 
or not related to cSVD, have been proposed. Possibly severe WMH lead to axonal loss by 
anterograde or Wallerian degeneration in the areas that are connected by these WM 
structures,102,103 such as the hippocampus, and as such lead to higher MD. Alternatively the 
accumulation of intraneuronal tau in the hippocampus 121 may lead to axonal damage and 
lower microstructural integrity of the hippocampus, and as a consequence to loss of function.
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Ideally a surrogate marker for dementia identifies those at higher risk during the pre-clinical 
period, because identification of this disease at an earlier stage (that is, before the irreversible 
damage has been done), might lead to early intervention with for instance vascular risk factors 
as a target. In turn, individuals identified as having a lower risk of developing dementia, can 
possibly be comforted. DTI of the hippocampus might identify the persons at risk in an earlier 
stage than possible with conventional MRI and may be a promising a surrogate marker of 
disease progression for use in therapeutic trials. However to answer the question whether 
dementia can really be prevented by treating or targeting these vascular risk factors we need 
randomized clinical trials with large sample size and sufficient long follow-up.122 
In conclusion, results of our study show that hippocampal diffusion parameters at baseline 
are associated with an increased risk of developing dementia five years later, even when 
macroscopical loss of hippocampal volume is not apparent. These results might suggest that 
diffusion changes in the hippocampus precede volumetric changes as seen in dementia. DTI 
may offer an earlier insight in the development of dementia, and therefore provide an earlier 
window for possible preventive strategies. 
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Abstract
Objectives: Traditional markers of cerebral small vessel disease (cSVD) are related to 
cognition and cognitive decline, but this relation is weak. Therefore other factors may 
determine the transition from intact cognitive performance to cognitive decline, such 
as the damage of the cerebral white matter at the microstructural level. Little is known 
about the association between microstructural integrity of the white matter and changes 
in cognition. In this study we investigated the relation between baseline microstructural 
integrity and change in cognitive function.
Methods: 503 participants of the RUN DMC study with cSVD without dementia, 398 of 
whom (79.1%) underwent repeated cognitive testing at follow-up, with a mean follow-
up time of 5.4 years (± SD 0.2), and amongst others FLAIR MRI and diffusion tensor 
imaging (DTI).  At baseline mean diffusivity (MD) and mean fractional anisotropy (FA) 
was measured in both white matter hyperintensities (WMH) and normal appearing white 
matter (NAWM). A linear regression analysis was performed assessing the association 
between baseline diffusion parameters and decline in cognitive domains. 
Results: An inverse association was found between baseline MD in the NAWM and 
decline in cognitive index, (β=0.17; p=0.035), adjusted for age, sex, education, presence of 
depressive symptoms at baseline, normalized TBV, lacunes and WMH volume. However, 
no significant associations were found between diffusion parameters and decline in any 
cognitive domain after Bonferroni correction.
Conclusions: In contrast to cross-sectional studies, in older adults with cSVD 
microstructural integrity of the white matter as assessed with DTI, is not related to decline 
in global cognitive function or any other sub domain. 
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Introduction
Cerebral small vessel disease (cSVD) is very common in older adults6 and is related to 
cognitive decline  and dementia.41 However, not everyone with cSVD visible on conventional 
structural MRI eventually develops cognitive decline or dementia. Therefore other factors may 
determine the transition from intact cognitive performance to cognitive decline, such as the 
damage of the cerebral white matter at the microstructural level. The interconnected neural 
networks, crucial for cognitive performance, are hypothesized to be disconnected by this 
damage in the white matter microstructure, also known as the “disconnection syndrome”.35 
As identical appearing white matter hyperintensities (WMH) on FLAIR MRI scanning are 
histopathologically heterogeneous,123 possibly only WMH with the highest loss of structural 
integrity are related to cognitive decline. Furthermore the degree of structural integrity of 
the surrounding Normal Appearing White Matter (NAWM) might be important in cognitive 
decline.  As conventional MRI is not sensitive to detect subtle damage of the white matter 
(WM), diffusion tensor imaging (DTI), using the diffusion properties of water molecules might 
be of use to provide an early marker for this cognitive decline.25,80 A low Fractional Anisotropy 
(FA) and high Mean Diffusivity (MD) are believed to represent low microstructural integrity.56
A low microstructural integrity of the WM has been associated with lower cognitive 
performance in both population based studies 124-126 and older adults with cSVD, albeit at the 
cross-sectional level. 95,127-129 Some of these studies even found that DTI parameters correlated 
better with cognitive performance than traditional markers of cSVD in patients with cognitive 
impairment,128 suggesting an important role of low WM microstructural integrity in cognitive 
impairment. At a cross-sectional level we showed that cognitive performance was associated 
with white matter microstructural integrity independent of traditional markers of cSVD,  both 
in the WMH and NAWM 95 and in specific WM tracts.129 However, we additionally showed that DTI 
of the NAWM and WMH had only limited additional value to the traditional cSVD parameters 
in explaining the variance in cognitive function.43 Two smaller prospective DTI studies did 
not find an association between microstructural integrity and cognitive functioning at follow-
up.72,76 A larger longitudinal study using diffusion weighted imaging (DWI) in individuals with 
SVD showed that DWI parameters within the NAWM were related to cognitive decline after 
3 years follow-up.104 We, however, recently showed no relation between microstructural 
integrity of the WM and incident dementia after five years.44 Taken together, results found in 
prospective studies are weak and conflicting.
We therefore investigated whether baseline microstructural integrity as assessed by DTI, both 
within the WMH and the NAWM, independently of traditional cSVD characteristics predicts 
decline in several cognitive domains after 5 years. Furthermore we investigated if this relation 
was different in those with low, moderate and high WMH severity at baseline.
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Material and methods
Study population
The Radboud University Nijmegen Diffusion Tensor and Magnetic resonance Cohort (RUN 
DMC) study prospectively investigates risk factors and clinical consequences of brain changes 
as assessed by MRI among 503, 50 to 85 year old non-demented older adults with cerebral 
SVD. The selection procedure of the participants and the study rationale and protocol were 
described in detail previously.60 In short, on the basis of established research criteria, cSVD 
was a radiological diagnosis, defined as the presence of lacunes and/or WMH on neuro-
imaging.61 Symptoms of cSVD include acute symptoms, such as TIAs or lacunar syndromes, 
or sub acute manifestations such as cognitive, motor disturbances and/or depressive 
symptoms.61  The baseline data collection was performed in 2006. Main exclusion criteria 
were dementia, (psychiatric) disease interfering with cognitive testing or follow-up, WMH or 
cSVD mimics and MRI contra-indications or known claustrophobia.60
Follow-up was completed in 2012 (mean follow-up time 5.2 years (SD 0.7). Of the 503 baseline 
participants, 2 were lost to follow-up (but not deceased according to the Dutch Municipal 
Personal Records database) and 49 had died. From all remaining 442 participants follow up 
was available (face-to-face follow-up was performed in 398 participants, 54 consented to the 
collection of clinical endpoints via their general practitioner (Figure 1). 
Baseline study-population 
n = 503 
2 Lost to follow-up  
 
49 Deceased 
 
54 Unable to visit centre 
19 illness that prevented visit 
5 moved away from the area 
30 lack of time 
 
 
 
 
 
 
 
 
Follow-up cognitive investigation 
n = 398 
398 change in MMSE 
380 change in Rey Auditory Verbal Learning Test (2 missing, 3 physical handicap, 5 dementia interference, 8 baseline exclusion) 
388 change in Rey Complex Figure Test (6 missing data, 3 physical handicap, 1 dementia interference) 
367 change in Stroop  Color Word Test (7 missing, 14 physical handicap (visual or colorblindness), 7 dementia interference, 3 baseline 
                         exclusion) 
372 change in Paper Pencil Memory Scanning Task(5 missing, 9 physical handicap, 5 dementia interference, 7 baseline exclusion) 
381 change in Symbol Digit Substitution Task (4 missing, 8 physical handicap, 5 dementia interference) 
392 change in verbal Fluency (animal and job) (2 missing, 1 physical handicap, 3 baseline exclusion) 
377 change in Verbal Series Attention Test (6 missing, 7 physical handicap, 5 dementia interference, 3 baseline exclusion) 
Figure 1: Flowchart study design baseline and follow-up
Baseline and Follow-up study population are indicated by double-lined boxes. MRI: Magnetic Resonance Imaging
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Cognitive function
Participants underwent the same neuropsychological test battery both at baseline and 
during follow-up examination, covering the main cognitive domains. These tests have been 
previously applied in large-scale epidemiological studies.53,130 The test battery included the 
Mini–Mental State Examination (MMSE),82 verbal fluency (animals and profession naming),131 
Rey Auditory Verbal Learning Test (RALVT; 3-trial version),132,133 Symbol Digit Substitution Task 
(SDST),134 Stroop Colour Word Test (short form),135 Paper-Pencil Memory Scanning Task,136 Rey 
Complex Figure Task (RCFT)137  and Verbal Series Attention test (VSAT).138 The same versions 
of the tests were used for baseline and follow-up assessment. 
Speed-Accuracy Trade-Off (SAT) scores were calculated where appropriate [accuracy(%)/
reaction time], to adjust for a number of faults. Performance across tests was made 
comparable by transforming the raw test scores into z-scores (individual test score minus 
mean test score, divided by the standard deviation). Z-scores for both baseline and follow-
up were calculated using the mean and SD of the baseline tests.139 Higher z-scores always 
indicate a better performance.
Change in cognitive functioning for separate cognitive domains was calculated within-
subject, by subtracting the baseline domain compound score from the follow-up domain 
compound score.
Subsequently, compound scores for global cognitive function (Cognitive Index), memory 
(verbal and visospatial memory) and executive function (psychomotorspeed, fluency, 
inhibition and attention) were calculated. The Cognitive Index was constructed to obtain a 
more robust outcome measure for global cognition. This was calculated as the mean of the 
z-scores of the SAT score of the 1-letter subtask of the Paper-Pencil Memory Scanning Task, 
the mean of the SAT score of the reading task of the Stroop test, the mean of the SDST, and 
the mean of the added score on the three learning trials of the RAVLT and the mean of the 
delayed recall of this test.53
 Verbal memory is a compound score of the mean of z-scores of the total correct words on 
the three learning trials of the RALVT and the delayed recall of this test. Visuospatial memory 
is calculated from the mean of the z-scores of the immediate recall and delayed recall trial of 
the RCFT. Psychomotor speed was calculated  as the mean of the z-scores of the SAT score of 
the 1-letter subtask of the Paper-Pencil Memory Scanning Task, the mean of the SAT score of 
the reading task of the Stroop test and the mean of the SDST. Verbal fluency was calculated 
from the mean of the z-scores of both fluency conditions. Inhibition was measured using 
the following formula: dividing the Stroop part III SAT score by the mean of the SAT scores of 
parts I and II. Afterwards a z-score for inhibition was calculated. Attention was computed as 
the z-score of the SAT score of the total time of the VSAT.  If one test of a particular domain 
was missing, the domain score was computed using the remaining tests of that domain 
(this occurred in less than 6.3% in the sub domains). For 98% of all participants a score for 
Cognitive Index was available, of whom 90% completed all five subtests without recording of 
any test problems. 
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MRI resonance imaging protocol 
MRI scans of all participants were acquired on a single 1.5-Tesla MRI scanner (Magnetom 
Sonata, Siemens Medical Solutions, Erlangen, Germany). The protocol included the following 
whole brain scans: a  T1-weighted 3D magnetization-prepared rapid gradient-echo (MPRAGE) 
imaging (TR/TE/TI 2250/3.68/850ms;flip angle15°; voxel size 1.0 x 1.0 x 1.0mm); Fluid-
attenuated inversion recovery (FLAIR) pulse sequences TR/TE/TI 9000/84/2200ms; voxel size 
1.0 x 1.2 x 5.0mm, with an interslice gap of 1 mm);  a transversal T2*weighted gradient echo 
sequence (TR/ TE 800/26ms; voxel size 1.3 x 1.0 x 6.0mm, with an interslice gap of 1 mm) and 
a Diffusion Tensor Imaging (DTI) sequence (TR/TE 10100/93ms; voxel size 2.5x2.5x2.5mm; 4 
unweighted scans, 30 diffusion weighted scans with b-value = 900 s·mm-²).60
MRI  analysis
WMH were manually segmented on FLAIR images and the total WMH volume was calculated 
by summing the segmented areas multiplied by slice thickness. The ratings of lacunes and 
microbleeds were revised according to the recently published STRIVE-criteria, by trained 
raters blinded to all clinical data.12 Excellent intra and inter-rater reliabilities were found with 
weighted kappa of 0.87 and 0.95 respectively for the presence of lacunes and 0.85 and 0.86 
for the presence of microbleeds, calculated in 10 percent of the scans. Inter-rater reliability 
(assessed using the intra-class correlation coefficient) for total WMH volume was 0.99. 
To obtain the grey matter (GM), WM and cerebrospinal fluid (CSF) volume, segmentation of 
the T1 MPRAGE images was revised using a recent version of Statistical Parametric Mapping 
12 unified segmentation routines (SPM12; Wellcome Department of Cognitive Neurology, 
University College London, UK  (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/). All 
images were visually  checked for co-registration errors and for motion and/or segmentation 
artefacts. The intracranial volume (ICV) was calculated by summing the volumes of GM, WM 
and CSF, by multiplying the probabilistic tissue segmentations by the voxel volume. Total 
brain volume (TBV) was taken as the sum of total GM and WM. All volumes were normalized 
to total ICV. 
DTI-analysis
Diffusion data were pre-processed and analyzed according to an extensively earlier described 
procedure. 60 The diffusion weighted images of each participant were realigned on the 
unweighted image using mutual information based co-registration routines from SPM5. 
The diffusion tensor and its eigenvalues were computed using linear regression, using an 
SPM5 add-on (http://sourdeforge.net/projects/spmtools). The spurious negative values 
were set to zero, after which the tensor derivates MD and FA were calculated64 The mean 
unweighted image was used to compute the co-registration parameters to the anatomical T1 
image, (SPM5 mutual information co-registration), which were then applied to all diffusion 
weighed images and derivates. All images were visually checked for motion artefacts and 
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co-registration errors. The mean MD and FA were then calculated in the WMH, NAWM and 
total WM.
Other parameters
Education was classified using 7 categories (1 being less than primary school, 7 reflecting 
academic degree) and then dichotomized in a group having only or less than primary school 
and a group having more than primary education.65 Depressive symptoms were assessed 
with the 20-item Centre of Epidemiologic Studies Depression Scale (CES-D); they were 
considered present in participants with CES-D ≥ 16 and/or participants who currently used 
anti-depressive medication, taken for depression.48,60
Statistical analysis
Baseline characteristics are presented as mean and standard deviation (SD) for the 
participants who had a face-to-face follow-up and those without. For the WMH median 
and inter quartile range (IQR) is shown. Group-differences between participants and non-
participants are calculated with age and sex-adjusted ANOVA or logistic regression for 
categorical variables. The associations between baseline microstructural integrity of the 
NAWM and WMH and the decline in different cognitive domains were assessed by means of 
linear regression analysis. The variance inflation factor (VIF) was calculated for all regression 
models to investigate if multicollinearity was present. The VIF scores were low for all multiple 
regression models (scores below 3, where scores above 5 is considered high multicollinearity). 
Data were presented as standardized betas. To correct for multiple testing, Bonferroni 
correction was used, therefore α was set to 0.007. The analyses were adjusted for the possible 
confounders age, sex, education level, presence of depressive symptoms, TBV, lacunes and 
for WMH volume where appropriate. A secondary analysis using stepwise backward selection 
was performed to confirm these results. First, age, sex and education were forced into the 
model and a backward stepwise selection procedure was used on the full regression model 
to remove the variables from the model one at a time, until these had p values smaller than 
0.10. To investigate if the microstructural integrity of the WM played a different role in the 
decline in cognition in those who have limited cSVD on FLAIR MRI vs. those who have a 
higher degree of cSVD, we repeated this analysis in strata (tertiles) of WMH volume. A post-
hoc analysis was performed, using age and sex-adjusted ANOVA, to investigate whether the 
microstructural integrity within the WMH and NAWM of the 10% least decliners and the 10% 
worst decliners in cognitive index differed.
Results
Baseline demographics and neuro-imaging characteristics of the 398 participants in the in-
person follow-up examination and the 105 subjects who did not participate are shown in 
Table 1. Average mean follow-up duration was 5.4 years (SD 0.2; range 4.5 to 6.2). Participants 
who did not return for in person-follow-up were significantly older at baseline, had a higher 
CHAPTER 5
80
Table 1: Baseline characteristics study-population
Follow-up-
complete
No Follow-up 
examination
p-value for
difference^
Demographics (n=398) (n=105)
Age at baseline (SD) 64.5 (8.5) 70.0 (8.4) p<0.001
Sex, male (n, %) 227 (57.0) 57 (54.3) p=0.554ⁱ
Education, only primary (n,%) 33 (8.3) 16 (15.2) p=0.396ⁱ
MMSE (SD) 28.3 (1.6) 27.6 (1.8) p=0.042
Cognitive Index  (SD)*   0.10 (0.76) - 0.44 (0.70) p<0.001
Depressive symptoms (n,%)** 266 (67.5) 65 (62.5) p=0.378ⁱ
MRI characteristics (n=397) (n=105)
Intracranial volume, ml (SD) 1459.0 (134.7) 1445.9 (147.3) p=0.707
White matter volume, ml (SD) 468.0 (39.6) 450.9 (57.1) p =0.285
      WMH volume, ml (IQR)† 6.0 (3.2-15.1) 14.4 (6.0-27.2) p=0.004
      NAWM volume, ml (SD) 455.6 (43.4) 430.5 (62.6) p=0.055
Lacunes, presence (n, %) 90 (22.7) 44 (41.9) p=0.008ⁱ
Microbleeds, presence (n, %)*** 58 (14.6) 23 (21.9) P=0.502ⁱ
Territorial infarcts, presence (n, %) 40 (10.1) 16 (15.2) P=0.422ⁱ
Grey matter volume, ml (SD) 621.5 (49.9) 595.3 (48.7) p=0.022
Total brain volume, ml (SD) 1089.4 (70.3) 1046.2 (77.3) p=0.012
Hippocampal volume, ml (SD)**** 6.83 (0.94) 6.68 (0.97) p=0.879
Global DTI characteristics  ͤ (n=395) (n=104)
White matter, mean FA, (SD) 0.33 (0.02) 0.32 (0.02) p=0.029
      WMH, mean FA, (SD) 0.34 (0.03) 0.33 (0.03) p=0.424
      NAWM, mean FA, (SD) 0.33 (0.02) 0.32 (0.02) p=0.026
White matter, mean MD,(SD) 0.88 (0.04) 0.91 (0.04) p=0.012
     WMH, mean MD, (SD) 0.99 (0.06) 1.02 (0.07) p=0.172
     NAWM, mean MD, (SD) 0.88 (0.04) 0.91 (0.04) p=0.016
Data shown represent numbers of subjects (%), mean (SD) or median † (inter quartile range), ^age and 
sex adjusted where appropriate (ANOVA or logistic regressionⁱ). MMSE: Mini-mental State Examination, ml: 
millilitres, SD: standard deviation, WMH: White Matter Hyperintensities, NAWM: Normal Appearing White Matter, 
FA: Fractional Anisotropy, MD: Mean Diffusivity (10-3 mm2/s). Brain volumes represent normalized brain volumes 
to the total ICV. *one was excluded because of missing cognitive data ** five were excluded because of missing 
values of depressive symptoms, ***three were excluded because of missing values of microbleeds.**** three 
were excluded because of missing values of hippocampal volume.  ͤ3 were additionally excluded for the DTI 
analysis because of baseline DTI-scan artefacts. 
Bold values indicate significance at p < 0.05. They performed worse on the raw test scores of almost all cognitive 
domains at baseline compared with participants who participated (Supplementary Tables A and B).
WMH volume, more lacunes, lower GM volume and a lower microstructural integrity of the 
WM compared with those with follow-up examination, adjusted for age and sex. 
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They performed worse on the raw test scores of almost all cognitive domains at baseline 
compared with participants who participated (supplementary Table A and B). 
Figure 2 shows compound z-scores of the cognitive domains at baseline and follow-up. 
Decline in cognitive performance is observed in all domains except visuospatial memory and 
concept shifting.
A correlation matrix with the predictors in the dataset is presented as supplementary Table 
C.  Low microstructural integrity (measured by MD) in the NAWM was related to decline in 
cognitive index (β=0.17;p=0.035), adjusted for age, sex, education, presence of depressive 
symptoms at baseline, normalized TBV, lacunes and WMH volume, however this was no 
longer significant after Bonferroni correction. No significant relation was found between 
white matter microstructural integrity and decline in any of the other cognitive sub-domains, 
adjusted for the above mentioned confounders after Bonferroni correction (Table 2). There 
was no significant relation found between diffusion parameters in the total white matter and 
any of the cognitive domains. Backward stepwise selection of all models confirmed these 
results (data not shown).
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Baseline 
Follow-up 
Cognitive 
Index 
Verbal  
Memory 
Visuospatial 
memory 
Psychomotor 
speed 
Fluency Concept 
Shifting 
Attention 
No. of patients  388              379              376                381               389               360              375 
 
Figure 2: Composite z-scores at Baseline and Follow-up, bar represents Standard Error. Apart from the domains visuospatial memory and 
concept shifting, participants score on average worse on follow-up test than at baseline. z-scores of the follow-up are calculated with the 
mean and standard deviation from the baseline                     
  
bar represents 
Standard Error 
(SE) 
Figure 2: Composite z-scores at Baseline and Follow-up
Bar represents Standard Error. Apart from the domains visuospatial memory and concept shifting, participants 
score on average worse on follow-up test than at baseline. z-scores of the follow-up are calculated with the mean 
and standard deviation from the baseline
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After stratification in tertiles of baseline WMH severity, we did not find a relation between 
white matter microstructural integrity and cognitive decline, in those with mild, moderate 
and WMH load, adjusted  for the above mentioned confounders.(data not shown)
A post-hoc analysis investigating the microstructural integrity within the WMH and NAWM in 
the 10% with the least decline in cognitive index and the 10% highest decliners, showed no 
significant difference in the mean MD or FA in both the WMH and NAWM, adjusted for age and 
sex. 
Discussion
In older adults with cSVD, microstructural integrity in the white matter was not  related with 
decline in global cognitive performance in all separate cognitive domains after adjustment 
for possible confounders, after 5 years of follow-up. This finding was independent of WMH 
severity. This finding is in line with our previous findings, in which we found only limited 
additional value to conventional cSVD parameters in explaining the variance in cognitive 
function,43 and the lack of relation between diffusion parameters and incident dementia 
after 5 years.44 Probably other factors, apart from WM microstructural integrity play a role in 
cognitive decline over time. 
Several methodological issues must be addressed. First and foremost, 79.1% of the baseline 
study population was available at follow-up for cognitive testing. The dropout might lead to 
attrition bias, although the response rate is considered high after 5 years. Drop-outs at follow-
up were significantly older at baseline, performed less on cognitive testing at baseline and 
had a higher WMH volume, more lacunes and a lower microstructural integrity at baseline. 
Since these variables were independently associated with cognitive performance in other 
studies, 51,53,129 exclusion of drop-outs might resulted in an underestimation of the effect of 
WM integrity on several cognitive domains.  The above mentioned issue is a well known 
paradox of follow-up studies: To prove a causal relation over time, long follow-up is required, 
however, the longer the follow-up period, the higher the risk of selective drop-out, which 
itself reduces the magnitude of the effect. 
Second, the same cognitive tests have been administered at baseline and follow-up 
examination. Therefore it is possible that learning effects may have occurred. Especially 
cognitive tests with a memory-component are prone for this learning effect.140 We think this 
would have had little effect in our study, because of the relatively long interval between the 
two moments of testing, and because in almost all cognitive domains, participants declined 
(Figure 2), which would be the opposite when learning effects would have great impact. A 
strength of our study design is that we collected our data in a single centre, which allowed 
us to administer baseline and follow-up assessments according to identical procedures, 
using the same test-instructions and even interview-rooms, reducing measurement errors 
(non-systematic errors of the test score because of coincident fluctuations in concentration, 
motivation or mood, or differences in the test-procedure), as much as possible.140 Finally, 
we were not informed on the genetic APOE status, CSF biomarkers or PET scan at baseline 
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of our participants, which prevented us from further excluding possible neurodegenerative 
processes.  
Three prospective studies described the relation between diffusion parameters and cognitive 
decline preciously. First, a large prospective study in older adults with cSVD104 reported a 
relation between baseline diffusion parameters and decline in executive function, memory 
and speed after a follow-up period of 3 years, after adjustment for age, sex, education, 
TBV, WMH and lacunes. However, they did not take depressive symptoms into account as 
a possible confounding factor. This is especially relevant since the same authors reported 
that depressive symptoms predicted cognitive decline and dementia in their cohort.118 In 
our study, the adjustment for depressive symptoms weakened the associations between 
baseline microstructural integrity and cognitive decline. Additional analyses confirmed no 
mediation effect of depressive symptoms in this relation. This was not expected because 
the associations between depressive symptoms and worse cognitive performance in older 
participants has previously extensively been described. 141. Second, a small prospective study 
(n=35) with one-year follow-up in participants with cSVD found a relation between diffusion 
parameters and executive function at a cross-sectional level, however they could not relate 
diffusion parameters to cognitive decline,72 possibly by the relatively short follow-up period 
and small numbers. The third study (n=84) in middle-aged community dwelling individuals 
found no correlations between baseline DTI parameters and changes in working memory, 
but showed that decline in working memory was correlated to decline in DTI parameters after 
2 years.76 This study however did not adjust for possible confounders. Taking the previous 
findings into account, in the future it could be interesting to investigate if the change in 
microstructural integrity over time instead of the baseline microstructural status, causes 
cognitive decline.  
Finally we have to consider we missed the (very weak) association between baseline DTI 
parameters and cognitive decline, because of a type A error. Possibly due to limited power 
and selective drop-out at follow-up, which was in our study, despite the high response, 
20.9%. As a result, our sample may consist of participants with a relatively good health and 
cognitive performance at baseline who may have less chance to deteriorate in cognitive 
functioning over time. However in our study this seems to be not the case, for post-hoc 
analyses comparing the microstructural integrity in of the 10% least decliners versus the 10% 
who declined most at follow-up showed no difference in any of the diffusion parameters, 
both within the WMH or NAWM. Moreover, participants at follow-up with low test-scores 
because of cognitive problems or dementia, have had difficulties performing complex 
neuropsychological tests which may have resulted in missing data (such as task 3 of the 
Stroop or the Rey Complex Figure).  This may have resulted in an underestimation of the 
decline in the domains assessed by these tests, which might have weakened the strengths 
of the associations. Finally, the cognitive change profile in our study shows predominantly 
a change in verbal memory, which does not reflect the core profile of cSVD where deficits in 
executive function, such as speed and fluency, are most prominent. Probably other factors 
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than white matter microstructural integrity play a role in cognitive decline. Such a factor could 
be the microstructural integrity of other areas in the brain known to be related to cognitive 
performance, such as the hippocampus, as we previously showed.45 
In summary, in older adults with cSVD, microstructural integrity of the WM was not associated 
with decline in cognitive performance after a 5-year follow-up. These results are not in line 
with cross-sectional reports, and therefore unexpected. The lack of association might be due 
to a type A error, due to selective drop-out at follow-up, however this was not supported by 
a post-hoc analysis. Other factors than microstructural integrity of the white matter, might 
underlie cognitive decline in older adults with cSVD. 
CHAPTER 5
86
Su
pp
le
m
en
ta
ry
 T
ab
le
 A
:  
Ra
w
 te
st
-s
co
re
s o
f p
ar
ti
ci
pa
nt
s w
it
h 
bo
th
 b
as
el
in
e 
an
d 
fo
ll
ow
-u
p 
ex
am
in
at
io
n
Ba
se
lin
e 
(2
00
6-
20
07
)
Fo
llo
w
--
up
 (2
01
1-
20
12
)
Co
gn
iti
ve
 te
st
s
Al
l
Co
m
pl
et
ed
 b
ot
h
B 
an
d 
FU
 te
st
Co
m
pl
et
ed
 b
ot
h
B 
an
d 
FU
 te
st
M
in
i M
en
ta
l S
ta
te
 e
xa
m
in
at
io
n 
(r
an
ge
 0
-3
0)
28
.1
 (1
.6
)
28
.3
 (1
.6
)
27
.8
 (2
.8
)
Re
y 
Au
di
to
ry
 V
er
ba
l L
ea
rn
in
g 
Te
st
 (n
o.
 o
f w
or
ds
 re
ca
lle
d)
    
    
  i
m
m
ed
ia
te
 re
ca
ll 
tr
ia
l 1
    
    
  i
m
m
ed
ia
te
 re
ca
ll 
tr
ia
l 2
    
    
  i
m
m
ed
ia
te
 re
ca
ll 
tr
ia
l 3
    
    
  d
el
ay
ed
 re
ca
ll
5.
1 
(1
.8
)
7.
3 
(2
.3
)
8.
6 
(2
.6
)
6.
0 
(3
.1
)
5.
3 
(1
.7
)
7.
6 
(2
.2
)
9.
0 
(2
.4
)
6.
4 
(3
.0
)
3.
6 
(1
.6
)
5.
5 
(2
.1
)
6.
7 
(2
.4
)
3.
9 
(2
.7
)
St
ro
op
 C
ol
or
 W
or
d 
Te
st
 (t
im
e 
in
 se
c.
-fa
ul
ts
)
    
    
  p
ar
t 1
 (w
or
d 
re
ad
in
g)
    
    
  p
ar
t 2
 (c
ol
ou
r n
am
in
g)
    
    
  p
ar
t 3
 (i
nt
er
fe
re
nc
e)
25
.8
 (6
.3
) -
 0
.2
33
.2
 (7
.7
) -
 0
.2
63
.8
 (2
2.
1)
 - 
1.
0
25
.1
 (6
.1
) -
 0
.2
32
.2
 (7
.4
) -
 0
.2
59
.9
 (1
9.
4)
 - 
0.
9
26
.3
 (6
.0
) -
 0
.3
33
.4
 (8
.6
) -
 0
.4
60
.9
 (2
4.
1)
 - 
1.
1
Pa
pe
r P
en
ci
l M
em
or
y 
Sc
an
ni
ng
 T
as
k 
(t
im
e 
in
 se
c.
-fa
ul
ts
)
    
    
  1
 c
ha
ra
ct
er
    
    
  2
 c
ha
ra
ct
er
s
45
.2
 (1
3.
7)
 - 
0.
7
62
.4
 (1
9.
8)
 - 
3.
1
43
.2
 (1
2.
3)
 - 
0.
6
60
.3
 (1
7.
8)
 - 
2.
8
51
.9
 (1
8.
9)
 - 
0.
6
72
.7
 (2
7.
4)
 - 
2.
8
    
    
  3
 c
ha
ra
ct
er
s
77
.6
 (2
6.
8)
 - 
2.
6
74
.6
 (2
3.
8)
 - 
2.
5
90
.2
 (3
5.
8)
 - 
2.
1
Sy
m
bo
l D
ig
it 
Su
bs
tit
ut
io
n 
Ta
sk
 (n
o.
 in
 6
0 
se
c.
)
27
.0
 (9
.7
)
28
.5
 (9
.4
)
23
.2
 (8
.5
)
Ve
rb
al
 F
lu
en
cy
 (n
o.
 in
 6
0 
se
c.
)
    
    
    
 a
ni
m
al
s
    
    
    
 p
ro
fe
ss
io
ns
22
.0
 (6
.5
)
16
.5
 (5
.3
)
22
.6
 (6
.5
)
17
.1
0 
(5
.3
)
19
.2
 (5
.5
)
14
.3
 (5
.0
)
Ve
rb
al
 S
er
ie
s A
tt
en
tio
n 
Te
st
 (t
im
e 
in
 se
c.
 - 
fa
ul
ts
)
       
    
to
ta
l t
im
e 
96
.0
 (3
8.
2)
 - 
2.
4
90
.1
 (3
4.
6)
 - 
2.
1
95
.9
 (3
5.
5)
 - 
2.
3
Re
y 
Co
m
pl
ex
 F
ig
ur
e 
Te
st
 (r
an
ge
 0
-3
6)
    
   c
op
y 
tr
ia
l
    
   i
m
m
ed
ia
te
 re
ca
ll 
tr
ia
l
    
   d
el
ay
ed
 re
ca
ll 
tr
ia
l
33
.4
 (3
.4
)
18
.2
 (6
.8
)
18
.1
 (6
.6
)
33
.8
 (3
.0
)
18
.9
 (6
.6
)
18
.7
 (6
.5
)
33
.2
 (4
.3
)
18
.7
 (6
.8
)
18
.6
 (7
.0
)
N
um
be
rs
 re
pr
es
en
t m
ea
ns
 (S
D)
 . 
Dr
op
-o
ut
 ra
te
 fo
r c
ha
ng
e-
sc
or
e 
pe
r t
es
t, 
be
ca
us
e 
of
 b
as
el
in
e 
an
d/
or
 F
ol
lo
w
-u
p 
m
is
si
ng
 d
at
a.
 M
SS
E:
 0
%
, R
AV
LT
: 4
.5
%
, S
tr
oo
p 
7.
8%
, P
ap
er
 
Pe
nc
il 
Te
st
 6
.5
%
, S
DS
T 
4.
3%
, V
er
ba
l F
lu
en
cy
 1
.5
%
, V
SA
T 
5.
3%
, R
CF
T 
co
py
 tr
ia
l 2
.5
%
, d
el
ay
ed
 re
ca
ll 
tr
ia
l: 
8.
8%
.
WHITE MATTER INTEGRITY IS NOT RELATED TO COGNITIVE DECLINE
87
Ch
ap
te
r 5
Su
pp
le
m
en
ta
ry
 T
ab
le
 B
: C
og
ni
ti
ve
 d
om
ai
n 
sc
or
es
 a
t b
as
el
in
e 
of
 p
ar
ti
ci
pa
nt
s a
nd
 n
on
-p
ar
ti
ci
pa
nt
s a
t f
ol
lo
w
-u
p
BA
SE
LI
N
E
(2
00
6-
20
07
)
Fo
llo
w
-u
p-
co
m
pl
et
ed
N
o 
Fo
llo
w
-u
p 
ex
am
in
at
io
n
p-
va
lu
e 
fo
r
di
ffe
re
nc
e*
De
ce
as
ed
 
pa
rt
ic
ip
an
ts
 
Re
fu
se
rs
Co
gn
iti
ve
 d
om
ai
ns
 
Gl
ob
al
 co
gn
iti
ve
 fu
nc
tio
n
    
   M
M
SE
28
.3
 (S
D 
1.
6)
27
.6
 (S
D 
1.
8)
p=
0.
02
6
27
.2
 (S
D 
1.
9)
27
.9
 (S
D 
1.
7)
    
   C
og
ni
tiv
e 
In
de
x
0.
10
 (0
.7
6)
- 0
.4
4 
(0
.7
0)
p<
0.
00
1
-0
.7
1 
(S
D 
0.
72
)
-0
.2
3 
(S
D 
0.
61
)
M
em
or
y
    
   V
er
ba
l m
em
or
y
0.
11
 (S
D 
0.
92
)
-0
.4
2 
(S
D 
0.
94
)
p<
0.
00
1
-0
.7
6 
(S
D 
0.
94
)
-0
.1
8 
(S
D 
0.
85
)
    
   V
is
uo
sp
at
ia
l m
em
or
y
0.
07
 (S
D 
0.
97
)
-0
.3
4 
(S
D 
1.
01
)
p=
0.
05
1
-0
.3
9 
(S
D 
0.
99
)
-0
.2
9 
(S
D 
1.
05
)
Ex
ec
ut
iv
e 
fu
nc
tio
n 
an
d 
at
te
nt
io
n
    
   P
sy
ch
om
ot
or
 sp
ee
d
0.
10
 (S
D 
0.
85
)
-0
.4
6 
(S
D 
0.
78
)
p<
0.
00
1
-0
.6
8 
(S
D 
0.
76
)
-0
.2
7 
(S
D 
0.
78
)
    
   F
lu
en
cy
0.
10
 (S
D 
0.
92
)
-0
.4
0 
(S
D 
0.
81
)
p=
0.
00
1
-0
.4
8 
(S
D 
0.
87
)
-0
.3
0 
(S
D 
0.
76
)
    
   I
nh
ib
iti
on
 (c
on
ce
pt
 sh
ift
in
g)
0.
07
 (S
D 
0.
94
)
-0
.2
7 
(S
D 
1.
17
)
p=
0.
54
4
-0
.3
9 
(S
D 
1.
01
)
-0
.2
1 
(S
D 
1.
30
)
    
   A
tte
nt
io
n
0.
11
 (S
D 
1.
01
)
-0
.4
3 
(S
D 
0.
84
)
p=
0.
00
1
-0
.3
7 
(S
D 
0.
85
)
-0
.4
7 
(S
D 
0.
84
)
Da
ta
 sh
ow
n 
re
pr
es
en
t c
om
po
si
te
 Z
-s
co
re
s o
f d
iff
er
en
t n
eu
ro
ps
yc
ho
lo
gi
ca
l t
es
ts
 to
 c
al
cu
la
te
 c
og
ni
tiv
e 
do
m
ai
ns
, *
 a
ge
 a
nd
 se
x 
ad
ju
st
ed
 d
iff
er
en
ce
 b
et
w
ee
n 
pa
rt
ic
ip
an
ts
 w
ith
 
an
d 
w
ith
ou
t F
ol
lo
w
-u
p 
pa
rt
ic
ip
at
io
n 
(A
N
CO
VA
). 
M
M
SE
: M
in
i-m
en
ta
l S
ta
te
 E
xa
m
in
at
io
n,
 m
l: 
m
ill
ili
tr
es
, S
D:
 st
an
da
rd
 d
ev
ia
tio
n.
 C
om
po
si
te
 Z
-s
co
re
 o
f F
ol
lo
w
-u
p 
is
 st
an
da
rd
iz
ed
 
to
 th
e 
ba
se
lin
e;
 (F
U
-te
st
 –
 m
ea
n 
Ba
se
lin
e)
 /(
SD
 B
as
el
in
e)
. 
CHAPTER 5
88
Su
pp
le
m
en
ta
ry
 T
ab
le
 C
:  
Co
rr
el
at
io
n 
co
ef
fi
ci
en
ts
 fo
r d
em
og
ra
ph
ic
al
 a
nd
 im
ag
in
g 
pr
ed
ic
to
rs
Ag
e
Ed
uc
at
io
n
De
pr
es
si
ve
sy
m
pt
om
s
TB
V,
 
m
L
La
cu
ne
s 
W
M
H
 
Vo
lu
m
e 
▲
N
AW
M
 
m
ea
n 
M
D
W
M
H
 
m
ea
n 
M
D
W
M
 
m
ea
n 
M
D
N
AW
M
 
m
ea
n 
FA
W
M
H
 
m
ea
n 
FA
Ag
e
…
Ed
uc
at
io
n
-0
.2
0*
*
…
De
pr
es
si
ve
Sy
m
pt
om
s
0.
01
- 0
.2
1*
*
…
TB
V,
 m
L
-0
.6
2*
*
0.
13
*
0.
02
…
La
cu
ne
s,
 
(p
)
0.
18
**
- 0
.0
8
0.
04
-0
.2
7*
*
…
W
M
H
 
Vo
lu
m
e
0.
47
**
- 0
.1
8*
0.
05
-0
.3
9*
*
0.
40
**
…
N
AW
M
 
m
ea
n 
M
D
0.
26
**
-0
.0
4
-0
.0
1
-0
.6
3*
*
0.
30
**
0.
57
**
…
W
M
H
 m
ea
n 
M
D
0.
41
**
-0
.1
1*
0.
02
-0
.5
8*
*
0.
28
**
0.
57
**
0.
73
**
…
W
M
 
m
ea
n 
M
D
0.
27
**
-0
.1
8*
*
0.
00
-0
.6
3*
*
0.
30
*
0.
61
**
1.
00
**
0.
86
**
…
N
AW
M
 
m
ea
n 
FA
-0
.2
6*
*
0.
14
*
-0
.0
9
0.
20
**
-0
.2
2*
*
-0
.5
3*
*
-0
.7
3*
*
-0
.6
8*
*
-0
.7
4*
*
…
W
M
H
 m
ea
n 
FA
-0
.2
9*
*
0.
14
*
-0
.1
2*
0.
26
**
-0
.2
3*
*
-0
.4
0*
*
-0
.4
2*
*
-0
.5
5*
*
-0
.4
3*
*
0.
58
**
…
W
M
 
m
ea
n 
FA
-0
.2
6*
*
0.
14
* 
-0
.0
9
0.
20
**
-0
.2
2*
*
-0
.5
3*
*
-0
.7
3*
*
-0
.6
8*
*
-0
.7
4*
*
1.
00
**
0.
59
**
*c
or
re
la
tio
n 
is
 s
ig
ni
fic
an
t 
at
 2
-ta
ile
d 
p<
0.
05
; *
*p
<0
.0
01
. F
or
 b
in
ar
y 
ch
ar
ac
te
ris
tic
s 
a 
Sp
ea
rm
an
 R
ho
 is
 u
se
d,
 w
he
re
as
 fo
r 
th
e 
co
nt
in
uo
us
 v
ar
ia
bl
es
 a
 P
ea
rs
on
 C
or
re
la
tio
n 
co
eff
ic
ie
nt
 is
 s
ho
w
n.
 E
du
ca
tio
n:
 o
nl
y 
pr
im
ar
y 
ed
uc
at
io
n,
 D
ep
re
ss
iv
e 
sy
m
pt
om
s:
 p
re
se
nc
e 
of
 d
ep
re
ss
iv
e 
sy
m
pt
om
s,
 T
BV
: t
ot
al
 b
ra
in
 v
ol
um
e,
 L
ac
un
es
: p
re
se
nc
e 
of
 la
cu
ne
s,
 
W
M
H
: W
hi
te
 m
at
te
r h
yp
er
in
te
ns
iti
es
, ▲
 lo
g 
tr
an
sf
or
m
ed
, N
AW
M
: n
or
m
al
 a
pp
ea
rin
g 
w
hi
te
 m
at
te
r, 
M
D:
 m
ea
n 
di
ffu
si
vi
ty
, F
A:
 F
ra
ct
io
na
l A
ni
so
tr
op
y,
 W
M
: w
hi
te
 m
at
te
r. 
N
ot
e 
th
e 
in
cl
us
io
n 
of
 a
ll 
th
e 
DT
I m
ea
su
re
s (
FA
 a
nd
 M
D 
w
ith
in
 W
M
H
 a
nd
 N
AW
M
) i
n 
th
e 
m
at
rix
, t
ho
ug
h 
th
es
e 
m
ea
su
re
s w
er
e 
no
t i
nc
lu
de
d 
to
ge
th
er
 in
 a
 re
gr
es
si
on
 m
od
el
. 
WHITE MATTER INTEGRITY IS NOT RELATED TO COGNITIVE DECLINE
89
Ch
ap
te
r 5

Part III: 
Depressive symptoms in cerebral SVD 
and its relation with cognition 

6.
Depressive symptoms and amygdala volume in 
elderly with cerebral small vessel disease
Ingeborg W.M. van Uden, Anouk G.W. van Norden, Karlijn F. de Laat, Lucas J.B. van 
Oudheusden, Rob A.R. Gons, Indira Tendolkar, Marcel P. Zwiers and Frank-Erik  de Leeuw
Journal of Aging Research 2011;(1-7):647869
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Abstract
Introduction: Late onset depressive symptoms (LODS) frequently occur in elderly 
with cerebral small vessel disease (cSVD). cSVD cannot fully explain LODS, therefore a 
contributing factor could be amygdala volume. We investigated  the relation between 
amygdala volume and LODS, independent of cSVD in 503 participants with symptomatic 
cerebral SVD. 
Methods: Patients underwent FLAIR and T1 scanning. Depressive symptoms were 
assessed with structured questionnaires, amygdala and WML were manually segmented. 
The relation between amygdala volume and LODS and early onset depressive symptoms 
(EODS) was investigated and adjusted for age, sex, intracranial volume(ICV) and cSVD.  
Results: Participants with LODS had a significantly lower left amygdala volume than 
those without (1.6 mL (SD 0.3) vs. 1.8 mL (SD 0.5); p = 0.02), independent of cSVD. Each 
decrease of total amygdala volume (by mL) was related to a increased risk of LODS (OR = 
1.77; 95%CI 1.02-3.08; p = 0.04).
Conclusion: Lower left amygdala volume is associated with LODS, independent of cSVD. 
This may suggest differential mechanisms, in which individuals with a small amygdala 
might be vulnerable to develop LODS. 
AMYGDALA VOLUME AND DEPRESSIVE SYMPTOMS 
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Introduction
A first depressive episode at older age is defined as late onset depressive symptoms (LODS). 
LODS are usually defined by their occurrence after the age of 60 years, while early onset 
depressive symptoms (EODS) appear before. The prevalence of LODS and EODS ranges 
from 10% to 32% in the elderly population.67,142-144 Patients with EODS show a higher rate 
of family history of depression than patients with LODS, therefore genetic factors appear to 
be important. While psychological and genetic factors presumably play an important role 
in EODS,38 there are probably other non-genetic factors that play a role in LODS such as 
structural changes in the brain.37,38,145,146
Population-based neuroimaging studies suggest a possible role for frequently occurring 
white matter lesions (WMLs) in the aetiology of LODS.36,147-149 Their dominant view is that 
WMLs disrupt white matter tracts connecting cortical and subcortical structures (e.g., fronto-
striatal circuits), which result in LODS.150,151 
As WML are part of the cerebral small vessel disease (cSVD) spectrum, also including lacunar 
infarcts, it could be that the association between WML and LODS is driven by lacunar infarcts 
as they reflect more severe structural damage than WML. In addition, cSVD might not fully 
explain the presence of depressive symptoms in elderly as there are patients with LODS 
without cSVD.
A functional or structural change in the amygdala may explain the residual depressive 
symptoms as the amygdala is involved in mood regulation, and structural MRI 
studies showed a lower amygdala volume in patients with both LODS and EODS 
than in healthy controls.152-155 However, these studies did not adjust for the possible 
confounding role of cSVD. Conversely, none of the population-based studies 
investigating cSVD and LODS, took amygdala volume into account. We therefore 
aimed to investigate the association between amygdala volume and the presence 
of depressive symptoms in older adults with cSVD, with adjustment for degree of 
this cSVD. 
Patients and Methods
Study population
The Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort 
(RUN DMC) study is a prospective cohort study that investigates the risk factors and cognitive, 
motor, and mood consequences of functional and structural brain changes among elderly 
with cerebral SVD.
Cerebral SVD is characterized on neuroimaging by either WML or lacunar infarcts. Symptoms 
include acute symptoms, such as transient ischemic attacks (TIAs) or lacunar syndromes, 
or sub acute manifestations, such as cognitive, motor (gait) and/or mood disturbances.34 As 
the onset of cerebral SVD is often insidious, clinically heterogeneous and typically with mild 
symptoms, it has been suggested that the selection of subjects with cerebral SVD in clinical 
studies should be based on the more consistent brain imaging features.61 
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Accordingly, in 2006, consecutive patients who visited the department of neurology, between 
October 2002 and November 2006, were selected for participation. Inclusion criteria were 
(a) age between 50 and 85 years; (b) cerebral SVD on neuroimaging (WML and/or lacunar 
infarcts). Subsequently the above-mentioned acute or sub acute clinical symptoms of SVD 
were assessed by standardized structured assessments. Patients who were eligible because 
of a lacunar syndrome were included only >6 months after the event to avoid acute effects 
on the outcomes. 
Exclusion criteria were (a) dementia and (b) Parkinson(ism) according to the international 
diagnostic criteria;85,156,157 (c) life expectancy of less than six months; (d) intracranial space 
occupying lesion; (e) (psychiatric) disease interfering with cognitive testing or follow-up; 
(f) recent or current use of acetylcholine-esterase inhibitors, neuroleptic agents, L-dopa, or 
dopa-a(nta)gonists; (g) WML mimics (e.g., multiple sclerosis and irradiation induced gliosis); 
(h) prominent visual or hearing impairment; (i) language barrier; ( j) MRI contraindications or 
known claustrophobia.
Patients were selected in a three-step approach. After reviewing medical records 1004 
individuals were invited by letter, 727 were eligible after contact by phone, and 525 agreed 
to participate. In 22 subjects exclusion criteria were found during their visit to our research 
centre (14 with unexpected claustrophobia, one died before MRI scanning, one was diagnosed 
with multiple sclerosis, in one there was a language barrier, one subject fulfilled the criteria 
for Parkinson’s disease, and four met the dementia criteria), yielding a response of 71.3% 
(503/705). From these 503 individuals one group had symptoms of TIA or lacunar syndrome 
(n = 219), and the remaining (n = 284) had cognitive disturbances, motor disturbances, 
depressive symptoms, or a combination thereof. All participants signed an informed consent 
form. The Medical Review Ethics Committee region Arnhem-Nijmegen approved the study.
MRI acquisition
Imaging was performed on a 1,5 Tesla MRI scanner (Magnetom, Sonata; Siemens Medical 
Solutions, Erlangen, Germany). The protocol included 3D MPRAGE imaging (TR/TE/TI 
2250/3.68/850 ms; flip angle15◦; voxel size 1.0 × 1.0 × 1.0mm) and fluid attenuated inversion 
recovery (FLAIR) sequences (TR/TE/TI 9000/84/2200 ms; voxel size 1.0×1.2×5.0 mm, with an 
interslice gap of 1.0 mm). All scans were performed on the same scanner.
Amygdala volumetry
One investigator, blinded to the clinical and other imaging data (IvU), performed manual 
segmentation of the amygdala, using the interactive software program “ITK-SNAP”88 (http://
www.itksnap.org/). Briefly, this program allowed simultaneous viewing of volumes in coronal 
sagittal and transversal view, thereby permitting a neat handling of anatomical borders while
segmenting the regions of interest. Left and right amygdalae were manually segmented 
in the coronal plane, from posterior to anterior. Next, segmentations were reviewed in the 
sagittal plane, because then boundaries were better visualized.158-160 Segmentation was 
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performed according to previously published protocols,160,161 and the correct segmentation 
of anatomical boundaries was 161,162 In short, the first slice of the amygdala, the posterior 
border, was identified superior to the hippocampus at the point where the white matter first 
starts to appear superior to the alveus and laterally to the hippocampal head. The anterior 
border of the amygdala was defined at the level where the amygdala no longer has an ovoid 
shape. The medial border is marked by the medial margin of the temporal lobe, which 
borders cerebrospinal fluid (CSF). The lateral/inferior border is the surrounding white matter 
and the inferior horn of the lateral ventricle. The amygdala and hippocampus were carefully 
separated on the sagittal view, moving from the medial to the lateral side of the brain.
Segmentations were done in a standardized way by rating the left amygdala first for half of 
the participants and the right amygdala first for the other half. Volume was calculated for 
the left and right amygdala separately by summing all segmented areas, multiplied by slice 
thickness. Intrarater on a random sample yielded an intra-class correlation coefficient for 
both left and right amygdala of 0.8. 
WML volumetry and lacunar infarcts
White matter signal hyperintensities on FLAIR scans, which were not, or only faintly hypo-
intense on T1-weighted images, were considered WML, except for gliosis surrounding infarcts. 
WMLs were manually segmented on transversal FLAIR images, by 2 trained raters, (IvU, LvO), 
blinded for all clinical data and amygdala volumes. Total WML volume was calculated in 
the same fashion as for both amygdalae. Inter-rater variability for total WML volume was 
determined on a random sample of ten percent and yielded an intra-class correlation 
coefficient of  0.99. 
Lacunar infarcts were defined as areas with a diameter >2mm and <15mm with low signal 
intensity on FLAIR and T1, ruling out enlarged perivascular spaces and infraputaminal 
pseudolacunes.163 Evaluation of infarcts was performed by one person, with a good intra-rater 
variability with a weighted kappa of 0.80. In ten percent of the scans inter-rater variability was 
calculated with a weighted kappa of 0.88.
Brain volumetry
Gray (GM), white matter (WM) tissue and CSF probability maps were computed using SPM5 
routines (Wellcome Department of Cognitive Neurology, University College London, UK). 
Total GM, WM and CSF volumes were calculated by summing all voxel volumes that had a p > 
0.5 for belonging to the tissue class. Intra-cranial volume (ICV) was taken as the sum of total 
GM, WM and CSF. 
Assessment of depressive symptoms 
Depressive symptoms were assessed with the Centre of Epidemiologic Studies Depression 
Scale (CES-D).164 Depressive symptoms were considered present in patients with a CES-D score 
≥ 16 and/or current use of anti-depressive medication, taken for depression, irrespective of 
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their actual CES-D score, because depressive symptoms were considered to be the indication 
for the medication prescription.
In addition, all patients were asked about their history of depressive episodes. If depressive 
episodes had occurred, the patients were asked for the age of onset and whether the 
episodes had prompted them to seek medical advice. A history of depression was considered 
present if depressive episodes in the past had required attention of a general practitioner, 
psychologist, or psychiatrist.67
According to the literature we used the age of 60 years as cut-off point to distinguish between 
LODS and EODS.67 Patients at the age or older than 60 years with a CES-D ≥ 16 and/or current 
use of anti-depressive medication, taken for depression, without a history of depressive 
episodes before or at the age of 60, were classified as having LODS. Individuals with a 
CESD < 16, without a history of depressive symptoms and without the current use of anti-
depressive medication, formed the reference group. All others fulfilled the criteria for EODS 
(first depressive episode <60 years). 
Statistical analysis
We compared the amygdala and WML volumes (overall, left, right) between the EODS and 
LODS group with the reference using ANCOVA. Adjustments for age, sex, ICV, WML (or amygdala 
volume with WML being dependent variable) and presence of lacunar infarcts were made.
The risk of LODS and EODS per millilitre increases in amygdala volume, WML volume, and 
presence (yes/no) of lacunar infarcts was calculated (expressed as the odds ratio (OR) with a 
95% confidence interval) by means of age, sex, ICV, adjusted logistic regression analysis with 
additional adjustment for the appropriate structural MRI measures (WML volume, lacunar 
infarcts or amygdala volume).  All data were analyzed using SPSS statistical software, version 
16.0. P-values < 0.05 were considered statistical significant. 
Results
Of the 503 patients one was excluded because of an automatic segmentation problem that 
could not be solved manually. Two patients did not complete the CES-D questionnaire and of 
two patients the history of depression was not known. There were 101 individuals with LODS 
(20.3%) and 108 with EODS (21.7%); the reference group comprised 289 persons (58.0%).
Demographic and neuroimaging characteristics of 498 patients are shown in Table 1. Mean 
age of the population was 65.6 years (SD 8.8), and 56.4% were male. Mean age of the LODS 
group was 71.4 years and of the EODS group 59.1 years. Mean age of onset of EODS was 45.1 
years (SD 10.9). 
Total amygdala volume was 3.4mL (SD 0.5), and mean volume of left amygdala was 1.8mL (SD 
0.3) and differed significantly (P < 0.001), from the right amygdala 1.6 mL (SD 0.3). Amygdala 
volume decreased significantly with age (β = −0.34; P < 0.001), and women had smaller 
amygdala (3.2 mL; SD 0.4) than men (3.5 mL; SD 0.5; P < 0.001). 
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Table 2 shows that patients with LODS had a higher WML volume (21.8mL; SD 20.2) than the 
reference group (14.7mL; SD 18.0), although not significant (P = 0.06). Independent of cSVD, 
patients with LODS had a significant lower left amygdala volume (1.6mL; SD 0.3; P = 0.017) 
than the reference group (1.8 mL; 0.28); this difference was not found for the right amygdala 
(1.5mL; SD 0.3, P = 0.432).
Patients with EODS did not differ from the reference group with respect to WML volume, 
amygdala volume and the proportion of lacunar infarcts. We found no significant differences 
between left, right and total amygdala volume, WML volume and presence of lacunar infarcts 
between patients with LODS and EODS.
Table 3 shows the risk of LODS and EODS and per mL decrease in total, left, and right 
amygdala volume, WML volume (mL), and presence of lacunar infarcts. Each decrease of 
both total and left amygdala volume (mL) showed a significant increased risk of the presence 
of LODS (OR = 1.77; 95%CI 1.02–3.08; P = 0.04, in total amygdala volume and OR 2.92; 95%CI 
1.22–7.01; P = 0.02 in left amygdala volume), independent of cSVD. In addition, there was a 
nearly significant (P = 0.08) increased risk for LODS per increase of WML volume. This was not 
found for EODS and decrease of amygdala volume (OR = 0.95; 95CI 0.56–1.61; P = 0.86) per 
increase of WML volume, or presence of lacunar infarcts.
Table 2: Adjusted mean Amygdala volume, White Matter Lesions (WML) volume and Lacunar Infarcts 
in patients with Late Onset Depressive Symptoms (LODS), Early Onset Depressive Symptoms (EODS) 
and patients without depressive symptoms
Patients 
with LODS
(n=101)
p-value †
Patients with 
EODS
(n=108)
p-value †
Reference 
group
(n=289)
Total amygdala 
volume(mL) *   
Left amygdala (mL)*
Right amygdala (mL)*
 
WML volume (mL)** 
Lacunar infarcts (%)***
3.2 (0.5)
1.6 (0.3) 
1.5 (0.3)
21.8 (20.2)
32.9%
0.05
0.02
0.43
0.06
0.42
3.5 (0.5)
1.8 (0.3)
1.7 (0.3)
9.5 (13.8)
35.8%
0.82
0.71
0.90
0.94
0.47
3.4 (0.5)
1.8 (0.28)
1.6 (0.28)
14.7 (18.0)
32.0%
Number represent mean (SD) or number. Data is shown of the comparison of LODS/EODS versus the reference 
group * adjusted for age, sex, ICV , WML volume and presence of  lacunar infarcts , ** adjusted for age, sex, ICV, 
presence of lacunar infarcts and amygdala volume, *** adjusted for age, sex, ICV, WML and amygdala volume. † 
compared with the reference group.
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Table 3: The risk of LODS and EODS per decrease in amygdala volume, white matter lesion (WML) 
volume and lacunar infarcts.
Patients with LODS
(n=101)
Patients with EODS
(n=108)
OR                 95% CI OR                 95% CI
Total amygdala volume*
Left amygdala volume*
Right amygdala volume*
1.77             1.02 - 3.08 †
2.92             1.22 – 7.01 †
1.53             0.59 – 4.03 
0.95                 0.56 – 1.61
0.98                 0.41 – 2.30
0.85                 0.34 – 2.14
WML volume**
Lacunar infarcts ***
0.99             0.97 – 1.00
1.32             0.78 – 2.23
1.01                 0.99 – 1.03
0.80                 0.46 – 1.39
Number represent odds ratio (OR), 95% confidence interval (CI); * adjusted for age, sex, WML, ICV volume and 
presence of lacunar infarcts; ** adjusted for age, sex, total amygdala volume, ICV and presence of lacunar 
infarcts; *** adjusted for age, sex, ICV, WML and  amygdala volume; † significance p < 0.05
Discussion
In this study of 498 elderly patients with cerebral SVD, left amygdala volume was related to 
LODS, independent of WML volume and the presence of lacunar infarcts; this was not found 
for EODS and amygdala volume (left, right nor total). 
Before conclusions can be drawn, there are some methodological issues that need to be 
addressed. The proportion of patients with depressive symptoms in our study is relatively 
high (42%) for LODS and EODS together. In other studies the proportion of patients with 
depressive symptoms varies between 9.6%–32%.67,142-144,165 A possible explanation for our 
relatively high proportion of patients with depressive symptoms could be the fact that we 
purposely included patients on the basis of presence of cSVD; consequently the median 
degree of WML volume in our study is higher than in population-based studies.6 As these 
lesions are related to LODS it seems reasonable to expect a concomitant increased presence 
of depressive symptoms. Our finding of the (borderline significant) association between 
WML volume and LODS is in line with findings from these population-based studies.67,142,166 
Another explanation is that we classified patients as suffering from depressive symptoms 
once they had had a depressive episode in their medical history or when they used anti-
depressive drugs at baseline examination (while previous studies usually did not assess 
detailed information on the use of medication).167 The third explanation could be that we 
included patients with a history of lacunar stroke and transient ischemic attacks. It is known 
that in this population the prevalence of depressive symptoms is higher compared to the 
general population.168 
To elucidate the etiological mechanisms of LODS its current widely used definition suffers 
from a conceptual problem, due to the fact that age during the first depressive episode 
determines the classification. It could very well be that recovery after EODS occurs while 
depressive symptoms develop again after sixty years of age. Despite the fact that these 
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patients still fulfil the definition of EODS because of their history, they may have developed 
their LODS on the basis of another underlying pathology including cSVD. This could have led 
to overrepresentation of WML among the EODS group. 
There is a conceptual problem with LODS and EODS. By definition the EODS sample included 
many subjects with major depression. All had consulted a doctor or were at one time treated 
with antidepressants. By contrast, the LODS sample was defined primarily by the CES-D score 
(and/or current antidepressant use). Some may have had major depression and some minor 
depression. These potential differences may affect results both ways.
Another limitation is the cross-sectional nature of our study, which prevents us from proving 
causality. The RUN DMC study has a longitudinal design, and follow-up is already planned to 
evaluate the effect of brain changes on depressive symptoms.60
Strengths of our study include its design of a homogeneous population that covers the 
whole spectrum of cerebral SVD, its size and high response rate of over 70%, and the use of a 
single expert who segmented the amygdala, blinded to clinical information. Particularly the 
definition of the anatomic boundaries of the amygdala is a notorious problem in amygdala 
segmentation. Our use of one single, experienced rater minimized the effect of differential 
segmentation between several raters thereby limiting the effect misclassification. Our results 
are in line with those from meta-analyses on amygdala volume in nonclinical samples that 
found a mean volume of both left and right amygdala in 39 studies of 1.7 mL, with a range 
from 1.0 to 3.9mL.161
Although the amygdala is critical to the interpretation of emotion153,154 and implicated in 
mood disorders, volumetric studies of the amygdala in patients with mood disorders have 
provided inconsistent results.155 Studies of chronic or recurrent depressive patients have 
found identical,169,170 smaller171-173 but also larger174 amygdala volumes compared to controls. 
Post-mortem studies showed a smaller amygdala in depressed patients compared to 
controls, probably due to fewer glial cells.152
Our data showed a significant relationship with LODS and left amygdala volume; we did not 
find this relation with the volume of the right amygdala. This is concordant with previous 
neuroimaging and post-mortem studies that have reported left lateralized atrophy in the 
prefrontal cortex and amygdala in mood disorders,152,173,175,176 however previous results are 
inconclusive as others also report on an association between a decrease in right amygdala 
volume and mood.172 In addition some functional imaging studies have shown lateralization, 
with activation of the left amygdala, in relation to emotion and emotional information 
processing.177,178 
A possible explanation for a smaller amygdala in patients with LODS could be the coexistent 
cSVD, abnormalities in blood flow, metabolism, and neurotransmitter receptors179,180 which 
may, either directly or indirectly, lead to amygdala atrophy. Intact connectivity of the fronto-
striatal circuits is important in mood regulation.151,181 According to the “vascular depression” 
hypothesis151,166 cSVD, that tends to have a high prevalence in the fronto-striatal regions, 
disrupts fibre tracts within these circuits, probably leading to depressive symptoms.36,166 
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There are two other studies that investigated the role of amygdala morphometry in LODS 
patients. One study showed that, despite insignificant amygdala volumetric findings, 
variations of amygdala shape can be detected and localized.182 They investigated so in 11 
healthy elderly individuals and 14 depressed elderly individuals. A population-based cohort 
study found a relation between a history of depression, particularly early onset, and an 
increased risk of for Alzheimer’s disease; however this risk was not mediated by smaller 
hippocampal or amygdala volumes at baseline165. In contrast to our results they did not 
find a relation between a history of depression or depressive symptoms at baseline and 
smaller amygdala volume. As discussed earlier, this could be because of the difference in 
degree of cSVD between this population-based cohort and our study sample in which we 
included only subjects with some degree of cSVD. As amygdala volume is related to the 
degree of cSVD,183 our study sample will probably have smaller amygdalae. In addition there 
was a difference in WML segmentation, most studies used semi-quantitative methods, and 
in contrast we manually segmented the WML volume. This in combination with the higher 
proportion of depressive symptoms in our study sample (42% versus 27%) can explain the 
relation we found between amygdala volume and LODS in contrast to the findings of this 
population-based cohort. Finally, the relation between LODS and amygdala volume in our 
cohort was mainly driven by the left amygdala, while this population-based cohort summed 
both amygdalae in their analysis. 
In conclusion, amygdala volume is associated with LODS, independent of cSVD and not 
with EODS. Future research should consist of prospective studies in order to assess whether 
baseline presence of cSVD increases the risk of amygdala atrophy at follow-up and whether 
this coincides with LODS. Innovative MRI techniques including diffusion tensor imaging (DTI) 
could offer promising tools in order to identify white matter tracts between the amygdala and 
other parts of the brain and the effects of cSVD in those tracts with respect to the incidence 
of LODS. 
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Abstract
Objectives:  Depressive symptoms are common in elderly with cerebral small vessel 
disease (cSVD). As not every individual with cSVD experiences depressive symptoms, 
other factors might play a role.  We therefore investigated the white matter (WM) integrity 
of the white matter tracts in elderly in elderly with depressive symptoms, independent of 
global cognitive function, by applying the tract-based spatial statistics (TBSS). 
Design: Prospective cohort study with cross-sectional baseline data.
Setting: Radboud University Nijmegen Medical Centre, The Netherlands.
Participants: 438 individuals between 50-85 years, with cSVD without dementia.
Measurements: Diffusion tensor imaging parameters and depressive symptoms, 
assessed with the Centre of Epidemiologic Studies Depression Scale.
Results: Compared to non-depressed participants (n=287), those with depressive 
symptoms (n=151) had lower fractional anisotropy in the genu and body of the corpus 
callosum, bilateral inferior fronto-occipital fasciculus, uncinate fasciculus and corona 
radiata. These differences disappeared after adjustment for white matter hyperintensities 
(WMH) and lacunar infarcts. Mean-, axial- and radial diffusivity were higher in these areas 
in participants with depressive symptoms. After additional adjustment for WMH  and 
lacunar infarcts, the changes observed in radial diffusivity also disappeared. Adding 
global cognition, as confounding variable altered the diffusion parameters only slightly.
Conclusions:  This study indicates that elderly with depressive symptoms show a lower 
WM integrity, independent of global cognitive function, and that the presence of cSVD is 
mostly responsible, affecting the fronto-subcortical regions and hereby disrupting the 
neural circuitry involved in mood regulation.
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Introduction
Cerebral small vessel disease (cSVD), including amongst others white matter hyperintensities 
(WMHs) and lacunar infarcts, is commonly seen in the elderly.6 Cognitive and motor 
impairment are known consequences of cSVD. The relation between cSVD and depressive 
symptoms is however less known.36,67,184 Depressive symptoms are also common in the 
elderly, with a prevalence ranging from 1% to 35%.67,185 cSVD might cause disruption of the 
fronto-striatal white matter tracts of the neural circuit mediating emotion perception and 
mood regulation, and thereby increases the risk of developing depressive symptoms in an 
older individual.39,186 However, as not every individual with cSVD experiences depressive 
symptoms, other factors apart from cSVD-related lesions seen on conventional MRI might 
be related to depressive symptoms at older age. One of these factors could be damage to 
the structural integrity of the normal-appearing white matter (NAWM) surrounding the WMH, 
which cannot be assessed by conventional MRI. 
This microstructural organization of the WM, including the NAWM can now be assessed by 
diffusion tensor imaging (DTI), an MRI technique, that provides valuable information on the 
microstructural organization of the WM, including the NAWM by measuring the molecular 
motion (diffusion) of water in biological tissue.80 Several common DTI-derived indices can 
be measured indexing global characteristics of WM integrity, such as fractional anisotropy, 
mean, radial and axial diffusivity and mode of anisotropy. 
To date, relatively few DTI studies have examined the microstructural integrity of WM in patients 
with depressive symptoms later in life.187-190 These studies reported compromised integrity of 
the WM in regions involved in emotional processing. However, these studies did not have 
large sample size (n<48), only used the fractional anisotropy as a global measure, and did not 
adjust for the possible confounders such as WM lesions and cognitive performance.187,191,192 
Tract Based Spatial Statistics (TBSS) can be used to investigate the structural integrity, by 
projecting the DTI indices on a virtual skeleton that is located at the centre of the white matter 
tracts. So far, few studies have performed TBSS in patients with depressive symptoms.193,194 
Although they found a lower fractional anisotropy in bilateral frontal, right temporal and 
midbrain in depressed participants, these studies also have limitations, such as relative small 
sample sizes and not adjusting for possible confounders such as cognition.
Our aim was to investigate the regional differences in microstructural integrity of the 
white matter tracts in a large sample of elderly people with cSVD and with or without 
depressive symptoms. We investigated the full spectrum of DTI-derived indices using 
TBSS. We hypothesized that participants with depressive symptoms have a compromised 
microstructural integrity (low fractional anisotropy and high mean diffusivity) of the WM 
compared with participants without depressive symptoms, located in critical regions for 
emotional processing. Additionally we hypothesized that these compromised regions are 
partially explained by the presence of cSVD and independent of global cognition. 
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Materials and Methods
Study sample
This study sample is embedded within the Radboud University Nijmegen Diffusion tensor 
and MRI Cohort (RUN DMC) study that prospectively investigates risk factors and cognitive, 
motor and mood consequences of brain changes, as assessed by MRI in elderly with cSVD.60 
On the basis of established research criteria cSVD was defined as the presence of lacunar 
infarcts and/or WMH on neuroimaging.61 The presence of any of these manifestations of 
cerebral SVD qualified for the cut-off for presence of cSVD. The selection procedure of the 
participants and the study rationale and protocol were described previously in detail .60 
In short, in 2006, consecutive patients referred to the Department of Neurology between 
October 2002 and November 2006, were selected for participation. Inclusion criteria were: 
(a) age between 50 and 85 years; (b) cerebral SVD on neuroimaging (WMH and/or lacunar 
infarcts). Exclusion criteria were: (a) dementia195 (b) Parkinson(-ism)156(c) life expectancy of 
less than six months; (d) intracranial space occupying lesion; (e) current (psychiatric) disease 
interfering with cognitive testing or follow-up, serious mental illness in their history, or a 
current depression (f) recent/current use of acetylcholine-esterase inhibitors, neuroleptic 
agents, L-dopa or dopa-a(nta)gonists; (g) WMH or cSVD mimics (e.g. multiple sclerosis and 
irradiation induced gliosis); (h) prominent visual or hearing impairment; (i) language barrier; 
( j) MRI contraindications or known claustrophobia. This study comprises of 503 elderly 
without dementia or parkinsonism, aged between 50 and 85 years with cerebral cSVD. For 
the present study, 65 participants were additionally excluded because of the presence of 
territorial infarcts (n = 55), inadequate quality of the MRI image (n=4) and incomplete data 
on neuropsychological tests (n=6). This study was approved by the Medical Review Ethics 
Committee region Arnhem-Nijmegen and all participants gave written informed consent 
prior to inclusion. 
Assessment of depressive symptoms 
Depressive symptoms were assessed with the Centre of Epidemiologic Studies Depression 
Scale (CES-D).196 Depressive symptoms were considered present in patients with a CES-D score 
≥ 16 and/or current use of anti-depressive medication, taken for depression, irrespective of 
their actual CES-D score, because depressive symptoms were considered to be the indication 
for the medication prescription. Those who mentioned psychiatric diagnoses during medical 
history taking and/or when this became apparent when retrieving the information form 
medical records, were excluded from participation, apart from those with a diagnosis of 
depression in their history. A total of 53 participants used antidepressants: 30 participants 
had a CES-D score ≥ 16, while other participants had a CES-D score < 16. All participants were 
taking antidepressant for depression (and not for other reasons such as anxiety, insomnia or 
neuropathic pain). All other participants in the RUN DMC study sample were considered as 
the comparison non-depressed group. 
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MRI acquisition
MRI scans of all participants were acquired on a single 1.5-Tesla MRI (Magnetom Sonata, 
Siemens Medical Solutions, Erlangen, Germany). The protocol included, among other 
sequences, 3-D T1 MPRAGE  (TR/TE/TI 2250/3.68/850ms; flip angle15º; voxel size 1.0 x 1.0 
x 1.0mm), a FLAIR pulse sequence (TR/TE/TI 9000/84/2200ms; voxel size 1.0 x 1.2 x 5.0mm, 
interslice gap 1mm) and a DTI sequence (TR/TE 10100/93ms voxel size 2.5 x 2.5 x 2.5 mm, 4 
unweighted scans, 30 diffusion weighted scans with b-value of 900 s/mm2).60
Conventional MRI analysis
WMHs were manually segmented on FLAIR images by two trained raters and the total WMH 
volume was calculated by summing the segmented areas multiplied by slice thickness.60 WMHs 
were defined as hyperintense lesions on FLAIR MRI without corresponding cerebrospinal 
fluid like hypo-intense lesions on the T1 weighted image. Gliosis surrounding lacunar and 
territorial infarcts is not considered to be WMHs.163 Inter-rater variability (assessed by intra-
class correlation coefficient) for total WMH volume was 0.99. Lacunar infarcts are defined 
as hypo-intense areas greater than 2 mm and less than or equal to 15mm on FLAIR and T1, 
ruling out enlarged perivascular spaces (≤ 2 mm, except around the anterior commissure, 
where perivascular spaces can be large) and infraputaminal pseudolacunes. 163 The intra- 
and inter-rater reliability for the lacunar infarcts yielded a weighted kappa of 0.80 and 0.88.60 
To obtain the grey matter (GM), WM and cerebrospinal spinal fluid (CSF) volume, the T1 
MPRAGE images were segmented using Statistical Parametric Mapping 5 unified segmentation 
routines. Total GM, WM and CSF volumes were subsequently calculated by summing all voxel 
volumes that had a p > 0.5 for belonging to that tissue class.  The sum of GM and WM volume 
was considered as total brain volume (TBV). The intracranial volume (ICV) was a summation 
of all tissue classes. To normalize for the head size, TBV was expressed as percentage of total 
ICV. 
DTI analysis
The in-house developed algorithm named ‘PATCH’ (www.ru.nl/neuroimaging/diffusion)91 
was employed to the raw diffusion data to detect and correct head and cardiac motion 
artefacts using an iteratively re-weighted-least-squares algorithm. Corrections of eddy 
current and motion artefacts from affine misalignment were performed simultaneously, 
which was based on minimization of the residual diffusion tensor error. Next, fractional 
anisotropy, mean diffusivity, axial and radial diffusivity, and mode of anisotropy images were 
calculated using DTIFit within the FSL toolbox, which were fed into the TBSS pipeline.93 The 
thinning procedure was conducted on the mean fractional anisotropy image to create a 
common skeleton using a threshold value 0.3 for the fractional anisotropy, which represents 
the core-structure of the white matter tract. The threshold value 0.3 was chosen to include 
major white matter tracts and to reduce inter-subject variability. These skeleton projection 
vectors were then applied to the mean, radial and axial diffusivity, and mode of anisotropy. 
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Fractional anisotropy represents a normalized ratio of diffusion directionality and can be 
used as a measurement of structural integrity of the WM. Mean diffusivity, which measures the 
averaged diffusion in all directions, can be used as a marker for fibre density. A low fractional 
anisotropy and/or a high mean diffusivity is typically inferred to the loss of microstructural 
integrity of the WM, due to various underlying pathophysiological mechanisms. Axial 
diffusivity reflects the diffusivity parallel to the white matter tracts, while radial diffusivity 
measures the diffusivity perpendicular to these tracts. Changes in axial diffusivity may 
implicate axonal damage, whereas changes in radial diffusivity indicates loss of myelin 
integrity.25  Mode of anisotropy denotes the shape of the diffusion tensor ranging from planar 
to linear anisotropy,197 and can reflect selective degeneration of fibres and/or reorganization 
of these fibres. The investigation of these diffusivities and mode of anisotropy197 may yield 
important information about these underlying mechanisms. Studies showed that DTI can 
be used to assess the cSVD-induced changes in the WM and that areas with WMH could have 
quite different DTI characteristics . To this end, a comprehensive analysis of the full spectrum 
of DTI-derived indices is necessary.
Other measurements
Age, sex, level of education,65 normalized TBV and global cognitive function were considered 
as possible confounders. Global cognitive function was evaluated by the Mini-Mental State 
Exam (MMSE) 82 and the cognitive index . The cognitive index is a compound score that was 
calculated as the mean of the z-scores of the 1-letter subtask of the Paper-Pencil Memory 
Scanning Task, the mean of the reading subtask of the Stroop test, the mean of the Symbol-
Digit Substitution Task and the mean of the added score on the three learning trials of the 
RAVLT and the delayed recall of this last test.53 Global cognitive function was considered as a 
possible confounder. For assessment of vascular risk factors, structured questionnaires were 
used together with measurements of blood pressure taken on separate occasions. The risk 
factors included presence of hypertension (mean blood pressure ≥ 140/90 mmHg and/or 
use of anti-hypertensive medications), diabetes (treatment with anti-diabetic medications), 
hypercholesterolemia (treatment with lipid-lowering drugs) and smoking status.
Statistical analyses
Demographic and neuro-imaging characteristics in Tables 1 and 2 were tested through 
univariate analysis, by an independent t-test, a Chi-square test or a Mann-Whitney U test. When 
the Levene’s test for equality of variances was significant, the significance of the difference 
between the groups was computed using Welch’s t-test (equal variances not assumed). To 
compare the DTI parameters (fractional anisotropy, mean, radial and axial diffusivity, and 
mode of anisotropy) between those with or without depressive symptoms, we performed 
two-sample t-test using a permutation-based statistical interference as a part of FSL toolbox 
(‘randomise’), with a standard number of permutation tests set to 5000.  Significant clusters 
were identified using the threshold-free cluster enhancement with a p-value less than 0.05, 
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family-wise error corrected to control for multiple comparisons. A stepwise analysis was 
performed. First, age, sex, educational level and normalized TBV were added as nuisance 
covariates when performing the group comparisons, to keep comparability with other 
studies. Second, the same analyses were done with additional adjustments for WMH volume 
and number of lacunar infarcts. Finally, we executed the analysis additionally adjusted for 
MMSE and cognitive index, to adjust for the possible confounding effect global cognition may 
have on the relation between microstructural integrity and depressive symptoms. 
Results
Demographic, clinical and neuroimaging characteristics are shown in Table 1. Mean age did 
not significantly differ between participants with (65.6 years SD 8.6) or without depressive 
symptoms (64.8 years SD 8.9). There were no significant differences for total WMH volume, 
lacunar infarcts, and normalized TBV between the groups. In both groups, WMHs were 
predominately periventricular located - especially in the frontal regions - as shown in Figure 
1.
A lower overall fractional anisotropy and a higher overall mean and radial diffusivity within 
the white matter skeleton was seen in participants with depressive symptoms compared to 
those without (see Table 2). Axial diffusivity did not differ significantly between the groups. 
The regions of the significant differences between the groups for each DTI parameters 
are shown in Figure 2. Participants with depressive symptoms exhibited lower fractional 
anisotropy in the genu and the body of the corpus callosum, bilateral inferior fronto-occipital 
fasciculus, uncinate fasciculus and corona radiata, than those without. Figure 3 displays the 
location of these white matter tracts. These differences disappeared after adjustment for 
WMHs and lacunar infarcts. The mean, axial and radial diffusivity were significantly higher 
in participants with depressive symptoms in the genu and body of the corpus callosum, 
bilateral inferior fronto-occipital fasciculus, uncinate fasciculus, and corona radiate, than 
in participants without depressive symptoms. This was also seen for fractional anisotropy 
(Figure 2). In addition to these regions, the spatial patterns of these diffusivities changes 
also include bilateral anterior cingulum bundle, internal and external capsule, and right 
inferior longitudinal fasciculus and parietal lobe. The mean diffusivity remained significantly 
higher in the genu and body of corpus callosum, right anterior cingulum bundle, bilateral 
superior corona radiata after adjustment for WMH’s and lacunar infarcts, as was the axial 
diffusivity in the right superior corona radiata and right superior longitudinal fasciculus. 
There were no regions with a higher mean, axial and radial diffusivity in patients without 
depressive symptoms. The changes observed for radial diffusivity disappeared after 
additional adjustment for WMH and lacunar infarcts. We observed a trend for lower mode 
of anisotropy in the body of corpus callosum, right superior corona radiata and right inferior 
fronto-occipital fasciculus not surpassing the P-value < 0.05 family-wise error-corrected (data 
not shown). Among those with depressive symptoms, there was no relationship between 
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Figure 1: The probability distribution of the white matter hyperintensities
WMHs are in red and colour-coded in percent (colour bar), thresholded from 5 to 90%. These images are 
projected onto the spatially normalized (Montreal Neurological Institute stereotactic space) and averaged 
(n=438) structural map. The statistical map (mean diffusivity) of the group comparisons adjusted for age, sex, 
education level, is presented in blue.
severity of depressive symptoms (measured by CES-D score) and the DTI measures (fractional 
anisotropy and mean diffusivity). 
Table 2: Neuro imaging characteristics of the participants with depressive symptoms and without 
depressive symptoms
participants  without 
depressive symptoms 
(n = 287)
participants  with 
depressive symptoms
(n=151)
significance
Neuro imaging
WMH volume, mL† (IQR) 6.0 (3.2-15.3) 7.7 (3.3-20.7) p = 0.127 (a)
Lacunar infarcts , 
presence, no. (%)
82 (28.6) 52 (34.4) p = 0.205 (b)
Normalized TBV, mL (SD) 1105.7 (87.0) 1097.2 (85.6) p = 0.332 (c)
Mean FA skeleton (SD) 0.423 (0.0292) 0.417 (0.0297) p = 0.037 (c)
Mean MD skeleton (SD) 8.14 x 10 -4  (4.57 x 10 -5) 8.23 x 10 -4  (4.19 x 10 -5) p = 0.038 (c)
Mean AD skeleton (SD) 1.20 x 10 -3  (4.16 x 10 -5) 1.20 x 10 -3 (3.54 x 10 -5) p = 0.051 (c)
Mean RD skeleton (SD) 6.16 x 10 -4  (5.14 x 10 -5) 6.26 x 10 -4 (4.86 x 10 -5) p = 0.049 (c)
Date represent mean (Standard deviation). TBV: Total Brain Volume. WMH: White Matter Hyperintensities. 
† represents median, IQR: inter quartile range; TBV is normalized to the intracranial volume. A) Independent 
T-test; df = 436.  b) Chi-square test; df = 1; c) Independent t-test.
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As antidepressant medication in itself can have effects on the structural integrity of the 
white matter, we repeated the analyses while controlling for current use of antidepressant 
medication. These analyses did not alter our findings. 
Adjustment for MMSE did not markedly alter our findings. After additional adjustment for 
cognitive index, the difference in fractional anisotropy between those with or without 
depressive symptoms disappeared. Higher mean, axial and radial diffusivity for patients with 
depressive symptoms compared with those without remained present in the similar regions 
as in the unadjusted analysis.
 Figure 2: Spatially distributed differences in DTI parameters between participants with depressive 
symptoms and without depressive symptoms
Voxel-wise analysis of the DTI parameters, A) fractional anisotropy, B) mean diffusivity, C) axial diffusivity and D) 
radial diffusivity. Fractional anisotropy is reduced in frontal regions in participants with depressive symptoms, 
while the mean, axial and radial diffusivity is increased in mainly the frontal regions (p<0.05, family-wise error 
corrected for multiple comparisons). The upper panels within each box display the statistical maps of the group 
comparisons adjusted for age, sex, educational level and normalized total brain volume. The lower panels 
within each box displays the statistical maps additionally adjusted for WMH volume and lacunar infarcts.
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Discussion
This study clearly shows regional differences in the microstructural integrity of the WM using 
TBSS in a large sample of elderly people with or without depressive symptoms. We found that 
participants with depressive symptoms had a lower microstructural integrity in several WM 
regions, predominantly located in the prefrontal white matter tracts. These differences were 
independent of global cognition and might, at least in part, be explained by the presence of 
cSVD. To the best of our knowledge, this is the first study conducting TBSS in a large group of 
participants, while controlling for multiple possible confounders, including global cognitive 
function.
Several methodological issues need to be addressed. First, a limitation is the cross-sectional 
nature of our study, which prevents us from making causal inferences. Second, participants 
with ≥ 16 points on CES-D and/or current use of anti-depressive medication were considered 
 
Figure 3: Map of the location of specific white matter tracts, with decreased white matter structural 
integrity, in participants with depressive symptoms
This map shows the mean diffusivity parameters of the group comparisons adjusted for age, sex, educational 
level and normalized total brain volume.  CB: cingulum bundle, UF: uncinate fasciculus, CC: corpus callosum 
(body and genu), IFOF: inferior frontal occipital fasciculus, ILF: inferior longitudinal fasciculus, SLF: superior 
longitudinal fasciculus, IC: internal capsule, EC: external capsule.
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to be participants with depressive symptoms. Using these criteria, not all participants with 
depressive symptoms will be diagnosed as major depressive disorder.198 Third, the CES-D is 
commonly used as a screening tool and could be considered a screen for general affective 
distress, including depression and anxiety. However, one has to keep in mind that it is not 
a specific screening tool for depressive symptoms. In order to exclude other psychiatric 
disorders that might have proven screen-positive with the CES-D, we excluded participants at 
baseline with serious mental illness, including an anxiety disorder by medical history taking 
and structured screening of medical records and subsequent adjudication of the psychiatric 
events to be excluded. Fourth, we applied TBSS, which is criticized for problems with the 
repetitive registration process required and for issues related to constraining analyses to only 
large and highly organized fiber bundles. Nevertheless, this observer-independent analysis 
method mitigates several methodological constraints of voxel-based analysis, such as 
misalignment due to registration procedure and smoothing effects. Finally, the proportion of 
participants with depressive symptoms in our study is relatively high (34.5%). The high rate of 
depressive symptoms is not so much a methodological limitation, but rather a consequence 
of the fact that we selected participants on the basis of cSVD, which is characterized (among 
other) by depressive symptoms.
On the other hand, major strengths of our study include its design of a homogeneous 
population that covers the whole spectrum of cerebral SVD, its large sample size, the single 
centre design, the use of a single scanner and high response rate over 70%. Furthermore, 
we manually segmented the WMH and the analyses were adjusted for various possible 
confounders. We intentionally did not adjust for vascular risk factors, such as hypertension 
or diabetes, as they were considered a part of the causal chain between cSVD and depressive 
symptoms. 
In this study, participants with depressive symptoms showed compromised microstructural 
integrity in several white matter tracts, predominantly located in the prefrontal regions. 
Especially frontal-subcortical circuits are thought to play an important role in the pathogenesis 
of mood, but also cognitive and motor symptoms.191 The vascular depression hypothesis 166 
entails that WMHs, caused by cerebrovascular disease, disrupt white matter tracts within the 
fronto-striatal-subcortical circuit and/or interrupt the connections with limbic structures.39,199 
Disruption of these circuits, which are involved in mood-regulation,200 may lead to a 
“disconnection syndrome” 35 and consequently to depressive symptoms. Brain areas that 
connect the prefrontal cortex with subcortical areas, such as the amygdala and the ventral 
striatum, are crucially involved in the (patho)physiology of mood. In a recent DTI study,201 we 
were able to show that subtle WM changes in the connectivity of the amygdala and medial 
prefrontal cortex might be key factors in the pathophysiology of major depressive disorder, 
which may account for functional changes. Indeed, a recent meta-analysis202 of patients with 
major depressive disorder showed changes in the white matter fascicles connecting the 
prefrontal cortex within cortical and subcortical areas (amygdala and hippocampus).
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We found lower microstructural integrity in the inferior longitudinal fasciculus. This is an 
associative bundle connecting the occipital and temporal lobes. These long fibres connect 
the visual areas to the amygdala and hippocampus, which are important components of the 
limbic system. The corpus callosum is the largest fibre bundle of the human brain and is 
involved in several perceptual, cognitive and motor functions. The genu (anterior portion) 
connects the prefrontal and orbitofrontal regions, and the body (central portion) connects 
the precentral frontal regions and the parietal lobes.203 Lower microstructural integrity was 
also evident in the genu and body of the corpus callosum in participants with depressive 
symptoms, which is consistent with previous findings.204  We found loss of microstructural 
integrity in the anterior cingulum bundle in patients with depressive symptoms, unlike a 
recent TBSS study, in which patients with depression showed a lower fractional anisotropy in 
the middle cingulate cortex.205 This region is activated during anger and fear and is reported 
as abnormal in functional and structural imaging studies.147 Most other areas in which we 
found lower microstructural integrity are consistent with other findings, such as the loss of 
structural integrity in the uncinate fasciculus 206 and the superior longitudinal fasciculus.207 
Both have frequently been demonstrated to be involved in mood regulation. Taken together, 
these findings suggest that the changes in white matter tracts might underlie the occurrence 
of depressive symptoms in participants with cSVD by disrupting the critical white matter 
tracts involved in emotional circuitry. These findings have implications in the understanding 
of neurobiological circuit of depression in elderly participants with cSVD.  Furthermore 
the disruption of the frontal-subcortical circuits has been associated with the presence of 
motivational symptoms. This also could play a role in the underlying pathophysiology of 
depressive symptoms in elderly with cSVD.
The occurrence of depressive symptoms in elderly might be a psychological reaction to 
(perceived) lower cognitive function.208 On the other hand, loss of the structural integrity 
of the WM in specific regions may increase susceptibility to depression and thereby, loss of 
motivation and can be expressed clinically as cognitive impairment. These cognitive changes 
add to the severity of symptoms and disability that older depressed patients experience.209 
To exclude the possibility of the effect of global cognition on the depressive symptoms, 
additional analyses were performed while adjusting for global cognition. These analyses 
did not markedly alter the conclusion, though increased the variance explained by global 
cognitive functioning. 
During the last decade, studies have shown higher volume of WMHs in elderly depressed 
patients compared to age-matched controls.210 In our study, the significant differences 
of the DTI parameters between the groups diminished after additional adjustment for the 
WMHs and lacunar infarcts. This suggests a major role of cSVD in the loss of microstructural 
WM integrity in the participants with depressive symptoms. However, after adjustment for 
WMHs and lacunar infarcts, these participants exhibit significantly higher mean and axial 
diffusivity, suggesting the occurrence of mechanisms other than cSVD. This is consistent with 
the concept that different pathological mechanisms often coexist in one participant.211 It is 
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interesting to note that the few white matter tracks that remained significant, such as genu 
of the corpus callosum and anterior cingulum bundle, have all been previously related to 
mood dysregulation, while other regions, which were no longer significant after adjustment 
for cSVD, such as internal/external capsule, have not been related to mood dysregulation.
Several pathophysiological mechanisms might have occurred governing the diffusion 
changes (lower fractional and higher mean, axial and radial diffusivity) in participants with 
depressive symptoms. First, the microstructural abnormalities of the WM could be caused by 
ischemic damage due to cSVD, hereby increasing the blood-brain permeability, subsequently 
leading to reduced myelination, axonal degeneration and/or gliosis.212 Second, indirect effects 
of SVD can lead to decreased microstructural integrity by means of antero- and retrograde 
degeneration of neuronal fibres surrounding the WMHs, e.g. Wallerian degeneration.213 Third, 
other factors might play a role in the aetiology of depression, independent of ischemic 
disease. The microstructural changes could also partially reflect the disorganization of the 
white matter tracts, alterations of the intracellular compartment and glial changes.214 This is 
further corroborated by the findings of the frontal WM infrastructure alterations in participants 
with major depression in post-mortem studies.215 These changes can lead to water molecule 
diffusion increases in every direction, which might govern the increase in mean, radial and 
axial diffusivity, and to a lesser extent, in the decrease of fractional anisotropy, as seen in our 
study. As our study is cross-sectional, the differences in structural integrity between those 
with or without depressive symptoms can also be a consequence of depressive symptoms 
rather than a cause.
In conclusion, our study provides evidence for microstructural damage in participants with 
depressive symptoms, independent of global cognition. This damage is predominantly 
located at the prefrontal white matter fibres, disrupting the fronto-subcortical circuits, which 
are involved in emotional processing. The loss of microstructural integrity in our participants 
with depressive symptoms might, at least in part, be related to the presence of cSVD. However, 
other mechanisms might also play a role in the aetiology of depression, independent of 
cerebrovascular disease. The analysis of the full spectrum of DTI-derived parameters is 
relevant and provides additional insights into the pathophysiological mechanisms that 
underline the occurrence of the depressive symptoms in elderly with cSVD. Both direct and 
indirect effects of cSVD may results in axonal loss (higher AD) and demyelization (higher RD). 
It also helps us to refine the imaging endo-phenotype of patients with depressive symptoms 
for future studies. Future studies are, however, needed to investigate the influence of cSVD 
on not only the structural connectivity, but also on functional connectivity and the effect 
of treatment. This information is important in understanding the pathology of depressive 
symptoms in elderly with cSVD and might be of added value to find a more specific medical 
treatment for elderly with depressive symptoms. 
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Abstract
Objective: We prospectively investigated the role of depressive symptoms (DS) on all-
cause dementia in a population with cerebral small vessel disease (cSVD), considering 
onset-age of DS and cognitive performance.
Methods: The RUN DMC study is a prospective cohort study among 503 older adults 
with cSVD on MRI without dementia at baseline (2006), with a follow-up of 5-years (2012). 
Kaplan-Meier curves stratified for DS and dementia risk were compared using log-rank 
test. We calculated hazard ratios using Cox-regression analyses.
Results: Follow-up was available for 496 participants (mean baseline age 65.6 years (SD 
8.8); mean follow-up time 5.2 years). All-cause dementia developed in 41 participants. The 
5.5-year dementia risk was higher in those with DS (HR 2.7; 95%CI 1.4-5.2), independent of 
confounders. This was driven by those with late onset depressive symptoms (LODS). The 
five-year cumulative risk difference for dementia was higher in depressed participants 
with high baseline cognitive performance (no DS 0.0% vs. DS 6.9% log-rank p<0.001), 
compared with those who had low cognitive performance at baseline.
Conclusions: Late-onset DS increase the dementia risk, independent of cSVD. Especially 
in those with relatively high cognitive performance, DS indicate a higher risk. In contrast 
to current practice, clinicians should monitor those with DS who also show relatively 
good cognitive test scores.
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Introduction
Depressive symptoms (DS) occur in approximately 30% of patients with dementia216 and have 
been coined a risk factor for,217 an early symptom of,218 or a reaction to perceived cognitive 
decline. Both cross-sectional and longitudinal population-based studies have investigated 
this, showing conflicting results.219-223 
Late-onset DS (LODS), initially occurring in older age, should be distinguished from early-
onset  DS (EODS), for a different aetiology is presumed.37,38 Particularly LODS, rather than 
EODS, were found to be related to incident dementia.224 It is unclear whether LODS increase 
dementia risk alone or whether this is mediated by the same underlying cerebral small vessel 
disease (cSVD).38 36,41,225 cSVD refers to neuroradiological findings, including white matter 
hyperintensities (WMH), lacunes of presumed vascular origin (lacunes) and microbleeds.12
One recent study in older adults with cSVD has already shown that DS were associated 
with an increased risk of cognitive decline after 3 years, independent of WMH.118 However, 
important adjustments for other aspects of the cSVD spectrum as well as grey matter (GM 
and hippocampal volume were not made. 
Therefore, we prospectively investigated the role of baseline DS on the risk of all-cause 
dementia in adults with cSVD, also considering cSVD characteristics and other well-known 
confounders. Second, we investigated the risk of dementia, stratified by age of onset of 
DS, as LODS and EODS might have different relations with incident dementia. Finally, we 
investigated the relation between DS and incident dementia in those with high and low 
cognitive performance at baseline. 
Methods
Study population
The Radboud University Nijmegen Diffusion Tensor and Magnetic resonance Cohort (RUN 
DMC) study, a prospective cohort study investigating risk factors and clinical consequences of 
brain changes during aging as assessed with MRI among 503 older adults without dementia 
aged 50 to 85 year with cerebral SVD. The recruitment, study rationale, and protocol were 
described previously in detail.60 cSVD was defined on established research criteria (presence 
of any WMH and/or lacunes of presumed vascular origin),61 as cSVD onset is often insidious 
and clinically heterogeneous with acute, (TIAs or lacunar syndromes), or sub acute (cognitive, 
motor and/or mood disturbances) symptoms. Baseline data collection was performed in 
2006. Main exclusion criteria were dementia, WMH or cSVD mimics, current (psychiatric) 
disease interfering with cognitive testing (such as current major depression) or follow-up, 
history of serious mental illness, and MRI contra-indications (e.g. pacemaker, vascular clips 
and known claustrophobia).60
Follow-up occurred in 2011-2012. Of 503 baseline participants, 2 were lost to follow-up (not 
deceased; supplementary Figure S1); five additional participants were excluded because of 
missing values on the CES-D, yielding a final sample of 496. This study was approved by the 
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Medical Review Ethics Committee region Arnhem-Nijmegen. All participants gave written 
informed consent prior to inclusion.
Assessment of depressive symptoms 
DS were assessed with the 20-item Centre of Epidemiologic Studies Depression Scale 
(CES-D).196 DS were considered present when participants had a CES-D score ≥16 and/
or currently used antidepressants, taken for depression. Sixty-one participants used anti-
depressive medication.48
Furthermore, participants were interviewed about their history of depressive episodes, 
onset-age and whether they asked for medical advice. If depressive episodes had required 
attention of a general practitioner, psychologist, or psychiatrist, a history of depression was 
considered present.67 To distinguish between LODS and EODS we used the age of 60 as the 
cut-off point.67 Those with a CES-D score ≥ 16 and/or current use of antidepressants, age 60 
years or older, without a history of depressive episodes before the age of 60, were classified 
as having LODS. Those with a CESD score < 16, without a history of DS and without current 
use of antidepressants, formed the reference group. The others (first depressive episode < 60 
years), fulfilled the criteria for EODS.47 (Supplementary Table S1) 
Dementia case finding 
At baseline all participants were free of dementia. Dementia case-finding, and assessment 
of time-to-dementia were described in detail previously.44,45 In short, dementia case finding 
was performed for all 501 participants: those who participated in the in-person follow-up 
and among those who could not (died or refused) (Supplementary Figure S1). Participants 
who screened positive at in-person follow-up (MMSE score ≤26 or a decline ≥3 points from 
baseline) were subsequently examined for dementia at the Radboud Alzheimer Centre. For 
those who refused this examination, the panel, consisting of members of the same Radboud 
Alzheimer Centre (to ensure a standardized approach), came to a consensus diagnosis. 
This panel reviewed all available neuropsychological45,60 and imaging information next to 
interference in daily functioning, confirmed by family or caregivers. 
For those who were not available for an in-person assessment, the same panel reviewed 
the medical records. Furthermore we contacted patients’ general practitioners and medical 
specialists for information on cognitive status. The dementia diagnosis was based on the 
Diagnostic and Statistical manual of mental disorders (IV) criteria.62 Incident dementia 
was diagnosed in 43 cases. Data on baseline DS were not available for 2 patients who 
developed dementia; therefore, 41 cases of incident dementia are included in the analysis 
(Supplementary Figure S1).
MRI resonance imaging protocol and analyses
MRI scans were performed on a single 1.5-Tesla MRI, on average 19 days after assessment 
at our research centre. The protocol included, among other sequences, a T1-weighted 
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3-dimensional magnetization-prepared rapid acquisition gradient-echo (MPRAGE) imaging 
(voxel size 1.0×1.0×1.0mm); a Fluid-attenuated inversion recovery (FLAIR); voxel size 
1.0×1.2×5.0mm, with an interslice gap of 1 mm); and a transversal T2* weighted gradient 
echo sequence (voxel size 1.3×1.0×6.0mm, with an interslice gap of 1 mm).60 
WMH were manually segmented on FLAIR images. Total WMH volume was calculated by 
summing the segmented areas multiplied by slice thickness. Lacunes and microbleeds were 
assessed by raters blinded to all clinical data, according to the Standards for Reporting Vascular 
changes on neuro-imaging (STRIVE) criteria,12 with good intra- and inter-rater variability.45 To 
obtain GM (cortex, basal ganglia and thalamus), white matter (WM) and cerebrospinal spinal 
fluid (CSF) volume, the T1 MPRAGE images were segmented using Statistical Parametric 
Mapping 12 unified segmentation routines (SPM12; Wellcome Department of Cognitive 
Neurology, University College London, UK http://www.fil.ion.ucl.ac.uk/spm/software/
spm12/).45 To obtain GM, WM and CSF volumes all voxel volumes that had a p > 0.5 for 
belonging to that tissue class were summed. Intracranial volume (ICV) was a summation of 
total GM, total WM and CSF volume. Total brain volume (TBV) was a summation of GM and 
WM volume. We visually checked all images for co-registration errors and for motion and/
or segmentation artefacts. Hippocampal volumes (HV) were manually segmented on the 
MPRAGE image using the interactive software program ITK-SNAP, as described previously.87,88 
(http://www.itksnap.org). To adjust for head size, all volumes were normalized to the ICV. 
Other measurements
Education was classified using 7 categories (1 represented less than primary school, 7 an 
academic degree).65 We then dichotomized in primary or less (levels 1-2), or more than 
primary education (levels 3-7). Speed-accuracy trade-off (SAT) scores were calculated where 
appropriate [accuracy(%)/reaction time], to adjust for a number of faults. The Cognitive 
Index was constructed to obtain a more robust outcome measure for global cognition. In 
short, this was calculated as the mean of the z-scores of the SAT score of the Paper and Pencil 
Memory Scanning Task, the mean of the SAT score of the reading task of the Stroop test, the 
mean of the Symbol Digit Substitution Task, and the mean of the added score on the three 
learning trials of the Rey Auditory Verbal Learning Task, and the mean of the Delayed Recall 
of this test.46  Functional independence was assessed using the Barthel Index (range, 0–20).60 
All other measurements were done at initial assessment.
Statistical analyses
WMH volume was log-transformed because of the skewness of the data. Cumulative risk 
of incident dementia was estimated with Kaplan-Meier analysis stratified by presence 
of baseline DS. Person-years at risk were calculated for each participant from date of the 
baseline assessment, until onset of dementia, death, or date of the follow-up assessment. 
Those who did not reach the endpoint or died were censored. Subsequently, we used 
Incidence curves to compare between subgroups using log-rank test. We used Cox regression 
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analyses to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for presence 
of baseline DS (total, EODS, and LODS), adjusted for age, sex, and education (model 1), 
additional for baseline Cognitive Index and TBV (model 2), additional for WMH volume, 
presence of lacunes and microbleeds (model 3), or additional for GM and hippocampal 
volume (model 4). Verification of proportionality of hazards was performed by examining 
Schoenfeld residuals; there were no indications that this assumption was violated. Finally, to 
identify the role of DS on the dementia risk  in “high cognitive performers” and “low cognitive 
performers” at baseline, (defined by compound Z-score Cognitive Index below the median 
at baseline; Supplementary Table S2) we performed Kaplan-Meier analyses and compared 
subgroups with log-rank test. 
Results
Baseline demographic and neuro-imaging characteristics (n=496) are shown in Tables 1 and 
Supplementary Table 3, respectively. At baseline, 33.7% of participants had DS. Dementia 
developed in 41 of the 496 participants during a mean follow-up of 5.2 years (SD0.7). Mean 
age at baseline was 65.6 years (SD 8.8), and 56.9% were men. Mean MMSE score at baseline 
was 28.1 (SD 1.6). The 5.5-year cumulative risk of dementia was higher in participants with 
DS at baseline compared with those without (DS 18.5% vs. no DS 7.4%, log-rank p = 0.003) 
(Figure 1). 
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Figure 1: Cumulative risk for dementia, stratified by presence of depressive symptoms at baseline 
Cumulative risk for dementia stratified by presence of baseline depressive symptoms, unadjusted percentages. 
Log-rank test pair wise over strata.
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                                                       Figure 2: Cumulative risk for dementia, stratified by onset of depressive symptoms 
Cumulative risk for dementia stratified by onset of depressive symptoms, unadjusted percentages. Log-rank test 
pair wise over strata.
Baseline DS significantly predicted incident dementia after 5 years of follow-up, adjusted 
for age, sex, and education (HR 2.7, 95% CI 1.4-5.2). Additional adjustment for baseline 
Cognitive Index and TBV; cSVD characteristics (WMH volume, lacunes and microbleeds), or 
GM structures (hippocampal and GM volume), did not significantly alter these findings (data 
not shown). The unadjusted cumulative risk of incident dementia in those with EODS and 
LODS separately compared to those who never experienced DS is presented in Figure 2. LODS 
predicted incident dementia (HR 2.5, 95% CI 1.3-4.8); adjustments for the above-mentioned 
confounders did not change this relation substantially (data not shown). For EODS this 
relation with incident dementia was not found (Table 2).
Finally, Figure 3 shows the cumulative risk of dementia in strata of baseline cognitive 
performance for participants with and without DS. In depressed participants with high 
baseline cognitive performance there was a significant 5-year cumulative risk difference for 
dementia (no DS 0.0% vs. DS 6.9%, log-rank p<0.001), whereas no such difference was found 
between participants with and without DS with low cognitive performance (no DS 9.7% 
vs. DS 12.2%, log-rank p=0.514). Adjustment for demographic and imaging confounders in 
Cox regression analyses in both good and poor cognitive performance did not change this 
relation. Low dementia risk in participants without DS with good cognitive performance, led 
to wide confidence intervals (HR 40.2, 95% CI 4.5-361.8). 
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Table 2: Cox Proportional Hazards for Dementia by baseline depression status, Early Onset 
Depressive Symptoms and Late Onset Depressive Symptoms
Progression to 
dementia, 
n, (%)
Hazard Ratio + 95% CI
Adjusted age, sex, 
education
Depressive symptoms
no depressive symptoms. (n =329)
depressive symptoms. (n= 167)
19 (5.8%)
22 (13.2%)
1
2.7 (1.4-5.2)
Early onset (<60 yr)
no depressive symptoms. (n =287)
Early Onset Depressive Symptoms (n=107)
19 (6.6%)
1 (0.9%)
1
0.2 (0.02-1.7)
Late onset (=/> 60 yr)
no depressive symptoms (n =287)
Late Onset Depressive Symptoms (n=101)
19 (6.6 %)
21 (20.6%)
1
2.5 (1.3-4.8)
Of the 503 participants at baseline, 2 were Lost to follow-up. 5 were additionally excluded because of missing 
values on the status of depression at baseline resulting in a total of 496 participants. Late onset depressive 
symptoms: Patients at the age or older than 60 years with a CES-D ≥ 16 and/or current use of anti-depressive 
medication, taken for depression, without a history of depressive episodes before or at the age of 60. Early onset 
depressive symptoms: a CES-D ≥ 16 and/or current use of anti-depressive medication, taken for depression, and/
or a history of depressive episodes before or at the age of 60. Individuals with a CESD < 16, without a history of 
depressive symptoms and without the current use of anti-depressive medication formed the reference group. 
Verification of proportionality of hazards was performed by examining Schoenfeld residuals.
The interaction between DS and cognitive performance on dementia risk showed a significant 
effect (HR 25.3, 95% CI 2.6-238.7;p=0.005).  We did not find a significant interaction between 
sex or low education and DS (data not shown).
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Figure 3: Cumulative risk for dementia, stratified by presence of depressive symptoms at baseline, 
in those with high and low cognitive performance at baseline.
Cumulative risk for dementia stratified by presence of baseline depressive symptoms, in those with high and low 
cognitive performance at baseline, unadjusted percentages. Log-rank test pair wise over strata. High cognitive 
performance defined as the upper half cognitive index at baseline, low cognitive performance defined as the 
lower half cognitive index at baseline. DS = depressive symptoms
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Discussion
Our results show that DS increase the dementia risk after 5 years in older adults with cSVD, 
a relation which is driven by those who develop a first depressive episode at later age. This 
relation is independent of SVD characteristics and GM and hippocampal volume, suggesting 
additional factors besides cSVD play a role in our cohort in development of dementia. We 
showed that DS are related to an increased risk of dementia in those without objective 
cognitive problems. The magnitude of this relation, however, cannot be estimated because 
of the small number of incident cases in this subgroup. Below we will discuss the significance 
of these findings in more detail. 
Strengths of our study include its longitudinal and single-centre design allowing us to collect 
both baseline and follow-up data according to identical procedures, reducing the risk of 
procedural bias. Subsequently, the large cohort that covers the whole spectrum of cerebral 
SVD and the high follow-up rate of 99.6% are major strengths. We manually segmented WMH 
and hippocampal volumes without prior knowledge of clinical data. Finally, the relation 
between DS and incident dementia was investigated with adjustment for demographics, 
baseline global cognition, cSVD and GM structures, reducing confounds. 
Several methodological issues need to be addressed. First, we investigated “overall 
dementia” as an outcome measure and did not investigate the risk of Alzheimer disease 
(AD) and Vascular Dementia (VaD) separately. This distinction is difficult to make in elderly 
persons  since at a later age vascular diseases and neurodegeneration often co-occur.30 Our 
dementia diagnosis was a clinical diagnosis, supported by MRI most closely performed to 
the moment of diagnosis. It is possible that we have missed few cases of incident dementia 
in participants who were not available for in-person follow-up, because of incomplete 
medical records or uninformed general practitioners. In those cases, misclassification could 
have occurred in relatively early stages of dementia.  Second, although widely used, the cut-
off point of 26 in the MMSE, might not be sensitive enough to detect all incident dementia 
cases, especially for those in early stage of the disease, those with VaD, or in participants with 
dementia who have higher education levels. Therefore, misclassification, which might have 
led to an underestimation of the effect, might have occurred. Third, the relation between DS 
and incident all-cause dementia was adjusted for demographic and imaging characteristics 
and for baseline cognitive performance, reducing confounders. However, the small 
number of dementia cases in some of the subgroups resulted in wide confidence intervals, 
preventing a reliable estimate of the magnitude of the effect. Therefore, these results should 
be interpreted with caution. Furthermore, our analyses were not adjusted for other relevant 
confounders such as lifestyle risk factors and functional health, which might have led to 
residual confounding. Finally, we used the CES-D and/or current use of anti-depressive 
medication to assess DS. Although used in large population-based studies,219,226 it is also 
considered a screen for general affective distress, and therefore not a specific screening tool 
for DS. To account for this, we excluded participants at baseline with serious mental illness. 
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We think that our study has an excellent external validity regarding vulnerability for cognitive 
and affective symptoms in patients between 50 and 85 years of age presenting with cSVD 
on neuroimaging in a neuropsychiatric clinic. All of our participants were functionally 
independent at baseline, with a mean MMSE score of 28.1 (SD 1.6), reflecting estimates in 
the general population. The incidence rate for dementia in our SVD cohort is higher than in 
a large population-based study.86 This is not surprising as cSVD is associated with incident 
dementia.41 When comparing our incidence rate of dementia with another cSVD cohort,118 
our incidence rate was actually lower. This could be explained by the approximately 10 years 
younger mean age of our population and also the less severe WMH at baseline; both factors 
are known to be related to the incidence of dementia.86,100
Our findings that DS are associated with all-cause dementia are accounted for by those 
participants with LODS. At the same time, we showed that EODS were not related to incident 
dementia in older adults with cSVD. This is an important finding because (longer existing) 
EODS would be expected to increase dementia risk, for they have shown to be associated with 
neurodegeneration through neurotoxic mechanisms, including hippocampus atrophy.227,228 
This could suggest that LODS present not a causal factor for incident dementia, but rather are 
an early symptom of the spectrum, ultimately leading to dementia, for they present relatively 
short before dementia onset.  
There are several hypothesized explanations for (late-onset) DS as an early symptom 
of dementia.229 Disruption of the subcortical-frontal circuit, for example, by cSVD or 
neurodegenerative processes could result in both LODS and cognitive difficulties, such as 
dysexecutive problems and slower speed of information processing.48,230-232 This structural 
defect might also explain resistance to treatment, which is common in late-life depression. Of 
note, in our study we found that the association between DS and incident dementia remained 
present after adjustment for cSVD characteristics, suggesting that additional factors besides 
cSVD play a role that may not be necessarily depicted at the macro-anatomic level. This was 
in line with other longitudinal studies on depression and dementia.118,233 
We showed in an cSVD population that participants with DS have a higher risk of incident 
dementia compared to those without DS while performing relatively well cognitively. This 
finding could not be merely explained by the level of education, as post hoc analyses showed 
that all of those with incident dementia in the group that performed relatively well cognitively 
had more than primary education (data not shown). While it seems somewhat counterintuitive 
at first glance, it may very well be that only in those with relatively high cognitive performance, 
DS are indicative for incident dementia. Because cognitive performance at baseline is a very 
strong risk factor for incident dementia, it is possible that in the group with relatively low 
cognitive performance, presence of DS adds no significant value to the overall dementia risk. 
This is another argument suggesting that both (cognitive and affective) symptoms are part 
of the same underlying pathophysiology, whereby DS may present an early symptom rather 
than a risk factor for dementia. 
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The information presented above could imply that presence of DS might be a sensitive tool 
to investigate future dementia-risk, possibly more sensitive than cognitive evaluation, in 
those with a relatively higher cognitive status. In contrast to current clinical practice, these 
patients in particular should be adequately monitored for occurrence of cognitive decline, 
while those without DS have a very low 5-year risk of developing dementia. This is important 
to acknowledge, beginning with the general practitioner, which must recognize these 
first DS at older age as an initial sign of dementia. After this, the diagnostic path calls for a 
multidisciplinary approach in which there must be a good cooperation between psychiatrists, 
clinical neuropsychologists and neurologists. 
Our results show that LODS increase the risk of all-cause dementia in elderly persons with 
cSVD, but independent thereof, suggesting that other factors also have a role.  It is possible 
that DS in older age are an early symptom rather than an independent risk factor for incident 
dementia. General practitioners and medical specialists should be alert on presence of DS, 
and also monitor also those with relatively good cognitive test scores while presenting with 
DS. 
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Supplementary Figures
503 Non-demented elderly with 
cerebral Small Vessel Disease 
 2 Lost to follow-up  
501 Follow-up study population 
37 events mentioned by general practitioner, 
family or participant reviewed by panel 
398 renewed cognitive assessment No new assessment but clinical endpoints assessed  
• 49 deceased 
• 54 unable to visit 
• 19 illness that prevented visit 
•   5 moved out of the area 
• 30 lack of time 
34 screening positive 
20 analysis  
memory clinic 
14 refused analysis: 
consensus meeting 
8 non- demented 
7 
dementia 
13 non- 
demented 
7 non-
demented 29 dementia 
4 MCI 
9 VCI 
2 mood 
5 other 2 MCI 2 VCI 
1 mood 
1 hypochondria 
2 incomplete data 
 Total 41 cases of incident dementia 
7 
dementia 
13 dementia cases with complete CES-D data 
28 dementia cases 
with complete  
CES-D data 
No In-person Follow-up 
In-person Follow-up 
Supplementary Figure S1: Flowchart diagnostic work-up dementia
MCI: Mild cognitive impairment, VCI: Vascular cognitive impairment, CES-D: Centre of Epidemiologic Studies 
Depression Scale
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Supplementary Tables
Supplementary Table S1: Baseline characteristics stratified by onset of depressive symptoms
Not ever 
depressive 
symptoms 
n=287
Early Onset 
Depressive 
Symptoms, 
n=107
Late Onset 
Depressive 
Symptoms, n=102
Demographics
Age at baseline (SD) 65.8 (8.8) 59.2 (6.2) 71.6 (6.2)
Men, n (%) 175 (61.0) 60 (56.1) 47 (46.1)
Only primary education, n (%) 20 (7.0) 5 (4.7) 23 (22.5)
CES-D  at baseline, (SD) 5.7 (4.4)
0 (0.0)
16.1 (11.0)
30 (28.0)
20.1 (8.2)
31 (30.4)Anti depressive medication use at 
baseline, n. (%)
History of depression, n (%) 0 (0.0) 88 (82.2) 39 (38.2)
MMSE baseline (SD) 28.3 (1.6) 28.4 (1.5) 27.4 (1.7)
Compound Z-score Cognitive 
Index (SD)  ͣ
0.08 (0.76) 0.21 (0.72) -0.53 (0.65)
Low cognitive performance, n(%)   ͣ 125 (43.6) 40 (37.4) 82 (80.4)
Dementia at follow-up, n (%) 19 (6.6) 1 (0.9) 21 (20.6)
Barthel Index (SD) 19.8 (0.7) 19.7 (1.1) 19.4 (0.8)
Of the 503 participants at baseline, 2 were Lost to follow-up. 5 were additionally excluded because of missing 
values on the status of depression at baseline,    ͣone was excluded because of missing cognitive tests at baseline. 
The Cognitive Index is a compound Z-score of the paper pencil test, Stroop test, SDST, and immediate and 
delayed recall of the 15 RALVT. MMSE: Mini-mental State Examination. Low cognitive performance is defined by 
dichotomization at the median of the compound Z-score cognitive index at baseline.  SD: standard deviation, FU: 
Follow-up, Data represent numbers (%), mean (SD)   ͦcomparison of those with Early and Late Onset Depressive 
Symptoms. ͯ (age and gender adjusted difference by binary logistic regression or ANOVA where appropriate)
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Supplementary Table S2: distribution of cognitive scores for high and low cognitive performers
Overall Low cognitive 
performance
High cognitive 
performance
MMSE (SD) 28.1 (1.6) 27.4 (1.7) 28.8 (1.2)
Stroop words, time (sec) 25.8 (6.3) 29.3 (6.7) 22.4 (3.5)
Stroop faults, no 0.2 (0.5) 0.2 (0.6) 0.2 (0.4)
Paper Pencil, time (sec) 45.2 (13.7) 53.3 (13.7) 37.5 (7.9)
Paper Pencil faults, no 0.7 (1.4) 1.1 (1.8) 0.4 (0.8)
SDST correct in 1 min, no 27 (9.8) 20.0 (6.5) 33.9 (7.1)
RAVLT, 3 trials correct, no 21.1 (5.9) 17.3 (4.4) 24.6 (4.9)
Delayed recall, correct, no 6.0 (3.1) 4.1 (2.2) 7.7 (2.7)
Compound Z-score Cognitive Index 
(SD)  ͣ
-0.02 (0.8) -0.66 (0.4) 0.62 (0.4)
MMSE: Mini-mental State Examination, SD: standard deviation, no: number, sec: seconds, SDST: symbol digit 
substitution task; RALVT: Rey Auditory Verbal Learning Task. The Cognitive Index is a compound Z-score of the 
paper pencil test, Stroop test, SDST, and immediate and delayed recall of the 15 RALVT. 
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Supplementary Table S3: Baseline neuro-imaging characteristics of participants with and without 
baseline depressive symptoms
Total, 
n=495
Depressive 
symptoms 
at baseline, 
n=167
No  depressive 
symptoms 
at baseline,  
n=329
p-value for
difference   ͦ
Baseline neuro-imaging 
characteristics  
White matter volume, mL 
(SD)
464.5 (44.3) 467.7 (37.1) 462.9 (47.6) p=0.255º
      WMH volume, mL (IQR)† 7.2 (3.5-18.0) 9.1 (3.5-22.2) 6.5 (3.4-17.1) p=0.085 α
      NAWM volume, mL (SD) 450.4 (49.0) 451.7 (42.4) 449.7 (52.2) p=0.661º
Lacunes, presence, n (%) 132 (26.7) 49 (29.3) 83 (25.3) p=0.327∞
Microbleeds, presence, 
n (%)*
80 (16.2) 26 (15.6) 54 (16.5) p=0.787∞
Territorial infarcts, presence, 
n (%)
55 (11.1) 13 (7.8) 42 (12.8) p=0.095∞
Grey matter volume, mL (SD) 616.0 (50.9) 612.3 (53.3) 617.8 (49.5) p=0.253º
Hippocampal volume, mL 
(SD)**
6.8 (0.95) 6.8 (0.98) 6.8 (0.93) p=0.594º
Of the 503 participants at baseline, 2 were Lost to follow-up. 5 were additionally excluded because of missing 
values on the status of depression at baseline,  one was additionally excluded because of baseline T1 artefacts 
ml: millilitres, WMH: White Matter Hyperintensities, NAWM: Normal Appearing White Matter, Brain volumes 
represent normalized brain volumes to the total ICV. Data shown are unadjusted values, and represent numbers 
(%), mean (SD) or median † (inter quartile range). *two were excluded because of missing values of microbleeds. 
** three were excluded because of missing values of hippocampal volume.   ͦcomparison of those with and 
without depressive symptoms at baseline. ͯ (Means are compared with independent º T-test, ∞ Chi-square test 
or α Mann-Whitney-U)
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Introduction 
Cerebral small vessel disease (cSVD) is a major health problem for its contribution to about 
45% of dementias, and about a fifth of all strokes worldwide, representing one of the most 
important causes of disabilities.234 The term cerebral small vessel disease refers to a group 
of pathological processes with various aetiologies that affect the small arteries, arterioles, 
venules, and capillaries of the brain. The most common forms are age- and hypertension-
related SVD and cerebral amyloïd angiopathy (CAA).13 Vessel wall changes may lead to both 
ischemic and hemorrhagic consequences: 1) a state of chronic hypoperfusion or vascular 
dysfunction responsible for incomplete infarction235,236 and 2) acute focal necrosis (lacunar 
infarct), or 3) vessel rupture manifesting as hemorrhagic cSVD. The clinical consequences of 
cSVD are various and mainly consist of cognitive, mood, and motor dysfunctions leading to 
functional disability in the late stages of the disease. 
MRI has become crucial in the diagnosis of cSVD enabling the evaluation of the disease 
progression both in the clinical and research settings. However, correlations between clinical 
features of cSVD and conventional MRI measures have been partially discordant. Some 
authors suggested that the cumulative effect of cSVD lesions, rather than the individual lesions 
themselves determines the clinical impact,237 whereas others suggested that the presence 
and severity of alterations non-visible on conventional MRI might also be an explanation.127
In the last decade, diffusion tensor imaging (DTI) has been increasingly used for the evaluation 
of cSVD patients because it is very sensitive to tissue damage and can show abnormalities 
in both areas of white matter hyperintensities (WMH) and in normal appearing WM (NAWM). 
However, despite the high sensitivity in detecting cerebral damage, DTI has a low specificity 
on detecting the underlying cause. In fact, we can only infer that DTI changes reflect a loss of 
WM integrity due to damage to structures that restrict molecular movement along the primary 
axis of the axon such as axonal cell membranes, myelin sheaths, and neurofilaments. DTI is 
suited to study cortical disconnection because it provides indices of microstructural integrity 
within interconnected neural networks. Most DTI studies evaluated WM microstructural 
damage in aging, Alzheimer disease (AD) and mild cognitive impairment (MCI) patients, but 
recently, studies in cSVD patients have documented a significant association between WM 
microstructural damage and clinical features, providing new insight in the biological basis of 
this condition.48,129,238 
The aim of this review is to analyze the evidence of the role of WM microstructural damage 
beyond the standard structural MRI imaging sequences, evaluated with DTI, in the clinical 
consequences of cerebral SVD. Although some definitions have been proposed,239 it is 
explicitly not our intention to clinically define a ‘cSVD’ patient, as cSVD is often accompanied 
by other processes, such as aging and neurodegeneration leading to a broad spectrum of 
clinical manifestations. Our review is based on those studies that enrolled patients with a 
predominant cSVD pathology and does not include those that enrolled non-SVD participants 
(e.g., healthy aging, AD, MCI) even though they evaluated the association between cSVD 
markers and WM microstructural damage.
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The review first part briefly examines the methodological aspects of DTI and the role of DTI 
in understanding cSVD pathophysiology analyzing also the relationship between risk factors 
and WM microstructural damage. In the second part, we review clinical studies that reported 
on the association between DTI and different clinical manifestations of cSVD, focusing on 
cognition, mood disorders, and motor dysfunctions. The last part of the review outlines 
possible future applications of DTI, in particular its role as a sensitive marker to evaluate SVD 
progression in clinical trials. 
Article search strategy
Articles were identified through Pubmed searches using these terms: DTI, diffusion, WM 
microstructural damage, WM integrity, structural network, brain connectivity AND each of 
the following: SVD, subcortical small vessel, Binswanger, vascular cognitive impairment, CAA, 
CADASIL, vascular dementia, motor symptoms, gait, falls, balance, parkinsonism, depression, 
depressive symptoms, mood, smoking, hypertension, blood pressure, diabetes, blood 
glucose, body mass index, hypercholesterolemia, physical activity, leukoaraiosis, lacunes, 
from any date to November 15, 2015. 
Methodological aspects 
DTI is a quantitative MR technique that measures the movement of water within the tissue 
microstructure applying a magnetic diffusion gradient in more directions (at least six) to 
acquire a diffusion tensor.57 From the tensor, two commonly derived quantitative measures 
that provide information about the in vivo WM microstructure are fractional anisotropy (FA) 
and mean diffusivity (MD). FA is a measure of anisotropic water diffusion, which reflects the 
degree of directionality of cellular structures within the WM tracts and ranges from zero 
(diffusivity equal in all directions) to one (entirely unidirectional). MD is the average rate of 
diffusion in the non-collinear directions and an increasing value represents an increase in 
water diffusion. A lower FA and corresponding higher MD are generally believed to reflect 
lower microstructural connectivity. Other tensor indices have been proposed as markers of 
neuronal damage, such as axial diffusivity and radial diffusivity. Once FA and MD maps are 
generated, post-processing procedures start with mainly three approaches: region of interest 
(Figure 1, panel A), tract-based spatial statistics (TBSS) (Figure 1, panel B), and voxel-based 
analysis (Figure 1, panel C). Each of these techniques has pro and cons. Technical aspects 
related to brain network analysis are briefly described in the figure (Figure 1, panel D).
DTI and cerebral SVD
Among DTI studies in patients with sporadic cSVD, mainly defined as presence of moderate/
severe WM hyperintensities and/or lacunar infarcts not related to a monogenic disease, the 
predominant findings are that FA is decreased and MD is increased both in NAWM and WMH 
suggesting decline in the composition and integrity of the WM.240 Similar results have been 
reported also in CADASIL patients (Supplementary Table S1). 
CHAPTER 9
144
A substantial loss of anisotropy in the regions of WMH compared with NAWM has been 
reported56 while NAWM showed lower FA values close to WMH compared to more distant 
areas.241 For this reason, the term WM penumbra has been proposed to describe the area just 
surrounding the WMH which is still composed of NAWM based on conventional MRI, but with 
already lower structural integrity as compared with more remote areas of WM.241
Figure 1: Diffusion tensor imaging (DTI) post processing techniques with pros and cons, construction 
of structural network based on diffusion tensor tractography and network measures. 
A) Region-of-interest (ROI-) based analysis, B) Tract-based spatial statistics (TBSS), C) Voxel-based analysis. 
D) Construction of structural network based on DTI followed by tractography. Each individual network is 
represented as a graph, a mathematical model of a network with nodes (brain regions) linked by edges (white 
matter connections), which can then be explored using graph theory. There is a wide variety of network 
measures, only some of which are depicted in the figure. Basic network measures, including degree and strength 
of a node, are depicted in the figure. Degree of a node represents the number of connections linked to a node in a 
network. Strength of a node is defined as the sum of the weights of all edges connected to a node. Characteristic 
path length is defined as the shortest path or the minimum number of connections between two given nodes. 
Efficiency is inversely related to path length, which is easier to use in a disconnected graph.
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A positive correlation has been reported between the total WMH load and diffuse WM injury 
in NAWM, suggesting WM damage to be more widespread rather than region-specific. Normal 
WM, WMH penumbra, and WMH all show a similar decline in WM integrity over time.241,242 
Accordingly, NAWM regions that ultimately converted into WMH had already significant lower 
FA and higher MD at baseline in both growing WMH (defined as WMH expanding from already 
present WMH at baseline) and de novo WMH (defined as a new WMH not adhering to an 
already present WMH at baseline) compared to persistent NAWM.24 These results highlight 
that WMH develop gradually, and that WMH are only the tip of the iceberg of WM pathology. 
DTI tractography can be used to spatially characterize WM diffusion abnormalities along 
the pathway of a specific tract. Using a reconstructed WM tract containing a lacunar 
infarct, Reijmer and collaborators showed that WM microstructural damage attenuates 
with increasing distance from the primary lesion.243 This finding was replicated also in CAA 
patients.244 Duering and colleagues applied serial cortical thickness measurements and 
tractography in CADASIL patients and showed focal cortical thinning in cortical regions with 
high probability of connectivity with the incident infarct. This result provided evidence for 
cortical neurodegeneration after subcortical ischemia as one mechanism for brain atrophy 
in cerebrovascular disease.245 The same group has replicated this finding in a non-CADASIL 
cohort.79 
Recently, new advances in network analysis have been used to study the whole brain 
connectivity employing graph theory. This can be applied after structural networks have 
been reconstructed from diffusion tensor tractography (Figure 1, panel D). cSVD patients have 
been reported to have networks less densely connected, and reductions in both global and 
local efficiency, compared to controls, especially in interhemispheric and prefrontal tracts.246 
A similar approach showed network disturbances, most pronounced in the occipital, parietal, 
and posterior temporal lobes, in CAA patients.237
Risk factors for microstructural damage within the WM in cSVD 
To date, the Radboud University Nijmegen Diffusion Tensor and Magnetic resonance Cohort 
(RUN DMC) is the only study investigating cross-sectionally the role of vascular risk factors on 
microstructural changes in cSVD247,248 (Supplementary Table S2). Increased blood pressure 
(average of 3 measurements of systolic and diastolic blood pressures) and hypertension 
(defined as blood pressure >140/80 mmHg and/or use of blood pressure–lowering agents) 
resulted associated with loss of WM integrity in both the NAWM and WMH.247 In particular, 
hypertension was associated with lower FA in the splenium of the corpus callosum and higher 
MD in both the anterior body and the splenium of the corpus callosum. These associations 
disappeared after adjustment for other cSVD markers, such as WMH volume, lacunes, and 
gray matter atrophy, evoking the possible role of mediator of cSVD between hypertension 
and low microstructural integrity.248 
In one cSVD cohort, both history and duration of smoking were associated with a low WM 
microstructural integrity, and diffusion values were comparable between those who had quit 
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smoking more than 20 years and those who had never smoked. This may suggest a beneficial 
role of quitting smoking on WM structural integrity.249
One cross-sectional study, using TBSS, investigated the relationship between physical 
activity and WM microstructural integrity showing that poor physical activity was associated 
with lower microstructural integrity in almost all voxels of the TBSS skeleton.250
No study has so far investigated the association between diabetes mellitus and microstructural 
damage specifically in a cSVD population. A recent review, however, reported on five cross-
sectional studies examining the relation between DTI parameters and diabetes mellitus 
and all found lower microstructural integrity in patients with type 2 diabetes compared to 
controls, adjusted for different confounders.251
Taken together, these studies may suggest that vascular risk factors could damage WM 
integrity in elderly patients with cSVD and that their control might be associated with better 
DTI parameters. This may not apply to normal aging because recently in a population-based 
cohort cardiovascular risk factors were not associated with longitudinal changes in white 
matter microstructure.252
Clinical expressions of cSVD and WM microstructural damage
Cognition
cSVD patients are prone to develop cognitive impairment and their neuropsychological 
profile is generally characterized by a predominant impairment of executive functions, 
attention and psychomotor speed. One of the most accepted mechanisms of cognitive 
impairment in cSVD is based on the disconnection theory by which it is hypothesized that 
impairment in attention, processing speed, and executive function is related to the disruption 
of fronto-subcortical circuits. Indeed, it has been demonstrated in both sporadic cSVD and 
CADASIL patients that the forceps minor and the thalamic radiation are strategic WM tracts 
for processing speed.253,254 
O’Sullivan and colleagues demonstrated that in cSVD patients DTI indices, especially 
in NAWM, correlated more strongly with cognitive function than T2-lesion volume, after 
controlling for conventional MRI parameters.240 Similarly, diffusion changes predict faster 
decline in psychomotor speed, executive functions, and working memory regardless of 
conventional MRI findings.104 Other groups have confirmed the strong association between 
WM microstructural damage and cognitive impairment in sporadic cSVD patients, especially 
in terms of executive functions, attention and psychomotor speed (Supplementary Table S3). 
In CADASIL patients, executive performances were reported to be correlated with MD in the 
frontal WM and through the major antero-posterior fasciculus of the cingulum bundle.255
A further contribution to the understanding of the relationship between WM microstructural 
damage and cognition comes from the RUN DMC study in which more than 500 independently 
living, non-demented patients with cerebral SVD, aged between 50 and 85 years, were enrolled. 
In this large cohort, the microstructural integrity of both WMH and NAWM was related to 
global cognitive function, memory and executive function.95 Moreover, TBSS post-processing 
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analyses were performed and corpus callosum especially in the genu and splenium showed 
the highest significant relation with global cognitive index. Analyses for each cognitive domain 
showed the strongest relationship between 1) cingulum bundle microstructural integrity and 
verbal memory performance, and 2) frontal WM and psychomotor speed.129 However, in the 
same cohort, the main predictors for the development of incident dementia at 5 years were 
WM and hippocampal volumes44 while baseline WM integrity was not associated with decline 
in cognitive performances.46
In the Vascular Mild Cognitive Impairment Tuscany study, WM microstructural damage was 
more strongly reflected in Montreal Cognitive Assessment (MoCA) than Mini Mental Status 
Examination performances,256 possibly for the presence in MoCA of items reflecting executive 
functions and psychomotor speed.
Interesting insights in the development of cognitive impairment related to cSVD come from 
the evaluation of network connectivity. In both cSVD and CAA cohorts, the importance of 
network disruption as a mediating mechanism between cSVD MRI burden and cognitive 
dysfunction, especially in executive functions, has been demonstrated.237,246,257 Moreover, it 
has been shown that structural network efficiency is a predictor of conversion to dementia.257 
Depressive symptoms 
Previous cross-sectional studies showed a positive association between conventional cSVD 
characteristics and depressive symptoms in older age, both at a cross-sectional level36 and 
prospectively.258 DTI studies performed in patients with late life depression consistently 
showed lower microstructural integrity in the fronto-striatal and limbic networks.259 
To date, four studies investigated the role of the WM microstructure in cSVD in relation 
to depressive symptoms (Supplementary Table S4).48,260-262  The first study found that 
microstructural WM damage, measured by median FA, at least partially mediated the 
association between SVD and depression.260 The second study, using TBSS, showed that 
low WM microstructural integrity in the genu and body of the corpus callosum, bilateral 
inferior fronto-occipital fasciculus, uncinate fasciculus, and corona radiata was associated 
with depressive symptoms. These associations almost fully disappeared after adjustment for 
WMH and lacunes, suggesting that the visible cSVD drives the association.48 The third study 
reported an association between WM microstructural damage and depressive symptoms in 
MCI patients with cSVD independently of disability or cognitive or motor impairment.261 The 
last study evaluated the relationship between FA and both apathy and depression, finding 
that only apathy was related to damage of cortical-subcortical networks.262
The majority of these studies suggest that the association between WM microstructural 
damage and depressive symptoms might be mediated by the underlying cSVD and to a lower 
extent by other factors such as disability. 
CHAPTER 9
148
Motor problems
Only a small number of studies have investigated the relation between WM integrity and motor 
impairment (gait, parkinsonism, falls and balance) in cSVD using DTI (Supplementary Table 
S5).90,96,237,238,263-267  Loss of WM integrity, most pronounced in the corpus callosum, especially 
the genu,90,263 was associated with lower gait velocity at a cross-sectional level.90,96,237,263 This 
association with gait was seen for both NAWM and WMH. Network efficiency results related 
with gait velocity in CAA patients, suggesting a role of network disruption in this relation.237 
Other studies investigated the cross-sectional associations between microstructural integrity 
and a clinical scale measuring extrapyramidal motor deficits,264 extrapyramidal movement 
disorders, such as freezing of gait,265 and mild parkinsonian signs.238 Three studies found an 
association between extrapyramidal motor symptoms and low microstructural integrity in 
both supratentorial (frontal lobes),238,266,267 and infratentorial (pedunculopontine nucleus) 
regions. A prospective study showed a low baseline microstructural integrity of several 
bi-frontal WM tracts involved in movement control in participants with incident vascular 
parkinsonism in comparison to those without also after adjustment for cSVD characteristics.266
These studies uniformly support the notion that, in cSVD, disturbances of frontal WM 
microstructure, especially the genu of the corpus callosum, are associated with motor 
deficits, and related to incident vascular parkinsonism.  
Future directions and conclusions 
The evaluation of WM microstructural damage has gained attention over the last 15 years in the 
study of cSVD because it provides in vivo an understanding of the pathogenesis of important 
clinical and neuroimaging consequences of cSVD. The majority of the studies that have used 
DTI demonstrated a very good correlation between WM microstructural damage and several 
clinical measures linked to cSVD such as cognition, mood disorders and motor performances. 
In the studies where a multimodal approach was used, DTI indices were generally strongly 
associated with clinical outcome measures also after correction for multiple conventional 
neuroimaging markers of cSVD. Furthermore, longitudinal studies showed that changes in 
DTI parameters could be detected over a period of 1 or 2 years.72,76 In CADASIL patients for 
example, Molko and collaborators found important changes in DTI parameters over a period 
of 20 months, while no changes were detected in the control group.268 These findings suggest 
that DTI might be considered a sensitive biomarker to monitor the progression of WM damage 
in patients with cSVD. This may be particularly relevant because DTI indices were shown to 
be predictors of clinical progression in both sporadic cSVD and CADASIL.72,75,76,268 Therefore, 
the measurement of diffusion will possibly become one important surrogate marker in future 
preventive trials in cSVD. 
There are at least three possible ways in which DTI can be of aid in a better understanding 
of the aetiology and clinical consequences of cSVD: 1) It may provide new insights in the 
understanding of the mechanisms of the main clinical consequences of cSVD, particularly 
by evaluating the structural integrity of the cerebral WM architecture; 2) it may furnish a 
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reliable surrogate marker, especially in clinical trials, of cSVD progression over time in order 
to appreciate the effects of beneficial therapeutic interventions; 3) it may help to better 
appreciate the real cSVD burden and its progression.
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The temporal dynamics of cerebral small vessel disease 
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Abstract
Cerebral small vessel disease (cSVD) progression is increasingly recognized as the 
most important vascular contributor to the development of dementia. However, our 
understanding of who will show cSVD progression and when this will occur is limited due 
to the lack of studies with more than one follow-up assessment. In this study we aimed 
to investigate the temporal dynamics of cSVD progression by three consecutive imaging 
assessments in participants with cSVD.
We assessed changes in cSVD markers at three time-points over nine years in 276 
participants of the RUN DMC cohort. We assessed white matter hyperintensities (WMH) 
volume by semi-automatic segmentation, and rated lacunes and microbleeds manually. 
We categorized baseline WMH severity as mild, moderate or severe according to the 
Fazekas scale. We performed mixed-effects regression analysis including a quadratic 
term for increasing age during follow-up.
Mean WMH progression over nine years was 4.7 mL (0.54 mL/yr; IQR 0.95–5.5 mL), 20.3% 
of the participants had incident lacunes (2.3%/yr) and 18.9% incident microbleeds (2.2%/
yr). WMH volume declined in 9.4% of the participants, and lacunes vanished in 3.6% 
and microbleeds in 5.7% of the participants. WMH progression accelerated over time: 
including a quadratic term for increasing age during follow-up significantly improved 
the model (p<0.001). cSVD progression was predominantly seen in participants with 
moderate to severe WMH at baseline, whereas those with mild WMH barely progressed 
(OR 35.5; 95% CI 15.8-80.0; p<0.001 for WMH progression; OR 5.7; 95% CI 2.8-11.2; p<0.001 
for incident lacunes and OR 2.9; 95% CI 1.4-5.9; p=0.003 for incident microbleeds).
Our findings demonstrate that cSVD progression is a non-linear, dynamic and highly 
variable process, sometimes interrupted by vanishing cSVD. cSVD progression was 
predominantly seen in participants with severe WMH, suggesting that therapeutic 
strategies to prevent cSVD progression should particularly be deployed in patients with 
moderate to severe WMH.
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Introduction
Markers of cerebral small vessel disease (cSVD) are present on neuroimaging in virtually 
every individual over 60 years of age, although in highly variable degree. They include white 
matter hyperintensities (WMH), lacunes of presumed vascular origin, cerebral microbleeds 
and (sub)cortical brain atrophy 12. cSVD, and its progression, has been recognized as the most 
important vascular contributor to the development of dementia 29,41. Therefore understanding 
of not only who will show progression of cSVD but also when this will occur, will result in 
better understanding of both aetiology and consequences of cSVD, and may in time lead to 
personalized treatment approaches.
Current knowledge regarding temporal dynamics of cSVD is limited due to lack of studies 
with more than one follow-up assessment. Consequently, these studies could only report 
the average, presumably linear change in cSVD severity between two time-points. Average 
WMH progression ranged between 0.2 and 2.5 mL/yr, depending on the study population 
14,15,22,269. Yearly incidence of lacunes varied between 0.7 and six percent 17,18, and that of 
microbleeds between three and nine percent 19,20. Previous studies have suggested that 
cSVD progression may in fact be a non-linear process accelerating over time 270,271, and that, 
besides age, baseline lesion load may predict cSVD progression 22,270-272. Actual proof for these 
assumptions is lacking.
Recently, decrease of WMH volume 270-274 as well as decrease in number of lacunes 275,276 
and microbleeds 277,278 have been reported, further challenging the assumption of linear 
progression of cSVD markers. Neither the time-course, nor the magnitude of this “vanishing 
cSVD” has been investigated.
There is increasing awareness that cSVD not only exerts its clinical effects in a direct way by 
disconnecting white matter tracts, but also by affecting remote brain structure and function 
79,279. The temporal relation between changes in cSVD and the subsequent atrophy of remote 
brain structures remains unknown because of the same methodological limitation of having 
only one follow-up moment.
In this study we investigated the temporal dynamics (“the rise and fall”) of cSVD by three 
consecutive assessments over a period of nine years in participants with cSVD, distinguishing 
progression from regression. In addition, we investigated the effect of cSVD progression on 
remote brain regions including grey and white matter. 
Methods
Study population
This study is part of the Radboud University Nijmegen Diffusion tensor and Magnetic 
resonance imaging Cohort (RUN DMC) study that prospectively investigates risk factors and 
clinical consequences of cSVD. The detailed study protocol has been published previously 60. 
Of 503 baseline participants, 281 underwent repeated MRI assessment at three time points 
(baseline in 2006, first follow-up in 2011 and second follow-up in 2015). Five participants 
were excluded because of insufficient scan quality, yielding a final sample of 276 participants 
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for the present study (Supplementary Fig. 1). The Medical Review Ethics Committee region 
Arnhem-Nijmegen approved the study and all participants gave written informed consent.
MRI protocol
Images were acquired at three time-points on 1·5-Tesla MRI (2006: Siemens, Magnetom 
Sonata; 2011 and 2015: Siemens, Magnetom Avanto) and included the following whole 
brain scans: T1-weighted 3D MPRAGE, FLAIR and T2*-weighted gradient echo sequence. 
Full acquisition details have been described previously 60. We made slight adjustments in 
the FLAIR sequence between baseline and first follow-up (baseline: voxel size 1·2×1·0×5·0 
mm; interslice gap 1·0 mm; first and second follow-up: voxel size 1·2×1·0×2·5 mm; interslice 
gap 0·5 mm). Follow-up FLAIR images were resliced using linear interpolation to match slice 
thickness of baseline images to prevent differences in partial volume effects. The same head 
coil was used at all three time points.
Cerebral small vessel disease and brain volumetry
cSVD was rated according to the STRIVE criteria 12. WMH volumes were calculated by a semi-
automatic WMH segmentation method at all time points 280. Segmentations were visually 
checked for segmentation errors by one trained rater, blinded for clinical data. Because 
of its easy use and clinical applicability, we used the modified Fazekas scale to categorize 
WMH severity at baseline (mild: Fazekas 0-1; moderate: Fazekas 2; and severe: Fazekas 3) 
281. Lacunes and microbleeds were rated manually on FLAIR/T1-weighted scans and T2*-
weighted MRI scans by two trained raters blinded for clinical data. Inter and intra-rater 
reliability were excellent 45. 
Grey matter (GM), white matter (WM) and CSF probability maps were computed using SPM12 
(http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on T1 images corrected 
for WMH. All images were visually checked for co-registration and segmentation artefacts. 
GM, WM and CSF volumes (GMV, WMV and CSFV) were computed by summing all voxels 
belonging to that tissue class multiplied by voxel volume in mL. Intracranial volume (ICV) was 
determined by summing GMV, WMV and CSFV and total brain volume (TBV) by summing GMV 
and WMV.
Longitudinal brain changes
We calculated brain volumes (TBV, GMV, WMV) and WMH volume (WMHV)) at all time-points 
in native space. To account for inter-scan-effects we corrected for differences in ICV between 
baseline and follow-up. We normalized all volumes to baseline ICV to account for head size 89. 
We determined longitudinal volume change by calculating differences in volumes between 
the three time-points. To correct for WM atrophy we also calculated WMH as percentage of 
WM. Change in the number of lacunes and microbleeds was expressed as difference between 
2015, 2011 and 2006, and included both increase and decrease. Incidence was expressed as 
number of participants with new lacunes or microbleeds.
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Supplementary Figures
Supplementary Figure 1: Flowchart 
Design of the RUN DMC study. Imaging assessments were performed at three time-points over the course of nine 
years at baseline in 2006, at first follow-up in 2011 and at second follow-up in 2015. Note that the 93 participants 
who were unable to undergo first follow-up assessment in 2011 were again contacted for second follow-up 
assessment in 2015 (dotted lines). In total 281 participants underwent imaging assessments at all three time-
points, of whom 276 participants were included in the present study.
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Vascular risk factors
We assessed presence of hypertension, smoking, alcohol use, diabetes and 
hypercholesterolemia, by standardized questionnaires, as described previously 60. 
Statistical analysis
We calculated differences in baseline characteristics between participants and those without 
follow-up using univariate analyses. We created WMH probability maps and distribution 
maps of lacunes for the three time-points separately as well as for change. WMH decline was 
defined as more than 0.25 mL volume decline, as previously this was shown to be smallest 
change that could be confirmed visually 274. Changes of WMH volume with increasing age 
were plotted at individual level using R package ggplot2 (version 2.1.0) 282. R package lme4 
was used to perform mixed-effects regression analysis with maximum likelihood estimation 
to analyse WMH change as function of baseline age and time (version 1.1-12) 283. We used a 
random intercept and random slope model, which permits the estimation of an average slope 
across the whole cohort while allowing for inter-individual variability. By smoothed curves 
using loess smoothing we explored average WMH change with increasing age. To evaluate 
a possible quadratic relationship, indicating non-linear progression of cSVD, we compared 
model fit between the full model and the full model with a quadratic term for increasing age 
during follow-up included, using χ2 test and change in Akaike information criterion (AIC). 
Multicollinearity between different cSVD markers was investigated using regression analysis. 
To determine remote effects of cSVD progression, we analyzed the relation between WMH 
progression in the first follow-up interval, and GM, WM and total brain atrophy in the second, 
adjusted for age, sex, baseline volume, and atrophy during the first follow-up period, by 
means of linear regression analysis. 
We created WMH probability maps stratified by baseline age (<60 years, 60-70 years and >70 
years) and by baseline WMH severity (mild, moderate and severe). We repeated mixed-effects 
regression analysis stratified by baseline WMH severity to explore change in WMH within these 
groups separately. We calculated odds of cSVD progression according to baseline Fazekas 0-1 
versus Fazekas 2-3 by logistic regression analysis, adjusted for age and sex.
Statistical analyses were performed using SPSS Statistics version 20 and R Programming 
Language version 3.2.1. 
Results
Baseline characteristics are presented in Table 1. Mean age at baseline was 62.5 ± 7.7 years 
and 59·1% was male. Mean follow-up duration was 5.4 ± 0.2 years until first and 8.7 ± 0.2 
years until second follow-up. Those lost to follow-up were significantly older, had more 
severe baseline cSVD characteristics, and more often had hypertension, diabetes and 
hypercholesterolemia compared to participants (Supplementary Table 1).
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Temporal dynamics of cSVD 
Probability maps of presence and increase of WMH are shown in Fig. 1A, Fig. 1B and 
Supplementary Movie 1. Mean WMH progression was 0.54 mL/yr (median 0.24; IQR 0.11-0.64 
mL/yr). Progression of WMH increased with higher baseline age (Fig. 2, Supplementary Movie 
2). In mixed-effects regression analysis including a random intercept and random slope, 
each year increase of age at baseline resulted in an increase in WMH as percentage of WM of 
0.10% (95% CI: 0.07-13.7%). Including a quadratic term for increasing age during follow-up 
significantly improved the model (AIC base model 2995.2 versus AIC extended model 2932.9, 
χ2 p<0.001). 
Fifty-six participants (20.3%) developed new lacunes over nine years (2.3%/yr; Table 2). The 
distribution of lacunes is shown in Fig. 1C and Supplementary Movie 3. Incidence of lacunes 
was higher for the second follow-up period (3.5%/yr) than for the first follow-up period (2.7%/
yr). 
Fifty participants (18.9%) developed new microbleeds over nine years (2.2%/yr) (Table 3). 
Incidence of microbleeds in the second follow-up period (4.2%/yr) was higher than in the 
first follow-up period (1.7%/yr). 
Multicollinearity between cSVD markers is shown in Supplementary Table 2.
Vanishing SVD
Besides progression we also noticed cSVD regression. We observed decline in WMH volume 
in 26 participants (9.4%; median decline -0.5 mL; IQR: -0.9 to -0.3 mL) during the first follow-
up period and in 5 participants (1.8%; median -0.5 mL; IQR: -0.9 to -0.4 mL) during the second 
follow-up period. In one participant WMH volume declined over the course of nine years 
(0.4%; -0.4 mL). In 10 participants (3.6%) 14 lacunes could not be found at follow-up imaging 
(Table 2). In 15 participants (5.7%) 37 microbleeds vanished after nine years of follow-up 
(Table 3). Examples of vanishing lacunes and microbleeds are shown in Fig. 3.
Remote effects of SVD
Mean WM atrophy was 21.6 mL over nine years (0.54%/yr) and mean GM atrophy was 22.2 
mL (0.41%/yr). WM and GM atrophy were higher for the second follow-up period (WM 0.73%/
yr; GM 0.58%/yr) compared to the first period (WM 0.43%/yr; GM 0.30%/yr). WMH progression 
in the first follow-up period was associated with total brain atrophy in the second follow-
up period (β=0.124; p=0.040) as well as with atrophy of WM (β=0.149; p=0.013) but not with 
atrophy of remote GM (β=0.045; p=0.461).
Heterogeneity in temporal dynamics of SVD
Mean WMH progression over nine years was 2.4 mL for participants with mild WMH at baseline, 
12.0 mL for those with moderate WMH and 15.2 mL for those with severe WMH (Fig.4, Fig.5 
and Supplementary Movie 4). From participants with mild WMH at baseline, six percent 
showed WMH progression beyond measurement error, compared with 75% of participants 
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Figure 1: Probability maps of WMH and lacunes
Probabilities of presence of WMH at three time-points (A) and probabilities to increase over these three time-
points (B), colour-coded in percentage from 5 to 75%. Probability maps through the whole brain can be seen in 
Supplementary Movie 1. Panel C shows the distribution of lacunes at three time-points. Whole brain distribution 
maps can be seen in Supplementary Movie 2.
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Examples of a vanishing lacune (A), who appear to be assimilated by the ventricle. Vanishing microbleeds (B) 
appear to have faded away over time. 
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Figure 4: WMH probability maps stratified by baseline WMH severity
Probabilities of presence of WMH stratified by baseline WMH severity, colour-coded in percentage from 5 to 
75%. Baseline WMH severity is determined as mild (Fazekas 0-1; n=211), moderate (Fazekas 2; n=33) and severe 
(Fazekas 3; n=20). The overall 9-year change is shown in the right column. Probability maps through the whole 
brain can be seen in Supplementary Movie 4. 
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with moderate or severe WMH. Participants with moderate to severe WMH at baseline had 36 
times higher risk of WMH progression compared to participants with mild WMH (OR 35.5; 95% 
CI 15.8-80.0; p<0.001). Participants with moderate to severe WMH also more often developed 
incident lacunes (OR 5.7; 95% CI 2.8-11.2; p<0.001) and microbleeds (OR 2.9; 95% CI 1.4-5.9; 
p=0.003) compared to participants with mild WMH at baseline. 
Discussion
In this study we showed the temporal dynamics of cSVD, revealing both cSVD progression and 
regression, using three imaging assessments over a period of nine years. We demonstrated 
that progression of all cSVD markers occurred in a non-linear fashion, accelerating over time 
consistent with a quadratic course. Progression of WMH was associated with atrophy of 
adjacent white matter, but not with atrophy of remote grey matter. In addition, we showed 
that participants with moderate or severe WMH had a high likelihood of progression of their 
cSVD, whereas participants with only mild cSVD rarely showed progression, not even over a 
period of nine years.
This is the first study to demonstrate that cSVD progression is not linear but accelerates with 
increasing age. While the average progression in our study is comparable with other studies 
14,15,17-20,22,269, the use of three imaging assessments allowed us to show that cSVD progression 
accelerated over time, providing evidence for a non-linear process 270,271. Moreover, our results 
suggest that a quadratic course of SVD progression over time is plausible, since including 
a quadratic term for increasing age during follow-up significantly improved the model. 
Although we would need more than three time-points to further study exponential functions, 
our study indicates non-linear temporal dynamics of cSVD progression. Our findings do not 
support the hypothesized ceiling effect in which WMH progression reaches a certain threshold 
at high age and high lesion volume,284 as we also saw WMH progression in those at high age 
and with high cSVD lesion load.
Imaging assessments at three time-points also enabled us to identify vanishing of cSVD 
markers followed by progression, in a cohort that on average showed progression. This 
observation provides further evidence that cSVD does not gradually evolve but is a dynamic 
process, with progression interrupted by regression in some. Thus far only few other studies 
have reported a decline in WMH volume 270,271,273,274, possibly because WMH decline within a 
certain time window was compensated by WMH progression thereafter (or vice versa). Two 
imaging assessments do not allow disentangling of episodes with regression from those with 
progression. 
The observed decline in WMH may have several explanations. First, WMH decline in the 
first follow-up period could be explained in part by partial volume effects caused by slight 
adjustments in FLAIR sequences between baseline and first follow-up. However, we think 
this explanation is unlikely because WMH volumes calculated from even and odd slices 
were identical and because we also found WMH decline between the second and third MRI 
assessment, performed with identical imaging protocols. Second, recently developed WMH 
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might represent areas of tissue oedema. Reduction in tissue oedema at a later stage could 
then lead to reduced WMH volume 273. Third, improved control of vascular risk factors or 
factors influencing the blood-brain-barrier might play a role by reducing WMH volume 273,274.
Disappearance of lacunes could be due to partial volume effects, due to “collapsing” lacunes 
or to incorporation of the lacune into the ventricle (Fig. 3) 275,276. Vanishing microbleeds may 
be explained by partial volume effects as well as by clearance of hemosiderin-containing 
macrophages 278. Our findings are in line with the latter hypothesis. In most cases microbleeds 
seemed to “fade away” between 2006 and 2011 and were no longer visible in 2015.
The relation between WMH progression in the first follow-up period and occurrence of WM 
atrophy and TBV atrophy during the second follow up, suggests that cSVD affects adjacent 
brain structures. In contrast to other studies 79,279, we did not find an association with overall 
remote GM atrophy. WM atrophy might be the result of disconnected white matter tracts due 
to cSVD, leading to axonal loss by anterograde or retrograde degeneration, and subsequently 
the loss of brain volume 29,103. The clinical observation that patients with similar cSVD burden 
show heterogeneity in clinical symptoms might be explained by disconnection of WM tracts.
All cSVD markers at baseline were important predictors for cSVD progression, in a non-linear 
way and independent of age. The differential progression of cSVD suggests heterogeneity in 
aetiology of mild versus severe cSVD. Small WMH volumes, representing punctuate WMH or 
small periventricular caps, probably are of mixed origin, consisting of enlarged perivascular 
spaces and subependymal gliosis 22. On the contrary, confluent WMH represent a continuum 
of ischemic tissue damage, ranging from mild fibre loss to complete infarction and may have 
a more malignant course in terms of cognitive deterioration. These different aetiologies call 
upon a different diagnostic and therapeutic approach. 
Strengths of this study include the large cohort of elderly participants with cSVD and the 
long duration of follow-up of almost nine years. Furthermore, imaging assessments at three 
points in time allowed us to characterize change in cSVD over time, including vanishing cSVD. 
cSVD was rated according to standardized procedures 12, minimizing risk of misclassification. 
Moreover, semi-automatic quantification of WMH volumes reduced risk of information bias 
41. Finally, to reduce chance of misclassification, brain volumes were determined with the 
newest segmentation routines of SPM12 and corrected for segmentation errors using WMH 
masks. Finally, our study has high external validity for older patients with cSVD in a general 
neurology clinic. 
A limitation of our study is change of MRI scanner between baseline and first follow-up 
leading to a distortion of the T1-images. However, by taking into account the third MRI 
assessment we are able to capture most of this possible bias. A slight adjustment in FLAIR 
sequence between baseline and first follow-up may have caused an overestimation of 
incident lacunes. However, we were able to limit the possible negative effects by reslicing 
follow-up to baseline FLAIR images before rating lacunes. Finally, selection bias may have 
led to an underestimation of progression of cSVD, since those who dropped-out at follow-up 
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were older, had more vascular risk factors and more severe cSVD at baseline than participants 
who completed follow-up examination.
Our study demonstrates that cSVD progression is a non-linear, dynamic and highly variable 
process, predominantly seen in patients with moderate or severe WMH at baseline. And, 
equally important, those with no or mild WMH rarely show progression over a nine year 
course. Since cSVD progression has been linked to cognitive decline and development of 
dementia, our study now allows for the early identification of those at high risk for cSVD 
progression. It is likely, although not directly investigated in this study, that these patients 
are also at the highest risk to develop dementia, suggesting that therapeutic strategies to 
prevent cSVD progression are particularly needed for patients with moderate to severe WMH. 
Further understanding of temporal dynamics of remote effects of cSVD can be obtained by 
performing serial imaging at much shorter time intervals. 
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Supplementary Table 1: Baseline characteristics of participants compared with those lost to 
follow-up
Participants 
n=276
Lost to follow up
n=227
significance
Demographics
Age (years), mean (SD) 62.5 (7.7) 69.5 (8.5) p<0.001
Sex, male, no (%) 163 (59.1) 121 (53.3) p=0.207
Education >primary school, no (%) 259 (93.8) 32 (14.1) p=0.004
MMSE score, mean (SD) 28.6 (1.3) 27.6 (1.8) p<0.001
SVD Characteristics
White matter hyperintensities, ml, 
median (IQR) 
2.3 (0.8-6.1) 7.7 (2.6-16.2) p<0.001
White matter hyperintensities, ml, 
Mean (SD) 
5.8 (9.5) 11.9 (13.6) p<0.001
% WMH of WM, mean (SD) 1.3 (2.3) 2.9 (4.4) p<0.001
Participants with any lacunes, n (%) 55 (19.9) 77 (33.9) p<0.001
Total number of lacunes 117 135 p=0.038
Participants with any microbleeds, 
n (%)  ͦ
36 (13.1) 47 (20.9) p=0.022
Total number of microbleeds ͦ 140 159 p=0.496
Territorial Infarcts, n (%) 23 (8.3) 34 (15.0) p=0.023
Modified Fazekas score
Mild WMH (0-1), no (%) 218 (79.0) 114 (50.2) p<0.001
Moderate WMH (2), no (%) 38 (13.8) 70 (30.8) p<0.001
Severe WMH (3), no (%) 20 (7.2) 43 (18.9) p<0.001
Brain volumes  
White matter volume, ml (SD)  465.6 (38.9) 441.5 (50.2) p<0.001
Grey matter volume, ml (SD)  620.7 (48.9) 588.7 (51.6) p<0.001
Vascular risk factors
Smoking, ever, no (%) 196 (71.0) 157 (69.2) p=0.696
Alcohol, glasses/week, mean (SD) 8.3 (9.0) 7.5 (9.7) p=0.367
Glucose lowering drugs, no (%) 23 (8.3) 43 (18.9) p=0.001
Hypertension, no (%) 190 (68.8) 179 (78.9) p=0.015
BMI, mean (SD) 27.1 (4.1) 27.2 (4.2) p=0.778
Lipid-lowering drugs, no (%) 118 (42.8) 119 (52.4) p=0.032
Data are represented as numbers (%), mean (SD) or median (IQR). Comparisons between participants and those 
lost to follow-up were performed by t-test, Chi-square or Mann-Whitney-U test . ͦ For ratings of microbleeds 4 
participants were additional excluded based on missing T2*or scan artefacts at baseline.
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Part VI: 
Summary and general discussion

11.
Summary
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Cerebral small vessel disease (cSVD) is frequently seen on FLAIR MRI of older adults. White 
matter hyperintensities (WMH), lacunes of presumed vascular origin (lacunes), microbleeds 
and (sub)cortical atrophy are the well known ‘traditional cSVD makers’. cSVD is very common 
in persons aged above 60 years, it’s incidence increases non-linearly with age, and its 
progression is thought to be related to baseline cSVD load and vascular risk factors. The 
clinical spectrum and the prognosis of cSVD is highly heterogeneous and ranges from very 
mild symptoms to full blown stages of dementia and even death. With the aid of conventional 
MRI it has proven to be very difficult to predict which patients with cSVD are at highest risk to 
develop these severe clinical symptoms, and who will not. Therefore other factors apart from 
the ‘traditional cSVD markers’ might determine the transition to incident dementia in some, 
while leaving others unaffected. Such ‘other factors’ could be the microstructural integrity 
of the white matter, (cSVD extending beyond lesions visible on conventional MRI) and brain 
volumes of structures known to be related to behavioural symptoms. 
Studies in this thesis are based on data from the RUN DMC study; a prospective cohort study 
among 503 independently living, non-demented elderly with cerebral cSVD between 50 and 
85 years old, that investigates causes and consequences of cSVD with baseline assessment 
in 2006-2007 with a 5- and 9-year follow-up period.  We describe the associations between 
baseline imaging characteristics (both macro- and microstructural) and the attendant 
behavioural consequences 5 years later. The focus of this thesis is on cognitive decline and 
depressive symptoms. Finally the 9 year temporal dynamics of traditional cSVD characteristics 
is described.
Macro- versus microstructural MRI in cognition and incident dementia
In Part I (chapter 2) we report on the possible (additional) clinical value of DTI over 
conventional MRI sequences with respect to cognitive performance at the cross sectional 
level. All MRI parameters together accounted for 1–6% of the variance in cognitive function 
on top of 22–36% already explained by age, gender, and level of education. Of the MRI 
parameters, the WM microstructural integrity did not substantially contribute to the 
explained variance of cognitive function (1%). The MD of the WM however had the strongest 
association with cognitive performance. Therefore we concluded that the cross-sectional 
relation between WM microstructural integrity and cognitive performance is rather weak, and 
has limited additional value to the macrostructural MRI parameters.  Part II prospectively 
describes the relation between baseline brain structures, both assessed with MRI (FLAIR, 
T1 and DTI) and the development of incident dementia or cognitive decline after 5 years. 
In chapter 3 we showed a 5.5-year cumulative risk of all-cause dementia of 11.1% (95% CI 
7.7–14.6) in our study. Furthermore we showed that both low white matter volume (HR 0.65 
(95% CI 0.44-0.96)) and low hippocampal volume (HR 0.68 (95% CI  0.47-0.99)) were related 
to the development of dementia 5 years later, independent of cSVD. Interestingly there 
was no additional diagnostic value of any of the cSVD characteristics (including global DTI 
parameters) in predicting the occurrence of dementia. We showed in chapter 4 that diffusion 
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parameters in the hippocampus, independent of hippocampal volume, brain volume and 
cSVD markers, are related to an increased dementia risk (HR 1.44 (95% CI 1.10-1.88)). Sub 
analyses revealed that low hippocampal microstructural integrity more than doubled the 
dementia risk in the group of healthy older adults without evidence of hippocampal atrophy 
(HR 2.66 (95% CI 1.30-5.44)). Therefore DTI of the hippocampus might identify persons at risk 
for dementia at an earlier stage than using volumetric measures of the hippocampus alone, 
and possibly serves as a surrogate marker of disease progression. In chapter 5 we report 
on baseline global DTI parameters and decline in cognition after 5 years. We found that 
baseline DTI parameters in the white matter were not related with decline in global cognitive 
performance or in other cognitive domains after adjustment for demographics and imaging 
markers (both volumetric and cSVD). This was in line with the baseline finding in which we 
showed only limited added value of global DTI measures over other MRI measures (chapter 
2) and the lack of relation between global DTI parameters and incident dementia (chapter 
3). 
Depressive symptoms in cerebral small vessel disease
In Part III we report on depressive symptoms, and the relation between depressive 
symptoms and cognition in older adults with cSVD. The association between amygdala 
volume  and depressive symptoms is described in chapter 6 on a cross-sectional level. We 
showed that lower volume of the left amygdala was associated with depressive symptoms 
occurring for the first time later in life (LODS), independent of cSVD markers. Each decrease 
of total amygdala volume (by mL) was related to an increased risk of LODS (OR = 1.77; 
95% CI 1.02-3.08; p=0.04). In chapter 7 we investigated the white matter integrity of older 
adults with and without depressive symptoms, using Tract-Based-Spatial-Statistics (TBSS), 
on a cross-sectional level. We showed that older adults with depressive symptoms had a 
lower microstructural integrity of the white matter compared to those without depressive 
symptoms, predominantly located in the prefrontal white matter tracts, which are thought to 
play an important role in the pathogenesis of mood. This was independent of global cognitive 
performance. After adjustment for cSVD markers, the magnitude of this association grossly 
disappeared suggesting that cSVD plays a role. In chapter 8 we prospectively report on the 
role of depressive symptoms on incident all-cause dementia after 5 years follow-up, taking 
both the age of onset and baseline cognitive performance into account. We showed a higher 
dementia risk in those with depressive symptoms at baseline (HR 2.7 (95%CI 1.4-5.2)), which 
was driven by LODS, and was independent of cSVD markers. In those with a high cognitive 
performance at baseline depressive symptoms are indicative for incident dementia, whereas 
there was no such risk difference between those with and without depressive symptoms in 
participants with a lower cognitive performance at baseline (no depressive symptoms 0.0% 
vs. depressive symptoms 6.9%; log-rank p<0.001). 
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In part IV (chapter 9)  we reviewed the clinical consequences; (cognitive, motor, mood) and 
the risk factors of microstructural damage of the white matter, as assessed with diffusion 
tensor imaging. 
Temporal dynamics in cerebral small vessel disease
Finally in part V we described the 9-year change of cSVD markers, using two follow-up 
moments (2011 and 2015). In chapter 10 we elaborate on the dynamics of cSVD, taking both 
new developed as well as apparent decline of the traditional cSVD markers into account. 
Mean WMH progression over nine years was 4.7 mL (0.54 mL/yr; IQR 0.95–5.5 mL), 20.3% of 
patients had incident lacunes (2.3%/yr) and 18.9% incident microbleeds (2.2%/yr). WMH 
volume declined in 9.4% of the participants, and lacunes vanished in 3.6% and microbleeds 
in 5.7% of the participants. These numbers were calculated using 2 follow-up moments, 
allowing us to report on the non-linear progression of cSVD. Furthermore we showed that 
those with very little cSVD at baseline showed little to no progression in contrast to those 
with already moderate to severe baseline cSVD load, who show most progression (OR 35.5; 
95% CI 15.8-80.0; p<0.001 for WMH progression; OR 5.7; 95% CI 2.8-11.2; p<0.001 for incident 
lacunes and OR 2.9; 95% CI 1.4-5.9; p=0.003 for incident microbleeds). 
Conclusion
The studies described in this thesis identified imaging markers which can help to gain more 
insight into the pathophysiological processes that underlie the behavioural consequences 
of cerebral small vessel disease. At the same time, studies underline the limited additional 
value of diffusion tensor imaging on top of the macrostructural imaging markers in an elderly 
population with already long-standing cSVD. Furthermore in those developing depressive 
symptoms for the first time at older age, while performing cognitively well during objective 
testing, depressive symptoms might be the first indication of incident dementia.
Future research should address whether an increase in cSVD (incident lacunes or microbleeds, 
decline in microstructural integrity, or increase of WMH volume), or brain atrophy (change 
in hippocampal, amygdalar, WM and GM volumes), precede newly developed behavioural 
consequences, and possibly has a better clinical correlate than the baseline imaging markers.
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12.
General discussion and future perspectives
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The overall aim of the studies described in this thesis was to gain better insight in the role of 
macro and microstructural aspects of markers of cerebral small vessel disease (cSVD) and 
the attendant behavioural consequences. Furthermore the relation between depressive 
symptoms and the risk of incident dementia was studied. Finally we described the frequency, 
severity and the temporal dynamics (both progression and reduction) of the macrostructural 
cSVD markers over a 9-year period in our cohort. 
These studies are based on data from the RUN DMC study; a prospective cohort study among 
503 independently living, non-demented elderly with cerebral cSVD between 50 and 85 years 
old, that investigates causes and consequences of cSVD with baseline assessment in 2006-
2007. In 2011-2012 and in 2015 both the extensive cognitive and motor assessments and also 
the cerebral MRI were repeated, resulting respectively in a 5- and 9-year follow-up period. 
In the previous chapters the individual studies have been addressed. In this chapter the 
overall methodological considerations will be discussed. Subsequently, the main findings 
of the studies will be put in perspective and potential clinical implications will be discussed. 
Finally suggestions for future research are given.
Methodological considerations
The studies in this thesis are based on cross-sectional43,47,48 and longitudinal data (5.4 years 
follow-up44-46,49 and 8.7 years follow-up285). The use of cross-sectional data limits causal 
inference. However our longitudinal design allowed us to investigate causal relations 
between imaging characteristics and incident dementia and decline in cognition, as well 
as the change in imaging characteristics. Because of the observational nature of our study, 
we have to interpret these results with caution. Further methodological considerations 
(precision, internal validity and external validity) will be discussed on the basis of principles 
described by Rothman and Greenland.286
Precision: minimizing ‘random error’ 
Precision (or reliability) reflects the amount of random error (or non-differential 
misclassification) in a measurement286 and with that the reproducibility of that measurement. 
Random error may result in imprecise (or unreliable) estimates, resulting in broad confidence 
intervals (PANEL 1). 
Especially in a longitudinal study random error tends to cause ‘regression towards the mean’, 
which makes it more difficult to detect a relation between determinant and outcome. A 
possible solution to reduce random error, and increase precision, is to increase the number 
of measurements.
In addition, in our study precision was enhanced by having a large sample size, n=503 at 
baseline to begin with. 
Precision in measurement of the outcome “cognitive performance” was enhanced by 
performing multiple neuropsychological tests. Tests within one compound score assessed 
the same cognitive domain, resulting in multiple measurements of the same variable.139 By 
doing so, the intra-individual variability was reduced, giving a better estimate of the true 
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value per domain. Cognitive scores were adjusted for a number of faults by using SAT scores, 
giving a better estimate of the test-score. 
The precision in assessing depressive symptoms was increased by the use of a valid 
questionnaire,196 used in large population based studies.67 
Although commonly used as a screening tool with high sensitivity and specificity for depressive 
symptoms,287 the CES-D is not specific for depressive symptoms, and could be considered a 
screening for general affective distress. Additional usage of the Geriatric Depression Scale 
(GDS) could have added to precision in measuring depressive symptoms in our study of older 
adults.
Internal validity:  limiting systematic error or bias
Validity (or accuracy) involves minimizing systematic error in a measurement. Systematic 
error may result in invalid, (or inaccurate) results, not reflecting the ‘true value’ (PANEL 1). 
Three types of systematic error often are identified: 1. selection bias, 2. information bias (or 
differential misclassification) and 3. confounding.
1 Selection bias
In the case of selection bias the study sample is not representative of the population that is 
to be analyzed.286 This occurs when the relation between the determinant (imaging markers) 
PANEL 1: Precision and Validity       
   
 Accurate Inaccurate 
(Systematic error) 
  
 
 
Precise 
 
 
 
 
 
 
Imprecise 
(methodological 
error) 
  Adapted from Ahlbom & Norell, 1990, 
Introduction to modern epidemiology 
 
 
A:  Precise and Accurate     OR Reliable and Valid 
B:  Precise but Inaccurate OR Reliable but not Valid 
C:  Accurate but Imprecise OR Valid but not Reliable 
D:  Imprecise and Inaccurate OR not Valid and not Reliable 
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and outcome (behavioural consequences) is not the same for participants as for the non-
participants, potentially eligible for the study. It is impossible to adjust for selection bias in 
the analyses, therefore the only thing one can do is to obtain a maximal response.
The response rate at baseline was 71.3%, which is high but incomplete. Non-participants 
were older, and had more severe WMH (as rated on the scan prior to inclusion) than 
participants. For both are related to cognitive performance and depressive symptoms, it is 
possible that those with the highest degree of cSVD and cognitive disturbances were not 
included in our study, resulting in an underestimation of the effect of cSVD on behavioural 
symptoms. To obtain the highest possible response at follow-up, participants were annually 
contacted by sending them both a Christmas card and a news letter in which we informed 
them on the study progression and the presumed start of the next follow-up. This resulted in 
an extremely high response of 99.6% for our primary outcome measure ‘incident dementia’ 
in 2011, resulting in virtually no selection bias with respect to this outcome. 
The response for in-person testing of the cognitive domains (2011) was 79.1% and in 
2015 54.9% underwent MRI scanning for the third time in a row. Those without follow-
up assessment, again, were older and had a worse baseline cSVD load. In addition they 
performed lower on cognitive testing, had lower brain volumes and more vascular risk factors 
at baseline. Since these variables were independently associated with cognitive performance 
and SVD progression,51,53,129  this probably resulted in an underestimation of the effect of 
imaging characteristics on cognitive decline, and an even further underestimation of cSVD 
progression after 9 years. This issue is a well-known paradox of follow-up studies: to prove 
a causal relation over time, long follow-up is required, however, the longer the follow-up 
period the higher the risk of selective drop-out, leading to selection bias.
2. Information bias
Information bias is also named (differential) misclassification. It results from incorrect 
information on the determinant, influenced by the outcome variable, or vice versa. For 
example, rating of the MRI-scans (determinant) can be influenced by prior knowledge 
of a dementia diagnosis (outcome) in that person. This error might lead to an over or 
underestimation of the results, affecting validity. 
In our study both at baseline and follow-up, the assessments of imaging markers and the 
outcome variables (depressive symptoms, cognitive performance) were performed blinded 
for, and independent of each other. Moreover, assessment of vascular risk factors and 
demographics was performed independently and blinded from the MRI scan. Thus it is very 
unlikely that misclassification has been differential, and with that the assessment of both 
these determinants and outcome variables suffer from non-random error. Remaining issues 
on differential misclassification are discussed below. 
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Possible systematic error in MRI measures
All baseline scans were performed on one single MRI-scanner, without adjustment of 
scan-protocol or software. Moreover, brain volumes (WMH, amygdalar and hippocampal 
volume) were manually segmented by one trained rater (IvU), with high inter- and intra-rater 
correlations on random subsamples of 10%, reducing systematic error. 
The change in MRI-scanner between baseline (SONATA) and the first follow-up (AVANTO) 
might have led to differences (geometric distortion of theT1 images) between baseline and 
follow-up images. To minimize these effects, follow-up brain volumes were corrected to the 
baseline intracranial volume before normalization. Furthermore, comparing brain volumes 
from the second follow-up with the first (both performed on the same MRI scanner), the 
scanner change did not seem to be a major problem. To further prevent systematic error 
the ‘traditional’ cSVD markers were manually revised according to the STRIVE criteria, 
(including the baseline cSVD markers), each time by the same person, which is the gold 
standard. WMH were assessed volumetric which is superior in a longitudinal design in 
order to show progression, for visual rating scales provide a ceiling effect.284,288 At follow-up 
WMH volumes were segmented using a (semi)automated WMH detection method, lowering 
misclassification. 
Brain volumes (WM, GM and CSF and ICV) were segmented using the newest segmentation 
version SPM 12 (instead of SPM 5) which is currently the most up-to date version. Because 
the use of this newest version, the amount of non-brain tissue being misclassified as GM or 
CSF is reduced.289 
Possible systematic error in cognitive testing and incident dementia
Possibly some patients with incident dementia might have been missed. The cut-off point 
of 26 points or lower on the MMSE (used as a screening tool for dementia) might not have 
been sensitive enough for cases of dementia in early stage of the disease, VaD (most likely to 
express executive dysfunction that is not adequately captured by the MMSE), or in participants 
with higher education levels, leading to an underestimation of the dementia diagnosis in 
the relatively early stages.  However the additional high IADL scores and the confirmation of 
little or no interference in daily functioning in screen-negatives, is an indication that if any 
misclassification is present, it is presumably limited.
Furthermore, incident all-cause dementia, was a clinical diagnosis, based on the DSM-IV,62 
preferably  confirmed by a visit to the Radboud Alzheimer center.  When a visit to the Radboud 
Alzheimer centre was not possible, all available information (neuropsychological testing, 
medical records, baseline/follow-up imaging or information from caregivers) was reviewed 
by a panel. The use of the MRI as a supportive feature (diagnosis was based on cognitive 
testing and interference in daily functioning) might have led to differential misclassification 
(incorporation bias) when we dealt with difficult cases with fully normal or pathological MRI-
scans. Finally we were not informed on the genetic APOE status, CSF biomarkers or PET scan 
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at baseline, which could have further improved our dementia diagnosis and we obviously did 
not have pathological confirmation. 
3. Confounding 
Confounding occurs when a third variable is accountable for the found relation between the 
determinant and the outcome variable.286 This is of particular importance in longitudinal 
research aiming to identify causal realations.290 Confounding variables are associated 
with both the determinant and outcome variable, but are not part of the ‘causal chain’ 
(intermediate factor) leading to the outcome. In our study we adjusted for these possible 
confounders in our multivariate regression models.  
Because the large number of subjects in our study in most of the analyses, we were able to 
adjust for multiple confounders. If this was not possible at once (in some of the longitudinal 
analyses), we investigated these relations using different models with different groups of 
confounders per model. 
Age, gender, level of education, depressive symptoms, brain volumes, but also some of the 
other cSVD characteristics were considered possible confounders. 
We intentionally did not adjust for vascular risk factors291 in our analyses, as they were 
thought to be an ‘intermediate factor’ (e.g. causing WMH and lacunes and microbleeds). 
Including these in the models, might cause an existing relation between MRI markers of cSVD 
and behavioral consequences to disappear, due to over-adjustment. In addition, since WMH 
and lacunes are presumed to result from largely the same underlying pathology, treating 
them as confounders in an analysis might have led to an underestimation of the effect of the 
determinant, for the above-mentioned reason. Finally, as WM microstructural integrity is now 
considered to be a part of the SVD-spectrum, the WMH (and other traditional cSVD markers) 
that are thought to cause this microstructural damage, probably are part of the causal chain, 
and therefore adjustments for these markers might have led to over-adjustment.
External Validity -- Generalization
An important aspect of study design is whether the results obtained in the study group 
represent the wider population in real world situations, and thus can be extended to make 
predictions about the entire population.286
Our study was performed in an university hospital-based cohort of older adults with cerebral 
cSVD on neuro imaging. We think that our results can be generalized to patients aged between 
50-85 years old with cSVD, (which is likely to be related to arteriolosclerosis and vascular risk 
factors), visiting a general hospital. This is based on the inclusion of all consecutive patients 
that were referred to the outpatient clinic of the neurology department who underwent 
neuro-imaging. The majority was referred by their general practitioner and seen as a first 
opinion. Moreover, patients were selected based on neuro-imaging characteristics of cSVD,61 
and cSVD is a common disorder with a prevalence over 90% in older adults over 60 years of 
age. 
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Main findings
Imaging markers that precede cognitive decline after 5 years
In our cohort, ‘traditional’ cSVD markers were not associated with incident dementia after 
adjustment for confounders, as was shown previously.41  WM and hippocampal volume did 
predict the dementia risk after 5 years.44 WM (subcortical) atrophy is now also seen as a part 
of the cSVD spectrum. The WM represents structural connectivity between different brain 
structures, including the neocortex and hippocampus, which are crucial in cognitive function. 
Therefore it is not surprising that a lower WM volume is a predictor for incident dementia. 
Possibly this WM atrophy occurs through remote (or better: adjacent) effects of cSVD. For 
example when lacunes occur, WM volume does not only diminish through local necrosis, 
but probably also by anterograde or Wallerian degeneration.103 Possibly this relatively severe 
brain damage (WM atrophy) has such severe clinical consequences (incident dementia), that 
the traditional cSVD markers do not substantially contribute to the (severity of the) clinical 
dementia syndrome in the presence of brain atrophy.  
Hippocampal atrophy is a well-known characteristic in dementia, and is thought to be a 
major cause of the profound deficit in episodic memory consolidation in dementia.33 We 
further investigated this hippocampus at a microstructural level, and found that a lower 
hippocampal microstructural integrity, especially hippocampi which are volumetrically 
intact, predict incident dementia.45 This might provide an early insight in the development 
of dementia.
We were the first study to investigate WM microstructural integrity and the risk of incident 
dementia, for at a cross sectional level WM microstructural integrity was suggested to play 
a role in dementia.81  We found no additional value of WM microstructural integrity on top 
of the macrostructural imaging characteristics on the risk of dementia. Possibly this loss 
of microstructural integrity of the WM is not severe enough to result in a clinical dementia 
syndrome44 (or cognitive decline)46 in the presence of WM and hippocampal atrophy, which 
probably both have a stronger relation with incident dementia. 
Taken together, in older adults with cSVD, WM volume, hippocampal volume and hippocampal 
microstructural integrity are independently related to the 5 year cumulative risk of dementia 
in older adults with cSVD. We did not find this for ‘traditional’ cSVD markers and WM 
microstructural integrity. These findings might provide a better insight in the development 
of dementia. Another important conclusion is the limited clinical added value of diffusion 
tensor imaging in quantifying the risk of dementia.
Depressive symptoms in cSVD and its relation to incident dementia
 Traditional cSVD characteristics were known to be related with depressive symptoms,36 but 
little was known about the role of the WM microstructural integrity in relation to depressive 
symptoms. We showed that older adults with depressive symptoms had a lower WM integrity 
compared to those without,48 especially in the fronto-subcortical region, independent of 
global cognitive functioning. After adjustment for traditional cSVD markers these results 
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almost disappeared, suggesting a role of this ‘visible’ cSVD. These findings suggest that 
microstructural WM damage might underlie the development of depressive symptoms in 
cSVD patients at older age, by disruption of the circuits that are involved in mood regulation. 
Furthermore we showed in our longitudinal analyses that depressive symptoms 
independently increased the dementia risk after 5 years,49  which was driven by those 
who develop depressive symptoms for the first time later in life. Our results suggest that 
depressive symptoms are a first symptom of cognitive decline later in life, rather than a risk 
factor, as we did not find the association with early onset depressive symptoms and incident 
dementia. Especially in those with good objective cognitive performance the depressive 
symptoms indicate a higher risk for the development of dementia 5 years later. This is an 
interesting finding, for in current practice in those who present with both subjective cognitive 
problems and depressive symptoms (but perform well during objective cognitive testing), the 
depressive symptoms are thought to be the cause of the perceived cognitive problems. Our 
findings suggest that those with a high performance on cognitive testing while presenting 
with depressive symptoms for the first time later in life, should be monitored more closely for 
the development of dementia in the following years. 
In those with low cognitive performance, depressive symptoms did not differentiate between 
those who are and are not at risk for dementia. Probably because low cognitive performance 
is a strong risk factor for incident dementia, depressive symptoms have no significant 
contribution to the overall dementia risk in this group.  
Small vessel disease; a dynamic process
Thus far, little is known about cSVD progression, especially not over a long time period. We 
showed that, over a 9 year period, cSVD  is a dynamic process which is, in general, progressive. 
Having a closer look into this process, it encompasses not only progression but also 
reduction, which is thus far not or only partly understood.285 WMH regression, as we found in 
some, could possibly be present due to reduction of tissue oedema, as could be explained 
by those individuals with WMH progression due through acute infarction.292 Few suggested a 
hypothesis for this reduction of lacunes and microbleeds, however evidence is still lacking. 
293 278 Because of the availability of 2 follow-up moments in the RUN DMC study over almost 
a decade, we were able to provide evidence for the non-linear progression of WMH volume, 
incident lacunes and incident microbleeds which was not fully explained by increasing age. 
Those with low (macrostructural) cSVD load at baseline rarely showed progression even 
after 9 years, whereas those with moderate or severe cSVD had highest risk to progress. We 
could not find a ‘ceiling effect’ for this cSVD progression (the progression reaches a certain 
threshold) as was suggested previously.41 
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Clinical relevance and implications 
Because patients with cSVD have an increased risk of not only behavioural symptoms, but 
also a tripled risk on stroke and even death,41,294,295 294,296  it is important to identify those at risk 
as early as possible, preferably before the irreversible damage has been done. 
Those who present with (or even without) cognitive problems, and have a relatively low WM 
or hippocampal volume on brain MRI, have a higher risk to develop dementia in the years 
to come compared to those with intact WM and hippocampal volumes. This implies a pre-
clinical period, where intervention might be possible before the development of dementia. 
Persons with low WM and hippocampal volume should possibly be monitored more closely, 
and medical care should be optimized. Probably our study does not change the current 
MRI protocols used in clinical practice, for  demographic characteristics (foremost age and 
cognitive performance) remain the main predictors for conversion to dementia, and in the 
clinical practice hippocampal atrophy measurements are already used in the diagnostic 
process. In those with relatively intact hippocampal volumes, hippocampal DTI parameters 
may be of added value in dementia risk stratification. In clinical practice however it is 
questionable if DTI scanning is of usage, as diffusion tensor imaging takes a lot of time, and 
this technique is not available in most clinical practices yet.68 In conclusion, these findings 
provide an early insight into the pathophysiology of cognitive decline in older adults with 
cSVD, however DTI does not, or only limited, add to conventional MRI in explaining clinical 
expressions of cSVD. 
Because depressive symptoms  increase the cumulative risk of dementia 5 years later, in clinical 
practice it is important to monitor those with depressive symptoms that first occur at older 
age, for these might precede dementia. Especially in the patients performing relatively well 
in objective cognitive testing, depressive symptoms could be an early symptom of dementia. 
Therefore these patients should be monitored in contrast to current clinical practice. On the 
other hand, those who present with both good objective test scores and without depressive 
symptoms have very little chance to develop dementia, and can be comforted.
Finally cSVD progression, is predominantly seen in participants with severe WMH at baseline, 
whereas participants with mild WMH, though highly prevalent, rarely showed progression, 
not even over a period of nine years. This knowledge results in better understanding of 
both the aetiology as the consequences of cSVD, for it is likely that those with most severe 
WMH progression are at highest risk to develop behavioural consequences. Personalized 
treatment strategies to prevent cSVD progression should be optimized for all those with mild, 
moderate and severe WMH. Those with mild cSVD are at a low risk to progress and therefore 
can probably be reassured together with optimal vascular care. Preventive strategies are 
especially needed for those with moderate and severe WMH at all ages, for we did not find a 
ceiling effect and progression was independent of age. 
Preventing cSVD progression therefore is useful in all cSVD patients, for reducing cSVD 
progression might have a beneficial effect on the number of people suffering from the 
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behavioural consequences of cSVD, and might eventually be a therapeutic strategy to reduce 
cognitive decline.
Possible treatment targets 
As we showed in our study, the association between cSVD and cognitive decline is weak. 
Possibly the additional concept of brain ‘reserve’ plays a role, in which individuals with 
more reserve capacity  (including both 1. brain reserve such as microstructural integrity or 
volume because of genetic factors or good nutrition and 2. cognitive reserve representing 
better coping mechanisms), presumably better tolerate cSVD and with that express less 
clinical symptoms with the same cSVD load than those with less ‘reserve’.297 As genetic factors 
cannot be modified, continuing a healthy lifestyle at older age, preventing malnutrition and 
stimulating older adults to remain cognitively active might help in better toleration of present 
cSVD. Finally as depressive symptoms increase the dementia risk, it could be suggested that 
treatment of depression at older age could influence the risk for cognitive decline.298
Until now no randomized clinical trials have been performed to study the different preventive 
and therapeutic strategies in those with cSVD on the risk of behavioral consequences.299 
Possibly specific clinics such as in Florence (VAS-COG clinic), are a first step into a better 
understanding of cSVD patients with behavioural consequences, using more specified 
screening, diagnostic methods and treatment strategies. 300
Future research
One of the remaining questions is whether an increase in traditional cSVD markers (incident 
lacunes or microbleeds, decline in microstructural integrity, or increase of WMH volume), or 
brain atrophy (change in hippocampal, amygdalar, WM and GM volumes), precede newly 
developed behavioural consequences. Because of the availability of 2 follow-up moments in 
the RUN DMC study, temporal dynamics of cSVD can be assessed. Moreover, it is interesting 
to investigate if microstructural integrity changes precede macrostructural changes, and 
whether these changes in this microstructural integrity better correlate with incident 
behavioural consequences than baseline imaging characteristics, or macrostructural 
changes over time.301 Finally the follow-up of the RUN DMC study should investigate the 
‘remote effects’ of cSVD, taking ‘change in cSVD’ and subsequent brain atrophy (WM, GM and 
hippocampal volume) into account.
An important clinical challenge is the identification of intervention targets, in order to provide 
a possible therapy. Therefore it is important to identify which (vascular) risk factors are most 
important in causing cSVD progression and incident dementia. With the availability of the 
2 follow-up moments in the RUN DMC study, we are in a unique position to investigate 
these riskfactors.302 Eventually randomized clinical trials have to be performed to identify if 
treatment or prevention of these vascular risk factors not only diminish cSVD progression, 
but also have a clinical effect by reducing incident dementia.
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In future studies novel imaging markers of cSVD can be used as surrogate markers for 
behavioural symptoms, possibly explaining another part of the variability in the relation 
between cSVD and cognition or mood. Such imaging markers are cortical superficial siderosis 
(cSS), micro-infarcts. Novel quantitative imaging techniques including MR Perfusion imaging 
with arterial spin labelling (ASL), functional MRI (fMRI) and Positron Emission Tomography 
(PET) might give new insights in the mechanisms causing cSVD.29 Network analyses to study 
the whole brain connectivity, for example the aid of the graph theory, are interesting new 
techniques in investigating the change of behavioural consequences in relation to (change 
in) network disruption (both connectivity and functional).303  
In order to gain more insight into the aetiology of cSVD, studies with repetitive imaging, using 
diffusion weighted imaging, should be conducted to further investigate the contribution of 
acute ischemia to cSVD progression as was suggested by a small pilot study.292 This study 
has already emerged from the RUN DMC study, and started in 2016. 50 Participants of the 
RUN DMC study will be monthly scanned to gain more insight into the contribution of acute 
ischemic pathology in the development of cSVD. 
It could be interesting to investigate if the total burden of the individual cSVD markers 
are possibly more representative for the severity of the brain damage, rather than every 
individual marker separately.291,304 The sum of these markers might correlate better with 
incident dementia, cognitive decline or mood disturbances than the (macrostructural and 
microstructural) cSVD markers separately.

13.
Nederlandse samenvatting
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Cerebrale micro-angiopathie wordt in het Engels ook wel ‘cerebral small vessel disease’ 
(cSVD) genoemd, en beschrijft het pathologische proces van schade aan de kleine 
bloedvaten van de hersenen. Witte stof afwijkingen (WSA), lacunes (kleine herseninfarcten), 
microbloedingen en (sub)corticale atrofie zijn de bekende of ‘traditionele’ cSVD markers. 
cSVD wordt zeer regelmatig gezien op MRI-scans van mensen ouder dan 60 jaar. De incidentie 
neemt niet-lineair toe met de leeftijd, en de progressie van cSVD lijkt gerelateerd te zijn aan 
de hoeveelheid cSVD op baseline en de aanwezigheid van vasculaire risicofactoren. Het 
klinische spectrum en de prognose van cSVD zijn enorm heterogeen. Het klinisch spectrum 
varieert van zeer milde cognitieve- of stemmingsklachten tot het eindstadium van dementie 
of zelfs overlijden. Met behulp van conventionele MRI technieken is het moeilijk gebleken om 
te voorspellen welke patiënten met cSVD het hoogste risico hebben op het ontwikkelen van 
deze ernstige klinische symptomen, en voor wie dat niet geldt. We denken daarom dat ook 
andere factoren (náást de “traditionele” cSVD karakteristieken), misschien wel meer bepalend 
zijn voor wie uiteindelijk dementie ontwikkelen, en wie niet. Zulke ‘andere factoren’ kunnen 
onder andere de microstructurele integriteit van de witte stof zijn (dat wil zeggen: cSVD welke 
je niet kunt zien op conventionele MRI) en hersenvolumina van structuren waarvan we weten 
dat deze geassocieerd zijn met gedrag (zoals bijvoorbeeld de hippocampus en amygdala).
De studies in dit proefschrift zijn gebaseerd op data van de RUN DMC studie. Dit is een 
prospectieve cohort studie onder 503 niet-demente, zelfvoorzienende ouderen (tussen 
de 50 en 85 jaar oud) met enige vorm van cSVD op cerebrale beeldvorming. In deze 
studie onderzoeken we de oorzaken en gevolgen van cSVD, waarbij het eerste onderzoek 
(baseline) heeft plaatsgevonden in 2006-2007 met tweemaal een vervolg (follow-up), 5 
jaar en 9 jaar later. We beschrijven de associaties tussen de MRI- karakteristieken (zowel 
macro- als microstructureel) op baseline  en de gevolgen voor het gedrag 5 jaar later.  De 
focus van dit proefschrift ligt op cognitieve achteruitgang en depressieve symptomen. Ten 
slotte beschrijven we het dynamische verloop (zowel de progressie als de regressie) van de 
traditionele cSVD karakteristieken over een periode van 9 jaar.
Cognitie en incidente dementie: macro- versus microstructurele MRI
In Deel I (hoofdstuk 2) beschrijven we op cross-sectioneel niveau de mogelijke (additionele) 
klinische waarde van diffusion tensor imaging (DTI) boven op de bekende (conventionele) 
MRI sequenties, met betrekking tot het cognitief functioneren. We laten zien dat  álle MRI 
parameters gezamenlijk 1 tot 6% van de variantie in cognitief functioneren verklaren, 
bovenop de 22-36% die al werd verklaard door leeftijd, geslacht en opleidingsniveau. Van 
deze MRI parameters (die de additionele 1 tot 6% verklaarden), droegen de DTI parameters 
(markers voor de structurele integriteit van de witte stof) niet substantieel bij aan de 
verklaarde variantie van cognitief functioneren (slechts 1%). Van deze DTI parameters, had de 
MD (mean diffusivity) de sterkste associatie met cognitief functioneren. We concluderen dat 
de cross-sectionele relatie tussen de microstructurele integriteit van de witte stof en cognitief 
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functioneren zwak is, en dat DTI een zeer beperkte toegevoegde klinische waarde heeft naast 
de conventionele beeldvorming.
In Deel 2 beschrijven we prospectief de relatie tussen de hersenstructuren op baseline, 
onderzocht met MRI (FLAIR, T1 en DTI) en het ontstaan van dementie en cognitieve achteruitgang 
na 5 jaar. In hoofdstuk 3 laten we een 5.5-jaar cumulatief risico van 11.1% (95%CI 7.7-14.6) 
zien op het ontwikkelen van all-cause dementie. Daarnaast tonen we aan dat zowel een laag 
witte stof volume (HR 0.65 (95% CI 0.44-0.96)) als een laag hippocampus volume (HR 0.68 (95% 
CI  0.47-0.99)), zijn gerelateerd aan het ontwikkelen van dementie, onafhankelijk van cSVD. 
Opvallend was dat we in deze studie in het geheel geen toegevoegde diagnostische waarde 
vonden van de cSVD karakteristieken (ook niet van de DTI parameters) op het voorspellen 
van het dementierisico na 5 jaar. In hoofdstuk 4 laten we zien dat diffusieparameters in de 
hippocampus, onafhankelijk van hippocampus volume, hersenvolume en cSVD markers, 
zijn gerelateerd aan een verhoogd risico op dementie (HR 1.44 (95% CI 1.10-1.88)). Sub 
analyse in de deelnemersgroep zonder duidelijke hippocampusatrofie, liet zien dat een lage 
hippocampale microstructurele integriteit het risico op dementie meer dan verdubbelde 
(HR 2.66 (95% CI 1.30-5.44)). Mogelijk geeft een toegevoegde DTIscan van de hippocampus 
ons de mogelijkheid om personen, die risico lopen op het ontwikkelen van dementie, eerder 
te identificeren dan wanneer alléén volumetrische metingen van de hippocampus worden 
gebruikt. Tevens zou DTI van de hippocampus gebruikt kunnen worden als een surrogaat 
marker van ziekteprogressie. In hoofdstuk 5 beschrijven we prospectief globale DTI 
parameters op baseline en cognitieve achteruitgang gemeten over verschillende domeinen 
,5 jaar later. Ook hier tonen we aan dat DTI parameters van de witte stof niet gerelateerd 
zijn aan achteruitgang in globaal cognitief functioneren, of in andere cognitieve domeinen, 
na correctie voor demografische karakteristieken en MRI parameters. Deze bevinding is 
in overeenstemming met de resultaten op cross-sectioneel niveau waar we slechts zeer 
beperkte toegevoegde waarde van DTI parameters vonden bovenop de andere MRI maten in 
relatie met cognitief functioneren (hoofdstuk 2) en het gebrek aan relatie tussen globale DTI 
parameters en incidente dementie na 5 jaar (hoofdstuk 3).
Depressieve symptomen en cerebral small vessel disease
In Deel 3 bespreken we depressieve symptomen in relatie tot hersenstructuren en de 
relatie tussen depressieve symptomen en cognitief functioneren, bij ouderen met cSVD. De 
associatie tussen amygdala volume en depressieve symptomen (op cross-sectioneel niveau) 
is het onderwerp van hoofdstuk 6. Hierin laten we zien dat een lager volume van de linker 
amygdala is geassocieerd met depressieve symptomen die voor het eerst voorkomen op 
latere leeftijd (LODS), onafhankelijk van cSVD markers. Elke afname van amygdala volume 
(per mL) is  gerelateerd aan een hoger risico op LODS (OR = 1.77; 95% CI 1.02-3.08; p=0.04).
In hoofdstuk 7 rapporteren we over de integriteit van de witte stof van oudere volwassenen 
met en zonder depressieve symptomen, op cross-sectioneel niveau. Hierbij gebruikten 
we Tract-Based Spacial-Statistics (TBSS). We laten zien dat ouderen met depressieve 
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symptomen een lagere microstructurele integriteit van de witte stof hebben in vergelijking 
met degene zonder depressieve symptomen. Deze verschillen bevinden zich met name in 
de prefrontale wittestof banen, welke een belangrijke rol lijken te spelen in de (patho)genese 
van gedrag en stemming. Dit verschil is onafhankelijk van cognitief functioneren. Onze data 
suggereren dat cSVD een rol speelt in het verschil in wittestof integriteit tussen personen 
met en zonder depressieve symptomen, want na correctie voor cSVD markers verdwijnt deze 
associatie vrijwel volledig.
In hoofdstuk 8 onderzoeken we prospectief de relatie tussen het hebben van depressieve 
symptomen en het ontstaan van ‘all-cause’ dementie na 5 jaar. Hierbij nemen we zowel 
de leeftijd waarop de depressieve symptomen zijn ontstaan en het cognitief functioneren 
op baseline in beschouwing. We laten zien dat diegenen met depressieve symptomen op 
baseline een hoger risico hebben op het ontwikkelen van dementie (HR 2.7 (95%CI 1.4-5.2)) 
dan de ouderen zonder depressieve symptomen bij de eerste meting. Deze relatie wordt 
bepaald door diegenen met depressieve symptomen voor het eerst in hun leven op latere 
leeftijd (LODS), en blijken onafhankelijk van cSVD markers. Juist bij de deelnemers die op 
baseline goed scoorden op de cognitieve testen, geven depressieve symptomen op latere 
leeftijd een hoger risico op het ontwikkelen van dementie (geen depressieve symptomen 
0.0% vs depressieve symptomen 6.9%; log-rank p<0.001). Een dergelijk verschil vonden we 
niet tussen de deelnemers met en zonder depressieve symptomen in de groep die lager 
presteerde bij de cognitieve testen op baseline.
In Deel IV (hoofdstuk 9) reviewen we de klinische consequenties; (cognitief, motoor en 
stemming) en de risicofactoren van microstructurele schade van de witte stof (gemeten 
middels diffusion tensor imaging (DTI)).
Het beloop van cerebral small vessel disease in de tijd
Tenslotte beschrijven we in Deel V het verschil in cSVD markers gemeten over een periode 
van 9 jaar, waarbij we naast de baseline meting (2006) twee follow-up momenten gebruiken 
(2011 en 2015). In hoofdstuk 10 weiden we uit over het dynamische proces van cSVD, waarbij 
we zowel de nieuw ontwikkelde cSVD als de ogenschijnlijke afname van de traditionele 
cSVD markers in beschouwing nemen. De gemiddelde WSA progressie 9 jaar later was 4.7 
mL (0.54mL/jaar; IQR 0.95-5.5mL), 20.3% van de deelnemers had incidente lacunes (2.3%/
jaar) en 18.9% incidente microbloedingen (2.2%/jaar). WSA volume nam af bij 9.4% van de 
deelnemers, en lacunes verdwenen bij 3.6% en microbloedingen bij 5.7%. Deze getallen 
zijn berekend over 2 follow-up momenten, hetgeen ons de mogelijkheid geeft om de niet-
lineaire progressie van WSA te beschrijven. Bovendien rapporteerden we dat diegenen die 
op baseline zeer weinig cSVD hadden, weinig tot geen progressie lieten zien, in tegenstelling 
tot diegenen die al matige tot ernstige cSVD op baseline toonden (OR 35.5; 95% CI 15.8-80.0; 
p<0.001 voor WSA progressie; OR 5.7; 95%CI 2.8-11.2; p<0.001 voor incidente lacunes en OR 
2.9; 95%CI 1.4-5.9; p=0.003 voor incidente microbloedingen).
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Conclusie
De studies in dit proefschrift identificeerden MRI-markers die ons kunnen helpen om 
meer inzicht te krijgen in de pathofysiologische processen die ten grondslag liggen aan 
de cognitieve c.q. stemmingsveranderingen als gevolg van cerebral small vessel disease. 
Tegelijkertijd laten we in dit proefschrift de zeer beperkte toegevoegde waarde op dit gebied 
zien van diffusion tensor imaging bovenop de bekende macrostructurele MRI-markers 
in een oudere populatie met al langer bestaande cSVD. Depressieve symptomen die zich 
voor het eerst openbaren op hogere leeftijd, juist bij personen die tegelijkertijd goed scoren 
op cognitieve testen, wijzen op een verhoogd risico op het ontwikkelen van dementie. Ten 
slotte is cerebral small vessel disease een niet-lineair, dynamisch proces, dat voornamelijk 
progressie vertoont wanneer de jaren verstrijken, maar bij enkele personen ook afname.
In de toekomst  zouden we moeten onderzoeken of een toename van cSVD (incidente 
lacunes of microbloedingen, toename van WSA volume, of afname in microstructurele 
integriteit van de witte stof) of atrofie van de hersenen (afname in hippocampus-, amygdala-, 
witte stof- en grijze stof volumina), voorafgaan aan nieuw ontwikkelde cognitieve of 
stemmingsproblemen. Mogelijk dat deze verandering in MRI-markers een beter correlaat 
met de klinische symptomen laat zien dan de baseline MRI-markers.
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List of abbreviations
3D: Three Dimensional
AD: Alzheimer’s Disease
AD: Axial Diffusivity
AIC: Akaike Information Criterion
AVLT: Auditory Verbal Learning Test
ANCOVA: Analysis of Covariance
ANOVA: Analysis of Variance
APOE: Apo lipoprotein E
ARWMC: Age-related with matter changes
BMIPB: Birt Memory & Information Processing Battery
BMI: Body Mass Index
CAA: Cerebral Amyloïd Angiopathy 
CADASIL: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leucoencofalopathy 
CARASIL: Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and 
Leucoencofalopathy 
CB: Cingulum bundle
CC: Corpus callosum
CES-D: Centre of Epidemiologic Studies Depression Scale
95% CI: Confidence Interval
CI: Cognitive Index
CSF: Cerebrospinal Fluid
cSS: cortical Superficial Siderosis
cSVD: cerebral Small Vessel Disease
CT: Compute Tomography
df: degrees of freedom
DM: Diabetes Mellitus 
DS: Depressive Symptoms
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders - IV
DTI: Diffusion Tensor Imaging
DWI: Diffusion Weighted Imaging
EC: External capsule
EODS: Early Onset Depressive Symptoms
EPI: Echo planar Imaging
EPVS: Enlarged Perivascular Spaces
FA: Fractional Anisotropy
FLAIR: Fluid Attenuated Inversion Recovery
FSL: FMRIB’s Software Library
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FTD: Fronto-Temporal Dementia 
FU: Follow-up
GDS: Geriatric Depression Scale
GM: Grey matter
HC: Healthy controls
HT: Hypertension
HV: Hippocampus volume / Hippocampal volume
HR: Hazard ratio 
IC: Internal capsule
ICV: Intracranial Volume
IFOF: Inferior Frontal Occipital Fasciculus
ILF: Inferior Longitudinal Fasciculus
IQ: Intelligence Quotient
IQR: Inter Quartile Range
Lacunes: Lacunes of presumed vascular origin
LODS: Late Onset Depressive Symptoms
MB: Microbleeds
MCI: Mild Cognitive Impairment 
MD: Mean Diffusivity
MET: Metabolic Equivalent
mI: myo-inositol 
MINI: Mini International Neuropsychiatric Interview
mL: milliliter 
MMSE: Mini–Mental State Examination
MNI space: Montreal Neurological Institute stereotactic space
MO: Mode of Anisotropy
MoCA: Montreal Cognitive Assessment 
MPS: Mild parkinsonian signs
MPRAGE: Magnetization Prepared RApid Gradient Echo
MRI: Magnetic Resonance Imaging
MRS: Magnetic Resonance Spectroscopy
MS: Multiple sclerosis
NAA:  N-acetylaspartate 
NABT: Normal Appearing Brain Tissue
NAWM: Normal Appearing White Matter
NC: Normal cognition
NIA-AA: National Institute of Aging/Alzheimer’s  Association
NINDS-AIREN: National Institute of Neurological Disorders and Stroke - Association 
Internationale pour la Recherche et l’Enseignement en Neurosciences 
n: number 
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OR: Odds ratio
PEPS: Pyramidal and Extra-Pyramidal Scale
PET: Positron Emission Tomography
PPN: Pedunculopontine nucleus
PTs: patients
PV: Periventricular  
PVR: Perivascular spaces
RAVLT: Rey Auditory Verbal Learning Test
RCFT: Rey Complex Figure Task 
RD: Radial Diffusivity
ROI: Region of Interest
ROCF: Rey-Osterrieth complex figure test
RUN DMC: Radboud University Nijmegen Diffusion Tensor and Magnetic resonance Cohort
SAT: Speed-Accuracy Trade-Off 
SD: Standard deviation
SDST: Symbol Digit Substitution Task
SIDAM : structured Interview for the diagnosis of Dementia of the Alzheimer Type, multi-
infarct dementia and other type of dementia
SLF: Superior Longitudinal Fasciculus
SPM5: Statistical Parametric Mapping 5
SPPB: Short Physical Performance Battery
STRIVE: Standards for research into small vessel disease
SVD: small vessel disease
TBSS: Tract-Based Spatial Statistics
TBV: Total Brain Volume
tCho: total Cholines,
tCr: total Creatines 
TE: Echo time
TI: Inversion time
TIA: Transient Ischemic Attack
TMT: Trail making test
TR: Time repetition
UF: Uncinate Fasciculus
UPDRS: Unified Parkinson’s Disease Rating Scale
UK: United Kingdom
VaD: Vascular Dementia
VADAS: Vascular Dementia Assessment Scale–Cognitive Subscale
VBA: Voxel Based Analysis
VBM: Voxel based Morphometry 
VCI: Vascular Cognitive Impairment
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VIF: Variance Inflation Factor
vs.: versus
VSAT: Verbal Series Attention test 
WAISR: Wechsler adult intelligence scale–revised
WCST: Wisconsin card sorting test
WM: White matter
WMH: White matter hyperintensities
WML: White matter lesions
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Dankwoord
Het voelt vreemd om het afsluitende dankwoord van inmiddels 10 jaar RUN DMC te schrijven. 
Ik ga het missen.  De kennismaking met, en de keuze en liefde voor de neurologie heb ik 
aan de RUN DMC studie te danken. Dat komt natuurlijk niet door de RUN DMC studie sec, 
maar door iedereen die mij door dit project heeft geleid, aangehoord, geholpen, begeleid en 
ondersteund op alle mogelijke manieren. 
Allereerst wil ik de deelnemers van het RUN DMC onderzoek bedanken voor hun vrijwillige 
deelname en inzet tot driemaal toe. Zonder jullie bijdrage was dit proefschrift er helemaal 
nooit geweest.
Professor H.F. de Leeuw, Frank-Erik, ik had me geen betere promotor kunnen wensen. Vanaf 
de aller eerste dag (ergens de zomer van 2006) gaf je me het gevoel dat je vertrouwen had 
in wat ik kwam doen (al had ikzelf geen idee…). Ik kreeg de kans om mee te gaan naar 
een congres in Bonn (doodeng), en niet lang erna mocht ik als student mee naar VASCOG 
in San Antonio, Texas (Fantastisch!) om mijn eerste poster te presenteren. Het was niet 
alleen inspirerend maar ook heel prettig om zo onder jouw vleugels mee te mogen. Zo heb 
ik je manier van begeleiden kunnen ervaren en de kwaliteit van het onderzoek van dichtbij 
gezien. Ik heb dan ook geen seconde getwijfeld toen je voorstelde of ik aan het vervolg van 
het RUN DMC onderzoek wilde deelnemen. Wanneer ik een artikel naar je toestuurde was 
het eerder regel dan uitzondering dat de volgende ochtend de gecorrigeerde versie weer in 
mijn mailbox zat. Ook veel dank aan Amanda, dat ze het goed vond dat je ‘vrije’ avonden 
en nachten hieraan besteedde. Kers op de taart is dat jij als begeleider nu ook écht mijn 
promotor bent! Dank je wel voor je vertrouwen en geduld, je (onderzoeks)ideeën (ook al kon 
ik die soms niet altijd volgen), je oog voor mij als persoon, je teamgevoel, je zorgvuldigheid, 
je correctheid, jullie vasculaire borrels en natuurlijk de M&M’s! 
Frank-Erik  écht kort van stof zal ik denk ik nooit worden.
Professor C.J.M. Klijn, beste Karin, je hebt 1,5 jaar geleden het UMCU verruild voor het 
RadboudUMC, en bent mijn mede-promotor geworden. Je heldere , doordachte en duidelijke 
beslissingen over dilemma’s geven rust, dank daarvoor. Als afdelingshoofd en opleider sta je 
achter me waar nodig.
Dr. E.J. van Dijk, Ewoud, je kritische en waardevolle opmerkingen als co-promotor, met name 
op methodologisch vlak heb ik erg gewaardeerd. Voor de rest van mijn leven zal je door 
mijn hoofd flitsen wanneer ik de woorden “confounding by indication”, “selection bias” en 
“reversed causality” hoor.  Het was prettig te discussiëren met een ervaringsdeskundige op 
het gebied van delta imaging.
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Bart Post, als mijn opleider heb je me de ruimte gegeven om mijn promotie, naast mijn 
opleiding en mijn gezin, in rust af te maken. Hetzelfde geldt voor Arnoud Kappelle de 
voorgaande jaren. Dank jullie, ik zou mijn opleiding nergens anders willen volgen.
Manuscriptcommissie, professor M.G.M. Olde Rikkert, professor W.M. van der Flier en dr. F.J.A. 
Meijer, dank dat ik mijn proefschrift aan u ter beoordeling mocht voorleggen.
Ellen van der Holst, Ellen, mijn co-promovendus en RUN DMC maatje, natuurlijk een speciaal 
plekje in mijn dankwoord voor jou! Ontzettend fijn dat we de perikelen rondom het data 
verzamelen samen hebben kunnen delen, in je eentje duurt het niet alleen langer maar is het 
ook een stuk minder gezellig! Samen hebben we ons door verschillende dilemma’s geslagen. 
Het rebooten van een MRI-scanner op zondagochtend (met papieren handleiding), het 
zoeken van de perfecte RUN DMC kerstkaart, het lokaliseren van ‘verdwenen’ deelnemers, 
maar ook het zetten (of drinken….) van koffie zetten bij huisbezoeken. MEMO: bij telefonisch 
contact volgende keer even direct mededelen van welke parochie je bent a.u.b... Heel erg 
bedankt voor de samenwerking de afgelopen jaren, en heel fijn dat we het ook samen in 2017 
kunnen afronden. Veel succes met je welverdiende plek in het mooie ’s-Hertogenbosch, zien 
we elkaar daar binnenkort?
Anouk van Norden, mijn voorgangster en mentor. Je hebt het bedje gespreid voor me 
achtergelaten, wat een luxe. Je bent altijd beschikbaar voor overleg, advies en tips, en niet 
alleen over het onderzoek. 
Esther van Leijsen, het is een geruststelling dat ik het stokje juist aan jou heb mogen 
overdragen.  Dank je wel voor al je energie en gezelligheid, je lekkere koken en biertjes en 
natuurlijk het samen-schrijven van ons laatste stuk de afgelopen maanden.  
Anil Tuladhar, van jouw kennis over diffusion tensor imaging heb ik dankbaar gebruik mogen 
maken. Zonder jou was het onmogelijk geweest om de ingewikkeldste analyses uit te voeren. 
Extra dank voor de mooie plaatjes die je voor me hebt gemaakt, mag de volgende er dan 
toch een keer in het roze?
Mohsen Ghafoorian, I would still be segmenting the follow-up scans today, if it wasn’t for 
your semi-automated white matter hyperintensity detection. Thank you for your patience 
and instant (technical) help whenever I asked. Congratulations and best of luck on the 
continuation of you project at Harvard University. 
Loes Rutten-Jacobs, voor mij ben je echt een statistiek-encyclopedie. Wanneer ik met mijn 
handen in het haar zat, had jij elke keer weer een oplossing, terecht dat je in Cambridge een 
plek hebt gevonden. Hopelijk zien we je hier snel weer terug. 
Karlijn de Laat, mede RUN DMCer, jij staat samen met Anouk en Rob aan de basis van het RUN 
DMC onderzoek. Ontzettend fijn dat ik op jouw werk heb mogen voortborduren. Natuurlijk 
ook dank voor alle gezelligheid op de congressen (San Antonio en Singapore)! 
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Mayra Bergkamp, jij stopt niet tot het af is. Terecht dat je een plekje binnen onze opleiding 
hebt weten te bemachtigen. We mogen erg blij zijn met jou als collega op de werkvloer, zeker 
als je dat net zo gedecideerd (en met altijd goede zin!) aanpakt als het opnieuw segmenteren 
van de lacunes en microbloedingen.
Alle mede auteurs wil ik bedanken voor hun bijdrage aan data-verzameling, opbouwende 
kritiek en/of adviezen. Pauline Schaapsmeerders, dank je voor je advies op het 
neuropsychologisch vlak. Fijn om een hippocampus-collega te hebben! Edo Richard, je bent 
iets later bij het onderzoek betrokken geraakt, maar van jouw kritische en realistische kijk 
op de gedragsneurologie heb ik erg veel geleerd. Ik ben het met je eens, over apathie is het 
laatste woord nog niet gesproken…  
Lucas van Oudheusden, via jou ben ik bij het RUN DMC onderzoek terecht gekomen. We 
hebben elkaar lange tijd niet meer gesproken, dank voor de muziek, de gezelligheid en de 
goede (studenten)tijd. Roy Kessels, Jurgen Claassen en Indira Tendolkar, jullie specialistische 
ideeën en commentaren waren zeer waardevol. 
Renate Arntz, Lieve Renaat, we waren dan misschien niet ‘officieel’ een team, maar zo voelde 
het vaak wel, zeker richting het einde van het promotie-traject. Op persoonlijk vlak zitten we 
met de kindjes in dezelfde fase, en is het ‘s ochtends telkens weer een feestje om samen met 
de kids voor de deur van het dagverblijf te wachten tot hij open gaat (we willen immers niet 
te laat zijn ;-) ). Zonder jouw gezelschap weet ik niet of ik het had kunnen opbrengen om de 
laatste maanden weer de hokjes van de radiologie in te duiken om alle scans opnieuw in te 
kleuren. Ook de afrondende fase; het afschrijven van het boekje, het zoeken van de drukker, 
de feestlocatie, alles is veel leuker wanneer je het samen met een vriendinnetje mag doen, 
dank je wel!
Speciale dank ook aan de gehele vasculaire groep;  Karin, Saskia, Sharon, Annet, Mayte, 
Merel, Bram, Tessa, Annemieke, Kim, Frank, Liselore, Joyce, Noortje, Nathalie, voor hulp 
bij dataverzameling en de input op de vasculaire besprekingen. In het bijzonder dank voor 
de student-assistenten (Willemijn Geense, Heleen van den Berg, Inge van der Holst) voor 
jullie hulp bij het scannen, telefoneren en compleet maken van de follow-up data. Eline 
Kooijmans, betrokken als student bij ons onderzoek, naast een prachtige scriptie die je hebt 
geschreven, ga je door met ons onderzoek naast je co-schappen. We hopen je hierna op de 
neurologie weer terug te zien! Valerie Lohner, een mooie scriptie en zelfs een presentatie op 
een internationaal congres ten tijde van je stage, heel knap! Wat een monnikenwerk hebben 
jullie verzet!
Zonder alle ondersteuning op het Donders Cenctum van Paul Gaalman bij het scannen, en 
de inventiviteit van Sandra bij de receptie, hadden we het scanwerk niet kunnen doen. Door 
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het plan-talent en de flexibiliteit van de dames op de polikliniek neurologie hebben we 400 
deelnemers in korte tijd op de poli terug kunnen zien. 
Ik mag van geluk spreken dat ik mijn opleiding mag volgen in zo’n fijn en collegiaal team. Een 
speciaal woord van dank voor de ‘neuro-ladies’ mag absoluut niet ontbreken:  Judith van 
Gaalen (Verbuuuuuuuurg!), Nicolien van der Kolk, Renate Arntz en Ellen van der Holst. 
Lieve Juud, direct vanaf het begin van de opleiding zijn we vriendinnen, en beiden getuigen 
op elkaars bruiloft… Volgens mij zegt dat genoeg, liefs!
Lieve Nico, onze maandelijkse etentjes, initieel met zijn 4en en dadelijk al weer met zijn 8en, 
eindigen altijd véél te laat! Meeten we volgend jaar weer in La France ?
 Ik vind het geweldig om zulke gezellige, warme en hilarische (en natuurlijk heel knappe) 
vriendinnen te hebben die ik ook nog bijna dagelijks zie. Dat maakt naar het werk gaan elke 
dag nóg leuker :-)
Lieve paranimfen, ik ben trots dat juist jullie op deze speciale dag naast mij staan. 
Allereerst Dineke Westra, lieve Dien, jij hebt me, toen ik even van het padje af was en ging 
roeien, weer op het rechte pad gezet en terug naar de hockey gehaald. Je bent een stabiele 
factor uit mijn studententijd, dat jij in mijn bestuur zat was voor mij als voorzitter een 
verademing. Daarnaast hebben we fantastisch gefeest! We hebben tegelijkertijd onze kindjes 
gekregen, en het is heerlijk te zien dat Emma ‘s ochtends staat te springen als ze naar Margje 
mag. Dien, dat jij mijn paranimf bent, is niet meer dan logisch.
Roel van Uden, lieve Roelieboelie, lieve broer, allereerst is er iets wat me van het hart moet. 
Het spijt me dat ik vroeger zo hard fietste tussen die 2 stoplichten langs de N65… ik zal tegen 
Emma zeggen dat ze dat bij Guus niet mag doen. Als kinderen waren we 2 handen op 1 buik, 
daar heb ik hele fijne herinneringen aan. Afgelopen jaren hebben we elkaar weer gevonden, 
dat voelt vertrouwd. Ik ben trots dat je mijn paranimf wil zijn.
Suzanne Claessens-Schraven, Lieve Suzy Q, eigenlijk ben je mijn grote zus; klein en blond 
(maar wel iets groter). Je vertelt me de waarheid als deze fijn is om te horen, maar ook als 
ik liever wat anders zou horen. Ik bewonder je oprechtheid en eerlijkheid zonder blad voor 
de mond, want we denken hetzelfde en stiekem zeg jij vaak, wat ik denk. Je gekheid (soms 
gewoonweg gestoord), humor, warmte en liefde voor de mensen om je heen zijn geweldig. 
Samen met Loek, Mathijs en Elise hoop ik dat onze gezinnen de rest van ons leven verbonden 
blijven én dat we onze 2-jaarlijkse weekenden met Renée en Eelke blijven continueren.
Lieve Saskia, Myrtille en Bianca, lieve co-groepvriendinnen, het lijkt al weer zo lang geleden! 
Allemaal mama en in opleiding tot specialist, ben best wel trots op ons. Sas, je bent een 
kanjer, niet alleen gepromoveerd, maar je sleept de subsidies binnen. Hoe doe je dat toch!? 
Myrt, als ik iets van je kan leren is het wel doorzetten. Er zullen veel baby’s en ouders blij 
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zijn dat jij hun gynaecoloog bent. Bianca, 2e kindje op komst.. zien we je daarna snel in het 
RadboudUMC? 
Lieve Noor, Neel, Siem en Tien als we elkaar zien is het altijd goed en vertrouwd. Dat is echte 
vriendschap.
Lieve Marijke, een lievere en gezelligere buurvrouw kan ik me niet wensen, we hebben 
ontzettend veel geluk gehad dat jullie naast ons zijn komen wonen. Ik hoop dat we nog vaak 
kunnen kletsen, wijn drinken in de tuin, kickfitten en natuurlijk parcoursen bouwen met de 
boeven (ok, en de mannen)!
Lieve hockeyvriendinnetjes; Anne, Anouk, Chironne, Dineke, Ellen, Eveline, Floor, Franka, 
Hanneke, Margo, Marie-Louise, Maud, Meike, Muur, Niké, Renee, Saskia, Silke, Sophie, 
Susanne, Suus, Willemijn en Jouke, de afgelopen 10 jaren hebben we tragische verliezen 
geleden, fantastische overwinningen behaald, onvergetelijke teamweekenden gehad, 
onnavolgbare gesprekken en vooral een onvergetelijke tijd. Ik had jullie niet kunnen missen. 
Wanneer gaan we weer naar ‘t feest van Ome Joop?
Lieve familie, ik hoef het maar te vragen, en jullie staan voor mij en mijn gezin klaar. In het 
bijzonder tante Pieternel, dank je wel voor al je ‘instant’ hulp en je heerlijke jam natuurlijk! 
Lieve Anke en Chiel, Emma en Guus zijn gek op jullie. Het voelt goed jullie zo dichtbij te 
hebben. Tante Marion, je bent vanaf jongs af aan mijn 2e mama (wel een hele stoere variant).
Lieve Mieke, dank je voor alle (oppas)hulp, steun en ideeën. Ik hoop dat je gezondheid weer 
beter wordt en dat we samen met het gezin heel veel leuke dingen kunnen (blijven) doen. 
Anne, dank je voor je wijsheid en luisterend oor als collega en als schoonzusje. Lieve Ton, 
dankzij jou (en pap) hebben we een huis, wat nu ook echt voelt als een thuis. 
Lieve Bassie, mijn kleinste broertje (inmiddels wel een kop groter), jouw onuitputtelijke 
enthousiasme en goede zin maken dat ik van jou altijd heel vrolijk wordt. Je bent een keiharde 
werker, en we zien elkaar nu ook als collega’s in het ziekenhuis. Dat maakt een dienst toch 
weer een stukje leuker! 
Lieve broers, Bas en Roel en lieve schoonzusjes Niké en Rianne. Het is zo gewoon, maar ook 
zo fijn dat we allemaal in Nijmegen wonen en elkaar wekelijks zien. Het voelt altijd als een 
warme deken als we allemaal bij elkaar zijn, de spelletjesavonden zijn onovertroffen. Ik zou 
er niks aan willen veranderen. 
Lieve pap en mam, zonder jullie was dit boekje er nooit gekomen. Jullie steun en liefde is 
onvoorwaardelijk. Van kinds af aan hebben jullie mij gestimuleerd en gefaciliteerd om alles 
uit mezelf te halen en mijzelf te ontwikkelen. Ons thuis is altijd warm en liefdevol geweest en 
dat is het nog steeds. Dat voel ik, en ook mijn gezin, elke dag. Het is veilig te weten dat jullie 
er altijd zijn en achter ons staan. Dank jullie wel.. ik hou van jullie.
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Aller áller liefste Eric, ik hou zoveel van je. Je denkt in mogelijkheden in plaats van in 
onmogelijkheden. Je geeft rust als ik onrustig ben. Je creëert tijd (en een huis) als ik denk 
dat het onhaalbaar is  je bent er altijd en doet alles voor mij en ons gezin,  je maakt dat ik me 
bijzonder voel en dat maakt me stil… ik zou nooit meer anders willen.
jbdlvdhwihvj…
Liefste Emma, Liefste Guus, allerliefste boeven… samen met je papa, zijn jullie het beste wat 
me ooit is overkomen.
Een liedje voor jullie
♫ In de maneschijn…. ♪
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•	 Karlijn F. de Laat. Motor performance in individuals with cerebral small vessel disease: an 
MRI study. Radboud University Nijmegen, 29 November 2011
•	 Anouk G.W. van Norden. Cognitive function in elderly individuals with cerebral small 
vessel disease. An MRI study. Radboud University Nijmegen, 30 November 2011
•	 Rob Gons. Vascular risk factors in cerebral small vessel disease. A diffusion tensor imaging 
study. Radboud University Nijmegen, 10 December 2012
•	 Loes C.A. Rutten-Jacobs. Long-term prognosis after stroke in young adults. Radboud 
University Nijmegen, 14 April 2014 
•	 Noortje A.M.M. Maaijwee. Long-term neuropsychological and social consequences after 
stroke in young adults. Radboud University Nijmegen, 12 June 2015
•	 Nathalie E. Synhaeve. Determinants of long-term functional prognosis after stroke in 
young adults. Radboud University Nijmegen, 28 September 2016
•	 Anil M. Tuladhar. The disconnected brain: mechanisms of clinical symptoms in small 
vessel disease. Radboud University Nijmegen, 4 October 2016.
•	 Pauline Schaapsmeerders. Long-term cognitive impairment after first-ever ischemic 
stroke in young adults: a neuroimaging study. Radboud Univesity Nijmegen, 24 January 
2017.
•	 Ingeborg W.M. van Uden. Behavioural consequences of cerebral small vessel disease; an 
MRI approach. Radboud University Nijmegen, 14 Februari 2017.
Parkinson Center Nijmegen (ParC)
•	 Jasper E. Visser. The basal ganglia and postural control. Radboud University Nijmegen, 17 
June 2008
•	 Maaike Bakker. Supraspinal control of walking: lessons from motor imagery. Radboud 
University Nijmegen, 27 May 2009
•	 W. Farid Abdo. Parkinsonism: possible solutions to a diagnostic challenge. Radboud 
University Nijmegen, 7 October 2009
•	 Samyra H.J. Keus. Physiotherapy in Parkinson’s disease. Towards evidence-based 
practice. Leiden University, 29 April 2010
•	 Lars B. Oude Nijhuis. Modulation of human balance reactions. Radboud University 
Nijmegen, 29 November 2010
•	 Maarten J. Nijkrake. Improving the quality of allied health care in Parkinson’s disease 
through community-based networks: the ParkinsonNet health care concept. Radboud 
University Nijmegen, 29 November 2010
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•	 Rick C.G. Helmich. Cerebral reorganization in Parkinson’s disease. Radboud University 
Nijmegen, 24 May 2011
•	 Charlotte A. Haaxma. New perspectives on preclinical and early stage Parkinson’s disease. 
Radboud University Nijmegen, 6 December 2011
•	 Johanna G. Kalf. Drooling and dysphagia in Parkinson’s disease. Radboud University 
Nijmegen, 22 December 2011
•	 Anke H. Snijders. Tackling freezing of gait in Parkinson’s disease. Radboud University 
Nijmegen,4 June 2012
•	 Bart F.L. van Nuenen. Cerebral reorganization in premotor parkinsonism. Radboud 
University Nijmegen, 22 November 2012
•	 Wandana Nanhoe-Mahabier. Freezing of physical activity in Parkinson’s disease, the 
challenge to change behavior. Radboud University Nijmegen, 13 February 2013
•	 Marlies van Nimwegen. Promotion of physical activity in Parkinson’s disease, the challenge 
to change behavior. Radboud University Nijmegen, 6 March 2013
•	 Arlène D. Speelman. Promotion of physical activity in Parkinson’s disease, feasibility and 
effectiveness. Radboud University Nijmegen, 6 March 2013
•	 Tjitske Boonstra. The contribution of each leg to bipedal balance control. University 
Twente, 6 June 2013
•	 Marjolein A van der Marck. The Many faces of Parkinson’s disease: towards a multifaceted 
approach? Radboud University Nijmegen, 10 January 2014
•	 Katrijn Smulders. Cognitive control of gait and balance in patients with chronic stroke and 
Parkinson’s disease. Radboud University Nijmegen, 21 May 2014
•	 Marjolein B. Aerts. Improving diagnostic accuracy in parkinsonism. Radboud University 
Nijmegen, 27 June 2014 
•	 Maartje Louter. Sleep in Parkinson’s disease. A focus on nocturnal movements. Radboud 
University Nijmegen, 13 February 2015
•	 Frederick Anton Meijer. Clinical Application of Brain MRI in Parkinsonism: From Basic to 
Advanced Imaging, Radboud University Nijmegen, 23 June 2015
•	 Jorik Nonnekes. Balance and gait in neurodegenerative disease: what startle tells us 
about motor control, Radboud University Nijmegen, 2 September 2015
•	 Martijn van der Eijk. Patient-centered care in Parkinson’s disease. Radboud University 
Nijmegen, 1 December 2015
•	 Ingrid Sturkenboom. Occupational therapy for people with Parkinson’s disease: towards 
evidence-informed care. Radboud University Nijmegen, 11 February 2016
•	 Merel M. van Gilst. Sleep benefit in Parkinson’s disease. Radboud University Nijmegen, 13 
April 2016
•	 Arno M. Janssen. Transcranial magnetic stimulation - measuring and modeling in health 
and disease. Radboud University Nijmegen, 2 June 2016
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Non-Parkinsonian disorders of movement
•	 Sacha Vermeer. Clinical and genetic characterization of autosomal recessive 
cerebellarataxias. Radboud University Nijmegen, 5 April 2012
•	 Susanne T. de Bot. Hereditary spastic paraplegias in the Netherlands. Radboud University 
Nijmegen, 20 December 2013
•	 Catherine C.S. Delnooz. Unraveling primary focal dystonia. A treatment update and new 
pathophysiological insights. Radboud University Nijmegen, 7 January 2014
•	 Ella MR Fonteyn. Falls, physiotherapy, and training in patients with degenerative ataxias, 
29 June 2016
Neuromuscular disorders of movement
•	 Mireille van Beekvelt. Quantitative near infrared spectroscopy (NIRS) in human skeletal 
muscle. Radboud University Nijmegen, 24 April 2002
•	 Johan Hiel. Ataxia telangiectasia and Nijmegen Breakage syndrome, neurological, 
immunological and genetic aspects. Radboud University Nijmegen, 23 April 2004
•	 Gerald JD Hengstman. Myositis specific autoantibodies, specificity and clinical 
applications. Radboud University Nijmegen, 21 September 2005
•	  M. Schillings. Fatigue in neuromuscular disorders and chronic fatigue syndrome, a 
neurophysiological approach. Radboud University Nijmegen, 23 November 2005
•	  Bert de Swart. Speech therapy in patients with neuromuscular disorders and Parkinson’s 
disease. Diagnosis and treatment of dysarthria and dysphagia. Radboud University 
Nijmegen, 24 march 2006
•	 J. Kalkman. From prevalence to predictors of fatigue in neuromuscular disorders. The 
building of a model. Radboud University Nijmegen, 31 October 2006
•	 Nens van Alfen. Neuralgicamyotrophy. Radboud University Nijmegen, 1 November 2006
•	 Gea Drost. High-density surface EMG, pathophysiological insights and clinical applications. 
Radboud University Nijmegen, 9 March 2007
•	 Maria Helena van der Linden. Pertubations of gait and balance: a new experimental setup 
applied to patients with CMT type 1a. Radboud University Nijmegen, 6 October 2009
•	 Jeroen Trip. Redefining the non-dystrophic myotonic syndromes. Radboud University 
Nijmegen, 22 January 2010
•	 Corinne G.C. Horlings. A weak balance: balance and falls in patients with neuromuscular 
disorders. Radboud University Nijmegen, 1 April 2010
•	 E. Cup. Occupational therapy, physical therapy and speech therapy for persons with 
neuromuscular diseases, an evidence based orientation. Radboud University Nijmegen, 
5 July 2011
•	 Alide Tieleman. Myotonic dystrophy type 2, a newly diagnosed disease in the Netherlands. 
Radboud University Nijmegen, 15 July 2011
•	 Nicol Voermans. Neuromuscular features of Ehlers-Danlos syndrome and Marfan 
syndrome. Radboud University Nijmegen, 2 September 2011
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•	 Allan Pieterse. Referral and indication for occupational therapy, physical therapy and 
speech- language therapy for persons with neuromuscular disorders. Radboud University 
Nijmegen, 13 February 2012
•	 Bart Smits. Chronic Progressive External Ophthalmoplegia more than meets the eye. 
Radboud University Nijmegen, 5 June 2012
•	 Ilse Arts. Muscle ultrasonography in ALS. Radboud University Nijmegen, 31 October 2012
•	 M. Minis. Sustainability of work for persons with neuromuscular diseases. Radboud 
University Nijmegen, 13 November 2013
•	 Willemijn Leen. Glucose transporter – 1 deficiency syndrome. Radboud University 
Nijmegen, 26 June 2014
•	 Barbara Jansen. Magnetic Resonance Imaging signature of fascioscpulohumeral 
muscular dystrophy. Radboud University Nijmegen. 14 September 2015
•	 Noortje Rijken. Balance and gait in FSHD, relations with individual muscle involvement. 
Radboud University Nijmegen, 8 December 2015
•	 Femke Seesing. Shared Medical appointments for neuromuscular patients and their 
partners. Radboud University Nijmegen, 2 September 2016
•	 Nicole Voet. Aerobic exercise and cognitive behavioral therapy in fascioscapulohumeral 
dystrophy: a model based approach. Radboud University Nijmegen , 14 October 2016. 
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Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established the 
Donders Graduate School for Cognitive Neuroscience (DGCN), which was officially recognised 
as a national graduate school in 2009. The Graduate School covers training at both Master’s 
and PhD level and provides an excellent educational context fully aligned with the research 
programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioural science, medicine and related 
disciplines. Selective admission and assessment centres guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni show 
a continuation in academia with postdoc positions at top institutes worldwide, e.g. Stanford 
University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, Hanyang 
University in South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.. Positions outside 
academia spread among the following sectors: specialists in a medical environment, 
mainly in genetics, geriatrics, psychiatry and neurology. Specialists in a psychological 
environment, e.g. as specialist in neuropsychology, psychological diagnostics or therapy. 
Positions in higher education as coordinators or lecturers. A smaller percentage enters 
business as research consultants, analysts or head of research and development. Fewer 
graduates  stay in a research environment as lab coordinators, technical support or policy 
advisors. Upcoming possibilities are positions in the IT sector and management position 
in pharmaceutical industry. In general, the PhDs graduates almost invariably continue with 
high-quality positions that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defences please visit:
http://www.ru.nl/donders/graduate-school/donders-graduate/ 
"Weten wat men weet en weten wat men niet weet, dat is het ware weten."
Confucius, 500 v.Chr.
